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Summary (300 words) 
Pulmonary arterial hypertension (PAH) is a rare disease and often heterogeneous at clinical 
presentation. There has been significant interest in the use of clinical parameters to assess risk, and 
two risk stratification tools exist. I aimed to assess whether additional non-invasive investigations 
could improve upon current approaches. In addition, I sought to evaluate specific phenotypes in 
pulmonary hypertension, including patients with idiopathic PAH (IPAH) who have mild lung disease.  
Data were obtained from clinical databases at a large PAH referral centre.  
When assessing clinical phenotypes, I identified that the presence of minor lung disease in patients 
with IPAH was a strongly negative prognostic marker, and these patients did not demonstrate an 
improvement in exercise capacity in response to PAH targeted therapy.  
For risk stratification I aimed to identify thresholds for low (<5%), intermediate (5-10%) and high 
(>10%) risk of one-year mortality, as in other widely-used approaches. Risk could be stratified using 
three non-invasive assessments: cardiac MRI, incremental shuttle walking test (ISWT) and emPHasis-
10 quality of life score. In contrast to current risk stratification approaches, thresholds for cardiac MRI 
were able to identify a large proportion of patients (63%) at low-risk of one-year mortality. In addition, 
cardiac MRI was able to add discriminative value to currently used risk stratification scores. EmPHasis-
10 was an independent predictor of mortality, and in a risk stratification approach was able to identify 
patients with distinct levels of one-year mortality. For the ISWT, a 10% improvement in exercise 
capacity was an independent prognostic marker of survival, and thresholds derived at baseline 
accurately stratified risk at follow-up. 
This thesis demonstrates that non-invasive assessments can be used either in isolation or in 
conjunction with other prognostic parameters in patients with PAH. The thresholds proposed could 
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1.1 An overview of pulmonary hypertension 
1.1.1 The Pulmonary Circulation and Pulmonary Hypertension 
The pulmonary circulation has evolved to allow maximal efficiency of gas exchange at the alveolar 
membrane, by operating at low pressure and high flow through the pulmonary arteries and capillaries. 
Persistent elevation of pressure in this system is termed pulmonary hypertension (PH), and was 
initially classified by the World Health Organisation (WHO) in 1973 into Primary (now known as 
idiopathic pulmonary arterial hypertension) and Secondary, depending on whether a specific cause 
was found (1). Pulmonary hypertension ranges from typically mild elevations of pulmonary artery 
pressure seen in the context of significant cardiac and respiratory disease (2-6) to more severe 
elevations of pulmonary artery pressure seen in pulmonary arterial hypertension which is 
characterised by a small vessel vasculopathy, and chronic thromboembolic pulmonary hypertension 
where a small vessel vasculopathy may be seen in addition to more proximal obstruction of the 
pulmonary vasculature (7-9).  Whereas pulmonary hypertension is not uncommon in the setting of 
significant cardiac and respiratory disease, forms of pulmonary hypertension for which specific 
therapies are licensed (specifically pulmonary arterial hypertension and chronic thromboembolic 
pulmonary hypertension) are relatively rare (10-12).  
1.1.2 Definition 
Normal pulmonary arterial pressure has previously been identified as 14.0 ±3.3 mmHg (13) and even 
at the first World Symposium on Pulmonary Hypertension (WSPH) it was identified that normal 
pulmonary arterial pressure does not exceed 20 mmHg (1). Despite this, until recently pulmonary 
hypertension was defined as a mean pulmonary arterial pressure (mPAP) ≥25 mmHg (14, 15). During 
the course of this research project, at the 6th WSPH in 2018, an updated haemodynamic definition of 
precapillary pulmonary hypertension was proposed, consisting of a mPAP >20 mmHg with associated 
pulmonary vascular resistance (PVR) ≥3 Wood units. In this research project, unless otherwise stated, 
pulmonary hypertension refers to patients with a mPAP ≥25 mmHg. The focus of this project is 
primarily on patients with pulmonary arterial hypertension (PAH), which refers to patients with 
elevated pulmonary arterial pressure related to a vasculopathy and has traditionally been defined 
haemodynamically as a mPAP ≥25, with a PVR ≥3 Wood units and a pulmonary arterial wedge pressure 
≤15 mmHg (16). 
The term exercise pulmonary hypertension has previously been used to refer to patients who 
developed a mPAP >30 mmHg on exertion (17). This definition was abandoned following the 4th and 
5th WSPH and current guidance advises avoidance of the term as it cannot be accurately defined (18). 
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1.1.3 Epidemiology and Classification 
Following several world symposia, most recently the 6th WSPH in Nice (2018), pulmonary hypertension 
is now subcategorised into groups based on diseases that exhibit similar clinical and pathological 
characteristics (Table 1), although an overlap between conditions is increasingly recognised (19-21).  
One of the most common causes of pulmonary arterial hypertension worldwide is thought to be 
schistosomiasis but this is uncommon in the developed world (22). Idiopathic PAH (IPAH) is rare and 
the exact incidence is unclear but is thought to be <5 cases per million per year (12).  Approximately 
4% of patients with PAH have a family history (termed heritable or familial PAH), with the majority of 
these patients having a genetic mutation, although sporadic cases with no family history may also 
have a genetic mutation (23-25). Patients with heritable PAH may have a similar clinical presentation 
to patients with IPAH, although often present at a younger age with more severe haemodynamics and 
are thought to have poorer outcomes (26, 27). In the past, idiopathic pulmonary arterial hypertension 
was considered to be a disease that exclusively affected young women and, while this is now 
recognised as inaccurate, females are more frequently affected than males, although males have a 
worse prognosis (28). 
Pulmonary arterial hypertension is associated with connective tissue diseases, particularly systemic 
sclerosis where the prevalence is around 10%, and screening programmes are in place which may use 
algorithms including DETECT (29, 30). Systemic sclerosis can also cause elevation of the pulmonary 
arterial pressures through a number of non-vasculopathic mechanisms, including interstitial lung 
disease, and left ventricular diastolic dysfunction (30). 
The onset of PAH has also been associated with the use of a number of drugs and toxins, including 
anorexigens, which led to a surge in cases in the 1960s due to aminorex, and in the 1990s due to 
fenfluramine (31). Benfluorex, used as a treatment for diabetes though has pharmacological 
similarities to fenfluramine, was also associated with PAH and was in use until 2009 (32). All of these 
drugs, which have now been withdrawn from the market, share molecular similarities to 
amphetamines, the use of which has been deemed a risk factor for PAH (33). 
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Figure 1: Summary diagram showing multiple mechanisms of pulmonary hypertension 
Abbreviations: PAH = pulmonary arterial hypertension, PH = pulmonary hypertension, CTEPH = chronic 
thromboembolic pulmonary hypertension, LV = left ventricular, LHD = left heart disease 
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Table 1: Classification of Pulmonary Hypertension 




1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3
1.2.3 Unknown
1.3 Drug and toxin induced
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart diseases
1.4.5 Schistosomiasis
1′ Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis
1′′. Persistent pulmonary hypertension of the newborn (PPHN)
2. Pulmonary hypertension due to left heart disease
2.1 Left ventricular systolic dysfunction
2.2 Left ventricular diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital
cardiomyopathies
3. Pulmonary hypertension due to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental lung diseases
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1 Haematologic disorders: chronic haemolytic anaemia, myeloproliferative disorders,
splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH
1.1.4 Pathophysiology of PAH 
A number of mechanisms can cause increased pulmonary vascular resistance, including hypoxic 
vasoconstriction as seen in obstructive lung disease, and conditions that reduce luminal flow at the 
pulmonary vascular bed, such as pulmonary emboIi (34). In PAH, however, there is typically 
remodelling of the small vessel pulmonary arteries. This consists of vasoconstriction, medial 
hypertrophy, micro-thrombosis, plexiform lesion formation, and adventitial proliferation; these 
pathological features are collectively termed a vasculopathy (35-37). Initially vasoconstriction was 
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thought to play a key role in the pathophysiology of PAH, however it is now recognised that this is a 
dominant feature in less than 10% of patients (38).  
The vascular changes cause a rise in pulmonary vascular resistance, which leads to right ventricular 
strain.  The usually thin-walled right ventricle hypertrophies and increases contractility without any 
change in stroke volume, termed “coupling”, allowing it to temporarily cope with mildly elevated 
pressures. As the disease progresses, the RV subsequently dilates and heart rate rises in an attempt 
to maintain cardiac output. This causes increased metabolic demand, and ventriculo-arterial 
uncoupling develops as a result. Right ventricular failure ensues and cardiac output falls, eventually 
leading to death (39). 
1.1.5 Genetic Mutations 
Bone morphogenic protein receptor type II (BMPR2) was the first causative mutation identified in PAH. 
It is still thought to be the most common, identified by genetic analysis in 84% of PAH patients with a 
family history, but only 14% of patients without. Since BMPR2 was identified in 2000, a number of 
other mutations have been described in PAH, as well as EIF2AK4 (Eukaryotic Translation Initiation 
Factor 2 Alpha Kinase 4) which has been demonstrated as predisposing to pulmonary veno-occlusive 
disease (PVOD) (40). 
Approximately 10-20% of patients affected by anorexigen-induced PAH carry a BMPR2 mutation (31, 
41). In addition, the penetrance of BMPR2 is low at around 20-30% (42). These factors suggest that 
susceptibility to PAH is increased in patients with genetic mutations but that a further provoking risk 
factor may be required to induce vasculopathic changes. 
Genetic counselling and screening are offered by some PAH centres, though due to incomplete 
penetrance not all patients who test positive for mutations will develop PAH (42). Some guidelines 
suggest screening asymptomatic patients who are found to have the mutation with yearly 
echocardiograms (43). As with all incurable diseases, genetic screening of affected relatives remains 
controversial.  
1.1.6 Clinical Presentation 
While patients may be asymptomatic at presentation, the majority present with significant disease, 
typically in WHO Functional Class III and with significant elevation of the pulmonary arterial pressures 
(44). Symptoms at presentation typically include dyspnoea, fatigue and exercise limitation but as the 
disease progresses symptoms and signs of low cardiac output develop, including pre-syncope, 
peripheral oedema and, in severe disease, syncope (45, 46). Palpitations may occur as a result of 
arrhythmias, usually supraventricular in nature and most commonly atrial flutter and atrial fibrillation 
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(47). Peripheral oedema and pericardial effusion signify significant right heart failure and are usually 
late manifestations (46). Pulmonary arterial hypertension is often thought of as a disease that affects 
the pulmonary circulation and right heart in isolation, however a number of systemic consequences 
have been identified. Whilst some of these consequences, such as liver dysfunction and renal failure, 
may in part be caused by reduced cardiac output and venous congestion (48), the pathophysiology of 
other systemic disorders such as thyroid disease, which has an prevalence of 20% in PAH, is unclear 
(49). 
1.1.7 Arrhythmias 
Patients with PAH are prone to developing supraventricular arrhythmias, and the cumulative 
incidence has been found to be as high as 25% over a 5 year period (50). Both atrial flutter and atrial 
fibrillation appear to develop with similar frequency (47, 51). The mechanism for the development of 
atrial fibrillation in PAH, which in the general population is caused by left atrial enlargement, is unclear. 
The proposed mechanism for atrial flutter is that increased right atrial pressure induces right atrial 
stretch and subsequent development of fibrosis, as suggested by electrophysiological studies (51).  
Arrhythmias appear to develop in those with more severe haemodynamics. Patients with a higher 
baseline mRAP, mPAP and PVR, as well as those with a lower cardiac output, have been found to be 
at greatest risk when compared with those who remain in sinus rhythm (50). 
Onset of arrhythmia correlates with clinical deterioration. Tongers et al demonstrated that 84% of 
patients with PAH who developed a supraventricular arrhythmia presented with clinical 
decompensation, and clinical condition improved in those who had restoration of sinus rhythm (52). 
Those refractory to cardioversion, who all had atrial fibrillation, had a mortality of 82% over an average 
of 11 months following onset of arrhythmia compared to patients who remained in sinus rhythm who 
had a mortality of 6% with an average follow-up of 26 months (52). This study is, however, limited by 
the relatively small number of patients with an arrhythmia (n=27).  These data may suggest that sinus 
rhythm restoration is important in patients with supraventricular arrhythmia, although large 
prospective data are lacking. 
1.1.8 Treatments 
Over the course of approximately 20 years, there has been significant development in treatments 
available for patients with PAH. At the time of the 2nd WSPH only two treatments were available for 
patients with pulmonary arterial hypertension: patients who exhibited a vasodilator response at right 
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heart catheterisation were treated with high dose calcium channel blockers, and patients with severe 
disease were treated with continuous infusions of intravenous epoprostenol (53).  
1.1.8.1 Supportive treatment 
Prior to the availability of targeted treatments, management of patients with pulmonary hypertension 
was focused on supportive care. Alongside targeted treatments, these still form an important part of 
clinical management. Oxygen prescription guidance in patients with pulmonary arterial hypertension 
is limited. Patients are typically considered for long term oxygen therapy when PaO2 falls below 8 kPa, 
in keeping with studies performed on patients with other forms of lung disease (54).  
No randomised controlled trials have assessed the use of diuretics in patients with PAH but they 
appear to provide symptomatic benefit to patients with peripheral oedema. Diuretics also reduce right 
atrial pressure which, when elevated, is recognised to be an important marker of adverse outcome 
(55, 56). 
Clinicians increasingly recommend exercise rehabilitation for patients with pulmonary hypertension, 
a treatment which is now recognised as safe, and a recent Cochrane review of five randomised 
controlled trials identified improvements of 60 metres in 6-minute walking test distance in response 
to structured exercise training (57, 58). Studies have typically focused on specialist pulmonary 
hypertension rehabilitation programmes, although community-based programmes such as pulmonary 
and cardiac rehabilitation may also be effective (59). 
1.1.8.1.1 Anticoagulation 
The role of anticoagulation in patients with IPAH remains unclear. Post mortem studies have revealed 
that thrombotic lesions are common in patients with IPAH (60), and clotting abnormalities have also 
been reported (61). Despite this, results from clinical studies and registry data have been conflicting 
and guidance is therefore limited (62). The German Comparative, Prospective Registry of Newly 
Initiated Therapies for Pulmonary Hypertension (COMPERA) registry identified a survival benefit in 
patients with IPAH who were on oral anticoagulation, whereas an analysis of the Registry to Evaluate 
Early and Long-Term PAH Disease Management (REVEAL) registry did not show such a benefit (63, 64). 
Randomised controlled trial data are lacking, and decisions regarding commencing anticoagulation are 
typically determined on a case by case basis. The role of anticoagulation in other forms of PAH is even 
less clear, particularly in PAH-CTD where patients may have increased risk of gastro-intestinal 
bleeding, and routine anticoagulation is not recommended (65). 
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1.1.8.2 Transplantation 
For patients with severe and refractory disease, lung or heart/lung transplantation may be 
recommended. Due to the rare nature of the disease, patients with PAH constitute a small number of 
those undergoing transplantation, and gastro-oesophageal dysmotility/reflux can prevent listing for 
transplantation in patients with PAH due to systemic sclerosis (66-68). Early referral for 
transplantation is recommended as it allows pre-transplant identification and optimisation of 
comorbidities (69). In addition, in the UK, patients may not be established on triple therapy (excluding 
selexipag) until they have been accepted as suitable for lung transplant (70). 
1.1.8.3 PAH-specific therapies 
Currently, in addition to calcium channel blockers, there are more than 10 individual pharmacological 
treatment options available, which target three main pathways (Figure 2). 
1.1.8.3.1 Calcium channel blockers 
The potential role for calcium channel blockers (CCBs) or calcium channel antagonists has been long-
recognised and was first described in the 1980s (71).   Pulmonary vasodilator testing identifies patients 
in whom the vasculopathy is particularly contributed to by reversible vasoconstriction (53), and 
vasoreactivity testing is performed at right heart catheterisation by administrating inhaled nitric oxide 
or intravenous prostanoid. The definition of a positive response to vasoreactivity testing has varied 
over time, but is currently defined as a drop in mPAP of ≥10mmHg, to reach an absolute value of 
≤40mmHg, with no deterioration in cardiac output (18).  The percentage of patients with IPAH who 
exhibit this positive response has differed between studies but is approximately 5-15% of patients 
tested, of whom approximately half display long-term response (72-74). Patients who have a positive 
response at vasoreactivity testing have better outcomes, even when not treated with CCBs (74).  
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Figure 2: The three major pathways targeted by current treatments in pulmonary arterial 
hypertension. Reproduced in print with permission of the rights holder; permission not granted for 
online repository. 
1.1.8.3.2 Nitric oxide pathway 
Nitric oxide (NO) is an important factor in smooth muscle relaxation, and reduced NO production and 
availability is a key feature of endothelial dysfunction (75, 76).  The nitric oxide pathway is targeted by 
phosphodiesterate-5 (PDE-5) inhibitors (tadalafil and sildenafil) and cyclic guanine monophosphate 
stimulators (riociguat).  
1.1.8.3.3 Endothelin pathway 
Endothelin-1 is a potent vasoconstrictor, and targets two receptors ETA and ETB (76, 77). Three specific 
pharmacological endothelin receptor antagonists (ERAs) are currently licensed to target this pathway: 
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bosentan and macitentan are dual endothelin-1 receptor antagonists, whereas ambrisentan targets 
ETA in isolation (78).   
1.1.8.3.4 Prostacyclin pathway 
Prostacyclin is a vasodilator produced by endothelial cells, and deficiency in PAH has been long-
recognised (79). Prostacyclin primarily targets the IP receptor, and in addition to causing 
vasodilatation, appears to reverse some of the vascular remodelling seen in PAH (80-82). Prostanoids 
are administered parenterally, via nebuliser or continuous subcutaneous/intravenous infusion. 
Epoprostenol is a synthetic equivalent of prostacyclin, whereas treprostinil and iloprost are analogues 
(80). Selexipag is an oral selective IP receptor antagonist which has recently been approved for use in 
the UK. 
1.1.8.4 Choice of treatment 
Selection of treatment for patients with PAH may depend on disease severity, comorbidities and 
interaction with other medications. The value of up-front oral combination therapy (typically a PDE-5 
inhibitor and ERA) in patients with PAH was recognised in 2015, and typically now constitutes the 
usual initial treatment strategy for the majority of patients with PAH (83). Patients with very significant 
disease at diagnosis, or those felt to be at high risk of early mortality, may commence immediately on 
prostanoid treatment (18). Funding in the UK limits individual treatment to two concurrent therapies, 
apart from selexipag which may be taken as a third agent, or patients who have been deemed suitable 
for lung or lung/heart transplantation who may take three concurrent treatments (70). 
1.2 Risk Stratification 
1.2.1 Risk Stratification in Medicine 
The concept of risk stratification is long-standing in medicine and its use is widespread. Many 
examples exist, including the Framingham data widely used in the primary prevention of 
cardiovascular risk. The principles apply across a wide range of fields from staging in cancer to 
assessing severity in pneumonia.  
Risk stratification is important as patients with the same disease often have varied outcomes. In a 
clinical setting, the use of risk stratification tools allows clinicians to use a number of parameters and 
variables to more accurately predict outcomes based on specific and individual features. Risk 
stratification tools can therefore be used to assist treatment decisions and inform advanced care 
planning decisions with patients. 
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1.2.2 Introduction to Risk Stratification in PAH 
In IPAH, life expectancy prior to the advent of specific and targeted therapies was very poor with a 
median survival of 2.8 years (84). With the development of treatments such as epoprostenol, 
prognosis and outcomes have improved (85, 86). These targeted treatments primarily act as 
vasodilators and are aimed at reducing pulmonary vascular resistance and preventing right ventricular 
failure.  
It is increasingly understood that patients with PAH are a heterogeneous group and that outcomes 
vary significantly between different phenotypes. While initial treatment may consist of oral 
combination therapy, patients with significant haemodynamic disease or adverse clinical signs may 
require more advanced therapies including nebulised or continuous intravenous treatment. These 
represent significant burden on patients (87). Being able to understand which patients are at highest 
risk of deterioration can guide treatment escalation decisions when considering parenteral treatment, 
and can assist with decisions regarding timing of transplantation. 
When describing patients with PAH, incident refers to those that are newly diagnosed whereas 
prevalent describes those that already have a diagnosis. It is recognised that incident patients have a 
poorer outcome than prevalent patients. The French registry followed 674 patients prospectively for 
3 years, and demonstrated that 3-year survival in incident patients was 51%, compared to 71% in the 
prevalent group (88). 
1.2.3 Initial risk stratification studies in PAH 
The first paper to assess risk in pulmonary hypertension was the National Institute of Health (NIH) 
published in 1991 (84). The registry reports on a relatively small number of patients (n = 194) recruited 
from multiple centres. It is noteworthy that this paper was published before pulmonary hypertension 
was defined beyond primary and secondary disease. In addition, diagnostic techniques in the 
assessment of pulmonary hypertension have evolved; for instance, the incidence of pulmonary 
embolus has increased three-fold between 1985 and 2009, presumably due to advances in imaging, 
which may potentially affect diagnostic certainty in this study (89). Finally, treatment at the time was 
limited to supportive management including diuretics and oxygen at a time when no PAH targeted 
therapy had been approved, resulting in a very poor median survival of 2.8 years. These factors affect 
comparisons of the NIH data with more recent studies.   
The study identified parameters conferring higher risk and derived an equation consisting of three 
variables: mPAP, mean right atrial pressure (RAP), and cardiac index. Although they lacked a validation 
cohort, they identified an equation to predict patient survival at one, two and three-years:  
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P(t) = [H(t)]A(x,y,z) 
H(t) = [0.88 - 0.14t + 0.01t2]  
A(x,y,z) = e(0.007325x + 0.0526y – 0.3275z) 
Where: 
P(t) indicates the patient's chances of survival and t = 1, 2, or 3 years) after diagnosis: 
x = mean pulmonary artery pressure  
y = mean right atrial pressure  
z = cardiac index 
The equation was subsequently validated in a cohort of 61 patients (90). The NIH registry was a 
landmark paper at the time that recognised the importance of right ventricular dysfunction, and has 
been utilised by a large number of clinical trials since when determining the effects of new treatments 
on survival. 
Thenappan et al sought to assess whether the NIH equation remained valid, following the now-
widespread use of PAH specific treatments. They demonstrated in a cohort of 576 patients that the 
equation underestimated life expectancy, which may be multifactorial but likely due in part to 
availability of PAH specific treatments (91). With heightened awareness of the disease compared to 
in 1991, it is also possible that patients were diagnosed earlier, facilitating prompt intervention. 
Thenappan et al proposed an updated equation but, again, they did not validate this (91). 
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1.2.4 Non-modifiable risk 
Non-modifiable risk is an important consideration in PAH; although these factors cannot be improved, 
they still contribute to the risk profile. Increasing age, male sex and family history of PAH have all been 
recognised as predisposing to poorer outcomes. Benza et al demonstrated that patients aged over 60 
had a greater risk of mortality (hazard ratio 1.9), while males aged over 60 had a hazard ratio of 2.78 
(44). While male sex appears to confer a poorer prognosis, PAH registries consistently report a 
significantly higher prevalence of the disease in females, ranging from 58% to 79% (28, 44). 
Genetic association is well-recognised in PAH; approximately 70-80% of patients with a family history 
of PAH are identified as having a mutation in the BMPR2 gene. Increasingly it is recognised that there 
are likely to be a number of other genetic mutations which contribute to the development of PAH 
(92). Benza et al were the first to identify that patients with a family history of PAH had a higher risk 
of early death (44). The reasons for this are uncertain; studies demonstrate that patients with BMPR2 
mutation have more severe haemodynamics, although whether having the mutation directly increases 
the risk of death is unclear, with conflicting findings between studies (44, 93).   
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1.2.5 Survival between different forms of PAH 
In addition to the non-modifiable risk factors outlined above, the specific cause of PAH is also 
important in determining prognosis. In the ASPIRE (Assessing the Spectrum of Pulmonary 
hypertension Identified at a REferral centre) registry, Hurdman et al demonstrated that while survival 
differed between pulmonary hypertension groups 1-4, even within group 1 survival was significantly 
different (94). In a large group of incident patients, those with PAH-CHD with Eisenmenger’s 
physiology lived longer than those with IPAH, and outcomes in PAH due to systemic sclerosis were 
significantly worse (Figure 3). This was also seen in the large, multi-centre French registry (88) which 
identified a number of important factors influencing survival, including the form of PAH, and 
concluded that forms of Group 1 disease other than IPAH (i.e. PAH-CTD, PAH-CHD, porto-pulmonary 
hypertension (PoPH), PAH related to HIV infection) should be separated from IPAH for survival analysis 
in future studies, as this appeared to affect outcomes. Therefore, while group 1 diseases share similar 
pathophysiological characteristics, there are clear differences in outcomes and the need for early 
treatment escalation may vary between the individual causes.  
Figure 3: Kaplan-Meier plot demonstrating survival between different forms of PAH and PH, indicating 
best prognosis in patients with PAH-CHD and worst prognosis in PAH due to systemic sclerosis (PAH-
SSc) Adapted from Hurdman et al (2012). Reproduced with permission of the ERS 2018.  European 
Respiratory Journal 2012 39: 945-955; DOI: 10.1183/09031936.00078411 
1.2.6 Lung disease in the context of IPAH 
Patients with PH due to lung disease have significantly poorer survival than patients with IPAH and 
PAH-CHD (94). Short term survival (less than 3 years) in patients with PH due to chronic lung disease 
(CLD-PH) is also worse than patients with PAH due to systemic sclerosis, although beyond three years 
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survival in CLD-PH is slightly better. Separating patients who have severe PH in the context of lung 
disease into either Group 1 or Group 3 represents a long-standing diagnostic challenge, and such 
patients have often been described as having PH “out of proportion” to lung disease, particularly when 
lung disease is not severe (95). Mild PH in patients with lung disease is common, but severe PH 
(defined as mPAP ≥35mmHg) is rare with a prevalence of approximately 10% (96-99).  
The use of PAH targeted therapy in patients with CLD-PH is controversial and studies have identified 
conflicting results regarding treatment response. Some retrospective studies of patients with non-
severe lung disease but severe PH have reported improved haemodynamics and exercise capacity 
following commencement of PAH therapies (100-102). Conversely, a retrospective registry analysis of 
patients at the Scottish Pulmonary Vascular Unit did not demonstrate an improvement in either 6-
minute walk distance or functional class in 118 patients with varying degrees of lung disease and 
severe PH following the compassionate use of PAH-targeted therapy. Hurdman et al previously 
reported treatment response to PAH targeted therapy in less than 20% of patients with severe CLD-
PH (103). There have also been prospective randomised controlled trials of PAH targeted therapies in 
patients with CLD-PH, but some of these have focused on using echocardiography rather than right 
heart catheterisation to measure pulmonary arterial pressures (104, 105). Other studies have assessed 
response to treatment in patients with only mild PH (106, 107), although a recent prospective study 
by Vitulo et al in a small cohort of patients with CLD-PH due to COPD with severe haemodynamics 
(n=31) showed improvements in pulmonary haemodynamics but not in exercise capacity (108). The 
role of PAH-targeted therapies in patients with chronic lung disease and severe PH remains unclear.  
1.2.7 Exercise assessment in PAH 
Exercise limitation is an early-presenting symptom in PAH, and regular assessment of exercise capacity 
is recommended in the ESC/ERS guidelines (18). Exercise capacity can be assessed by either field 
walking tests or cardiopulmonary exercise testing. The most widely used field walking test is the 6-
minute walking test (6MWT) which, in early studies assessing PAH therapies, was demonstrated to be 
a marker of treatment response (86). Absolute distances are recognised to be prognostic, and 
deterioration of 6-minute walking test distance is strongly associated with poor prognosis (85, 109).  
An alternative field walking test, the incremental shuttle walking test (ISWT), is used in our centre. It 
is used in other forms of cardiac and respiratory disease (110-112) and a number of recent studies 
from other centres have also highlighted its use in pulmonary hypertension (113, 114). Previous 
studies have demonstrated correlation between ISWT distance and haemodynamic parameters at 
right heart catheterisation (RHC) in PAH, and distances at baseline and follow-up predict survival (115). 
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Unlike the 6MWT, the ISWT is a maximal test and does not suffer from a ceiling effect (115, 116). Both 
the 6MWT and ISWT are inexpensive and simple to perform (115, 117, 118). 
Cardiopulmonary exercise testing is regarded as the gold-standard for objective assessment of 
exercise capacity and provides a comprehensive evaluation of multi-organ response to physical effort 
(119). Parameters from CPET are associated with prognosis in PAH but its utility in routine clinical 
practice may be limited by cost, complexity and duration of procedure (120).  
Thresholds for risk stratification for both 6MWT and CPET have been suggested, but no thresholds yet 
exist for the ISWT (18, 26).  
1.2.8 Right Ventricular Function as a Marker of Prognosis 
A common finding amongst risk stratification tools is the use of direct or indirect markers of right 
ventricular function. This provides important prognostic information, and right ventricular failure is 
recognised as the main cause of death in patients with PAH (121). As seen in massive pulmonary 
emboli, the right ventricle is poorly adapted to cope with acute increases in afterload and pressure 
due to its thin wall, however it is able to remodel in response to gradual increases in PVR (122). In 
PAH, patients with similar haemodynamics at baseline often have different outcomes, and it appears 
that how the right ventricle remodels and adapts to increased afterload is crucial (123). The ability to 
accurately assess and monitor right ventricle function at baseline and follow up is an important aspect 
of risk stratification. Right ventricular function may be measured directly using imaging modalities 
such as cardiac MRI or echocardiography, and cardiac output is typically measured invasively at right 
heart catheterisation although may also be assessed at cardiac MRI. Serum biomarkers may also 
provide indirect assessment of right ventricular function.  
1.2.9 Blood biomarkers 
There are a number of circulating serum biomarkers which are of interest in PAH. Natriuretic peptides 
(NPs) are a family of hormones secreted primarily from the heart, kidneys and brain that cause 
vasodilation and natriuresis. These primarily comprise atrial natriuretic peptide (ANP), brain 
natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). Compared to ANP, which is affected 
by temperature and has a short half-life, blood samples containing BNP are more stable and its half-
life is approximately 22 minutes (124-126). N-terminal pro b-type natriuretic peptide (NT-proBNP) has 
an even longer half-life of approximately 70 minutes (126, 127). There has therefore been significant 
interest in BNP and NT-proBNP as clinical biomarkers. 
Nagaya et al were the first group to demonstrate a link between right ventricular afterload and 
elevated levels of BNP, also identifying that it appeared more sensitive than ANP (128). They 
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subsequently demonstrated that elevated serum levels at diagnosis were an independent predictor 
of death in primary pulmonary hypertension, and also that patients with a rise in levels during follow 
up had a worse prognosis (129). Correlation with haemodynamics was confirmed by Leuchte et al who 
demonstrated that BNP levels rise in response to reduced 6MWD, cardiac index and peak VO2 (130).  
As a marker of right ventricular function, levels of BNP and NT-proBNP have been shown to have an 
inverse correlation with right ventricular ejection fraction (RVEF). A small study of patients with PAH 
(n=14) found a moderate inverse correlation between RVEF and BNP (r = -0.54), and RVEF and NT-
proBNP (r = -0.61) (131). In another study of patients with PAH and CTEPH (n=25), a moderate inverse 
correlation (r = -0.66) between RVEF and NT-proBNP was identified (132). In congenital heart disease, 
a study of 21 patients who were either minimally symptomatic or asymptomatic with chronic right 
ventricular pressure overload also found that BNP levels inversely correlated with RVEF (r = -0.65) 
(133). Studies have also assessed response of these biomarkers to treatment in PAH, and changes in 
NT-proBNP have been shown to correlate with changes in metrics taken at cardiac MRI including right 
ventricular end-diastolic volume, right ventricular mass and RVEF (132, 134, 135). Both BNP and NT-
proBNP are now widely used in the routine assessment of patients with PAH and guidelines suggest 
that there is no clear advantage of one over the other (43). Both BNP and NT-proBNP are incorporated 
into widely used risk stratification scores. 
1.2.10 Recent developments in risk score calculators 
It is increasingly recognised that no single marker can accurately prognosticate, and a wide number of 
markers have been proposed as outcome predictors in PAH. In the REVEAL registry, the authors 
identified variables which were associated with increased mortality at one year (26). As well as 
including non-modifiable factors, and underlying cause of PAH, modifiable risk factors were identified. 
A calculator was developed based on the above (Figure 4), although in the development cohort only 
13.5% of patients were newly diagnosed with PAH, whereas the validation group consisted exclusively 
of incident patients. This may have been the cause of significant discordance between baseline 
variables. 
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Figure 4: The REVEAL Risk Calculator. Reproduced from Benza et al (2012) with permission of the rights 
holder, Elsevier. 
The original REVEAL risk score calculator attracted significant attention for a number of reasons, 
particularly as it has been robustly developed through statistical modelling on large population of 
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patients from a number of US centres, and allows risk assessment in all subtypes of PAH. This is in 
contrast to other risk score calculators which are only applicable in certain subtypes of PAH, such as 
IPAH or PAH-CTD. In the REVEAL risk score calculator, this has been facilitated by the addition of points 
for groups which are recognised to be high risk (particularly porto-pulmonary hypertension and 
heritable PAH), although it is important to note that that these comprised relatively small numbers in 
the REVEAL registry: in the validation cohort there were 13 (2.6%) patients with heritable PAH, and 34 
(6.8%) patients with porto-pulmonary hypertension. While comprehensive, the wide range of 
investigations required in the REVEAL risk score calculator may make routine clinical use of this model 
challenging. The calculator does allow for missing data, though it is not suggested how many variables 
may be absent.  
In addition to the REVEAL risk score calculator, there have been further attempts at producing 
accurate prognostic equations. Seeking to design a simple formula, Humbert et al prospectively 
followed 674 patients diagnosed between 2002 and 2003 with PAH for three years, although only 
published their findings in 2010 (88). They identified female sex, increased 6MWD and higher cardiac 
output were predictive of improved outcomes, and developed an equation predicting survival termed 
the French Pulmonary Hypertension Network (FPHN) predictive model.  
In an effort to cross validate both REVEAL and the FPHN predictive models in independent populations, 
each model was applied retrospectively to the opposing population (136). In this study both models 
demonstrated reasonable discrimination: the c-statistic for the REVEAL equation was 0.73, and for the 
French Registry equation was 0.72. In addition, at Kaplan Meier analysis, survival using the REVEAL 
equation in the FPHN population demonstrated similar survival to that predicted by the model. The 
FPHN equation slightly under-estimated survival in the REVEAL population, where outcomes were 
slightly better than expected. This may relate to the time difference between model development and 
assessment in this study (a difference of approximately six years), as treatment regimens may have 
changed significantly over this time period due to the development of novel therapies (137).  
 
1.2.11 REVEAL 2.0 risk score calculator 
An updated version of the REVEAL risk score calculator (REVEAL 2.0) was developed and published in 
2019 (138). In the development of the updated risk assessment tool, patients who had survived at-
least one-year beyond diagnosis were included in the multi-variate model resulting in a number of 
changes to the initial REVEAL calculator. By including patients who had survived to at-least one-year 
beyond diagnosis, Benza et al were able to identify the previously unevaluated and negatively-
prognostic variable of all-cause hospitalisation within the preceding 6 months. Renal insufficiency, 
38 
 
previously a semi-subjective assessment, was updated with an eGFR of <60 ml/min/1.73m2, if 
laboratory data were available, and thresholds were changed for the modifiable variables of BNP/NT-
proBNP, heart rate, 6MWD, PVR and DLco %pred. In addition, the number of points deducted for WHO 
functional class I symptoms was reduced, and the presence of porto-pulmonary hypertension scored 
an additional point. These changes resulted in a minor improvement in the predictive ability of the 
model, increasing the c-statistic from 0.74 (95% CI 0.72-0.76) to 0.76 (95% CI 0.74-0.78).  
At present, only one validation study of the REVEAL 2.0 risk score calculator has been performed, 
which was undertaken in a cohort from the Pulmonary Hypertension Society of Australian and New 
Zealand (PHSANZ). A smaller subset of the entire registry was used, consisting of 1011 mixed incident 
and prevalent patients with greater than 7 variables available for analysis (139).  Demographic data 
for the cohort were comparable to those in the REVEAL 2.0 validation cohort, with a very similar 
proportion of patients with IPAH (47% in PHSANZ vs 46% in REVEAL 2.0) although more patients with 
PAH-CTD (31% in PHSANZ vs 26% in REVEAL 2.0). In addition, the REVEAL 2.0 population was younger 
(mean age 54 vs 58) and had a slightly higher proportion of patients in WHO functional class I (8% vs 
3%) and II (41% vs 39%), while exercise capacity as measured by 6MWD was similar (384m in PHSANZ 
vs 374m in REVEAL 2.0).  
In this external validation, the c-statistic was identical (0.74) to the REVEAL 2.0 cohort and in a three-
tier model of low, intermediate and high-risk there were significant differences for one-year mortality 
levels (2.6%, 8.6% and 25.4%, respectively). 
This retrospective assessment of REVEAL 2.0 supports the validity of the risk score calculator. While 
there were missing data from patients in the study, one of the main strengths of REVEAL 2.0 is its 
development based on a heterogeneous population with only partially-available data, which improves 
its clinical usability in comparison with other risk stratification tools where the validity of such tools in 
the assessment of patients with incomplete data is unclear (140, 141). 
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Figure 5: The REVEAL 2.0 updated risk score calculator. Reprinted without changes from Chest Journal, 
Benza et al, Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score 
calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies, 2019, under the 
Creative Commons open access license agreement (CC BY-NC-ND 4.0) (138) 
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1.2.12 ESC/ERS Risk Stratification 
In 2015, the European Society of Cardiology/European Respiratory Society (ESC/ERS) published 
guidelines for the diagnosis and assessment of patients with pulmonary hypertension (43). These 
guidelines were the first to feature tools for prognostic evaluation and risk stratification. In contrast 
to the REVEAL and REVEAL 2.0 risk score calculators, the prognostic parameters in the ESC/ERS 
guidelines were primarily based on expert opinion. Thresholds were suggested for routinely 
performed investigations at diagnosis and routine reassessment. Recognising that no single factor can 
predict outcome, they identify a goal of achieving a low-risk “profile”. In a different methodology to 
other studies, Galiè et al proposed dividing risk outcomes into three categories based on risk of short 
term mortality, which has since been termed a traffic light assessment: low (<5%), intermediate (5-
10%), and high-risk (>10%) of mortality at one-year (Table 2) (43). This approach does present some 
difficulties: it is unlikely that all of a patient’s variables will fit into one of the risk thresholds, so 
application to individual patients is challenging. In addition, no weighting is given to each individual 
variable, but it is unlikely that they all confer equal risk.  The authors do not provide references for the 
specific thresholds and acknowledge their reliance on expert opinion. To date, three large 
retrospective validation studies have been published and are discussed in further detail. 
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Table 2: Risk stratification model from ESC/ERS guidelines 
Reproduced from Galie et al (2015) with permission of the rights holder, Oxford University Press. 
Reproduced in print with permission of the rights holder; permission not granted for online repository. 
Abbreviations: WHO = World Health Organisation, 6MWD = six-minute walking test distance, NT-
proBNP = N-terminal pro b-type natriuretic peptide, BNP = brain natriuretic peptide, CMR = cardiac 
magnetic resonance, VO2 = oxygen uptake, VE = ventilation, vCO2 = carbon dioxide uptake, RA = right 
atrial, RAP =right atrial pressure, CI = cardiac index, SvO2 =  mixed venous oxygen saturations. 
1.2.12.1 Validation of the ESC/ERS Risk Stratification Tool 
Kylhammar et al attempted to validate the ESC/ERS profile prognostication by retrospective registry 
analysis (142). The Swedish PAH Registry (SPAHR) consisted of 530 patients with Group 1 PAH, enrolled 
between 2008 and 2016. Retrospective registry analysis is often limited to some extent as new 
treatments may become available during the period of follow up which may affect results (137). In 
addition, follow-up regimes are not pre-defined as they are in prospective trials although conversely 
these less-rigid assessments may support the usage of such tools in a “real world” environment. 
Subgroups of IPAH and other forms of PAH were analysed, and variables were assigned a score of 1-3 
based on low, intermediate or high-risk. For individual patients these were summated and divided by 
the number of variables for each patient to provide an averaged or mean overall risk. As already 
identified, this strategy does have obvious weaknesses as it assumes equal weighting between 
variables. In addition, if few variables are available for individual patients then this may cause sampling 
error. In fact, there was no single variable available in all patients, either at baseline or follow up, for 
instance right atrial area was only available in 24% of patients at baseline, and cardiac index was 
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available in 33% at time of follow-up risk assessment. Data are not presented for the per-patient 
availability of variables. Nonetheless, allowing for these data availability issues, the study 
demonstrates that the proposed ESC/ERS profiling strategy accurately predicts risk at both baseline 
and follow-up when assessed in the same cohort of patients. This appeared to be true of IPAH and 
PAH-CTD; data are not given for other subtypes of PAH, but numbers are small which may have limited 
analysis. Of particular importance they successfully demonstrated that achieving a low-risk profile at 
follow-up produced the best outcomes. In clinical practice this may support the use of aggressive early 
treatment.  
Hoeper et al provide the most comprehensive set of data for analysis by the ESC/ERS risk stratification 
(143). They assessed the risk profile in patients entered into the COMPERA registry between 2009 and 
2016, which is a large European registry of patients with PAH. Of the variables and investigation 
modalities listed in the guidelines, a number were not available: history of syncope, history of disease 
progression, echocardiographic results and cardiopulmonary exercise test (CPET) data. In their 
abbreviated analysis, the authors therefore use six variables which were recorded in the COMPERA 
database consisting of WHO FC, 6MWD, either NT-proBNP or BNP, mRAP, cardiac index (CI), and mixed 
venous oxygen saturation (SvO2).  They identified 1588 patients who had at least two variables 
available for analysis, and 82.6% of patients had 5 of the 6 variables recorded at baseline. Using a 
similar methodology to the SPAHR approach, this study also calculated the mean score of available 
variables to assess risk profile and outcomes in patients established as low, intermediate or high-risk 
(142). The population consisted of 1060 (67%) with IPAH, HPAH or drug-associated PAH, 347 (22%) 
patients with PAH-CTD, 70 (4%) patients with PAH-CHD and 111 (7%) patients with other forms of PAH 
(143). 
They demonstrated that, using this approach, the proposed ESC/ERS thresholds effectively stratified 
patients into low (<5%), intermediate (5-10%) and high (>10%) risk of mortality in patients with IPAH, 
HPAH and drug-associated PAH. In PAH-CTD the model was unable to discriminate between low and 
intermediate risk patients but did still identify those at high risk. As found in the studies by Boucly et 
al and Kylhammar et al the survival model appeared to work at both baseline and follow up 
assessment (28, 142). In keeping with the findings from the SPAHR study, this study also identified 
that patients whose risk profile had improved between baseline and follow up had significantly better 
outcomes than those whose risk profiles had not improved.  
Boucly et al (28) applied the ESC/ERS criteria to the French Registry. In contrast to the SPAHR and 
COMPERA approach, they sought to identify specifically how achieving a low-risk profile affected 
outcomes. They used four criteria from the ESC/ERS guidelines: WHO FC, 6MWD, mRAP, and cardiac 
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index. These were assessed in a population of IPAH, heritable PAH and drug associated PAH at baseline 
and follow up (n=1017). The rationale for choosing these criteria is not presented, but presumably 
relates to availability of data. Defining a low-risk profile as consisting of three or four low-risk criteria, 
they identified that patients who had multiple low-risk criteria had better outcomes. Prognosis was 
not affected by which of the three low-risk criteria were present, suggesting that these variables may 
be similarly weighted. Achieving or maintaining a low-risk profile at follow-up conferred a one-year 
mortality risk of 0-1%. Those who had fewer than 3 low-risk criteria at baseline but improved to at 
least 3 criteria at follow-up had similar outcomes to those who maintained a low-risk profile from 
baseline. Patients who had one or more high-risk features and did not have any low-risk variables 
appeared to be compatible with the high-risk profile, with a one-year mortality of 13-30%. 
Intermediate-risk profile was difficult to characterise, which may relate to the large number of 
potential combinations. In a subgroup of patients with data available for WHO FC, 6MWD and either 
BNP or NT-proBNP (n=603), they demonstrated that a non-invasive assessment at follow-up also 
identified groups of patients with different outcomes.  
Subsequently, Hoeper et al sought to identify whether they could replicate the results of the French 
approach,  and applied the French risk assessment methodology to the COMPERA database (28, 141). 
They also demonstrated that having multiple low-risk criteria appeared to predict excellent long-term 
survival: using WHO-FC, 6MWD and BNP/NT-proBNP, they identified that patients with low-risk 
parameters for all three variables had 5-year survival of 95%. The mean age was higher in the 
COMPERA database compared to the French registry (64 vs 57), which may explain why fewer patients 
met three low risk criteria (9% vs 19%). Data from both of these studies assessing the role of non-
invasive parameters in the routine follow-up of patients with PAH suggest that repeated 
haemodynamics are not necessarily routinely required at follow-up although some experts still 
recommend this (144). 
In all of the validation studies, there were missing data when compared to the published ESC/ERS risk 
table. This is likely to be ubiquitous through all units and registries as clinician approach to 
investigation and management will differ based on experience and availability of investigations. 
Nonetheless these studies do demonstrate that even abbreviated scores using data obtained in 
routine clinical practice could effectively risk stratify patients.  
There are a number of shortcomings shared by the ESC/ERS risk stratification tool and subsequent 
validation attempts. The risk assessment tool is primarily based on expert opinion, whereas ideally 
variables and parameters should be produced from a large and varied derivation cohort and undergo 
subsequent validation. None of the validation studies examined prevalent cohorts, although risk 
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profiles were reassessed in the same patient cohort at follow-up. All of the validation studies 
demonstrated good discrimination between patients at low and high-risk, but the large percentage of 
patients categorised as intermediate risk (70% in Hoeper et al and 67% in Kylhammar et al) and the 
inability of the model to discriminate well in this group suggests that further work is required in order 
to refine current risk stratification approaches (142, 143).  
1.2.13 The Role of Imaging in Risk Stratification 
As a modality, imaging is included in both the ESC/ERS guidelines and the REVEAL 2.0 risk score 
calculator, however it is limited to the detection of pericardial effusion (included in both risk 
assessment tools) and measurement of right atrial area (included only in the ESC/ERS guidelines). 
Neither pericardial effusion nor right atrial area has been included as a variable in any of the ESC/ERS 
validation studies. In addition, the data upon which inclusion of right atrial area was presumably based 
are relatively small, and the prognostic nature of this variable in addition to other risk stratification 
parameters is therefore unclear (56, 145). In both REVEAL 2.0 and the ESC/ERS the focus of risk 
assessment is upon the use of echocardiography, rather than more detailed metrics taken from 
cardiac MRI. 
A number of studies have evaluated the role of cardiac MRI in PAH. As outlined previously, right 
ventricular function is an important prognostic marker, and deteriorating function strongly correlates 
with mortality in PAH. While echocardiogram remains the most commonly used investigation, cardiac 
MRI is now recognised as the gold standard in the assessment of right ventricular dimensions and 
function, even in congenital heart disease (146, 147). It has significantly better reproducibility than 
echocardiography making it potentially valuable in serial assessments. It also allows for a more 
comprehensive assessment of cardiac morphology than any other imaging modality, allowing 
measurement of blood flow, assessment of regurgitant valves and determination of systolic function 
without any restrictions relating to acoustic windows (147). As a research tool in the context of 
assessing novel treatments, the improved precision of cardiac MRI over echocardiography may mean 
that sample sizes in randomised control trials can be smaller, reducing the cost of developing new 
treatments (148). As an assessment in PAH, echocardiography is particularly limited by complex right 
ventricular structure and geometry (149), although some studies have shown a good correlation 
between assessment of right ventricular ejection fraction on cardiac MRI and markers of right 
ventricular function using echocardiography, including right ventricular fractional area change, which 
in one study of 36 patients with a spectrum of non-PAH disorders had a correlation coefficient of 0.8 
(149).  
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A wide range of measurements can be taken at cardiac MRI, and a number of these have been 
proposed as important prognostic markers in PAH. As a cardiac MRI metric, right ventricular ejection 
fraction has received the most attention. This may in part be due to conceptual familiarity, given the 
widespread use of left ventricular ejection fraction in the cardiology community. In a multi-centre, 
heterogeneous cohort consisting of patients with PAH, CTEPH and PH due to lung disease, the EURO-
MR study identified that RVEF significantly improved following the commencement of PAH targeted 
therapy (150). In a large study of 110 patients with PAH, an RVEF <35% was predictive of a poorer 
prognosis (151). Despite familiarity with RVEF, a number of other cardiac MRI biomarkers have been 
proposed. 
Right ventricular stroke volume is an important marker in PAH and preserved stroke volume suggests 
that the right ventricle is able to cope with the increased afterload experienced in PAH. Reduced stroke 
volume has been associated with a high-risk of mortality (152, 153). In addition to its use as an isolated 
measurement, stroke volume may be used to estimate RV-PA coupling. Coupling is defined as the 
matching between right ventricular contractility and PA afterload, and has traditionally been 
calculated using pressure-volume loops and measurements of elastance from cardiac catheterisation 
(154). Such procedures are invasive, complicated and require conductance catheters, and increasingly 
it is recognised that coupling can be estimated from measurements obtained non-invasively, using 
stroke volume and end-systolic volume (155). In some studies these non-invasive measurements have 
been strongly associated with mortality, although other studies in larger cohorts have failed to show 
that coupling measurements have prognostic significance over simpler volumetric measurements 
(156, 157). 
In a large study of patients with Group 1 PAH, Swift et al identified that volumetric measurements and 
measures of pulmonary arterial stiffness appeared to provide important prognostic value and 
specifically found that measurements of right ventricular volume and pulmonary artery relative area 
change were identified as strongly prognostic markers (157). An indexed right ventricular end-systolic 
volume has been identified as prognostic in a number of studies, although volumetric measurements 
of the left ventricle are also prognostic as it may become compressed in severe PAH by an enlarged 
right ventricle  (151, 157). A dilated right ventricle is also prognostic in patients with left ventricular 
failure (158). 
While raw MRI measurements can be useful, cardiac volumes are affected by age and sex and 
therefore adjusting MRI measurements for age and sex (expressed as percent predicted), and indexing 
for body surface area is recommended (159, 160). These corrected measurements are less convenient 
from a clinical perspective as adjusting for age, sex and body surface area is time consuming. This may 
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make calculated values less clinically useful, although some MRI software packages may be able to 
undertake these calculations automatically.  
Nonetheless, there are some limitations with cardiac MRI and it remains an unsuitable imaging 
modality for some patients. Claustrophobia causes premature termination of scans in around 1-2% of 
patients (161, 162). Some patients are unable to undergo MRI due to metallic implants and devices 
such as pacemakers, which is an issue in the increasingly elderly and comorbid PAH population, 
although MRI conditional pacing systems may be fitted in patients in whom regular cardiac MRI follow-
up is anticipated (163). Cardiac MRI is also a more expensive investigation than echocardiography 
(164). Furthermore, a range of MRI scanners and software packages are in use throughout hospitals 
and different sequences and protocols are used which may affect the reproducibility of measurements 
between difference centres. Standardising protocols between different centres would establish 
clinician confidence in this imaging technique and further encourage the uptake of cardiac MRI. In 
addition, normal values are not universally accepted for cardiac MRI parameters and different sets of 
normative data are available. 
The ESC/ERS guidelines suggest repeated right heart catheterisation to assess haemodynamic 
parameters during follow-up in order to accurately prognosticate, however this is an invasive and 
resource-intensive procedure. Given the prognostic nature of cardiac MRI there is potential to non-
invasively risk stratify patients at follow-up using the gold-standard measure of right ventricular 
function. There have, however, not been any direct studies to assess patient tolerance of cardiac MRI 
compared to right heart catheterisation and it is possible that some patients may prefer invasive 
rather than non-invasive follow-up, although it is likely that this represents a minority. The ability to 
non-invasively monitor the right ventricle over time and stratify by prognostic markers is therefore 
likely to be beneficial in PAH, but no study has yet looked at identifying predictive thresholds from 
candidate markers at cardiac MRI. For instance, it may be possible to identify thresholds for markers 
of right ventricular function or other cardiac MRI metrics that stratify patients into low, intermediate 
and high-risk of mortality in a similar manner to the ESC/ERS guidelines.  
The reasons behind the current absence of cardiac MRI thresholds from existing risk stratification 
models are likely multi-factorial and relate to cost, availability, lack of widespread use and absence of 
thresholds for mortality. Nonetheless, it is well recognised to have a high degree of reproducibility 
and is validated for serial assessment of right ventricular function and, given the importance of right 
ventricular function in the prognosis of patient with PAH, further investigation into whether it can be 
used in risk-stratification is warranted (165). Cardiac MRI is potentially well-placed to form an integral 
part of risk assessment in patients with PAH, either as an individual test or as part of a wider algorithm. 
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1.3 Conclusion and Hypothesis  
Comprehensive risk stratification is essential in pulmonary arterial hypertension due to the 
heterogeneity and varied course of the disease. While a number of attempts have been made to 
produce accurate modelling, these risk stratification tools provide modest predictive accuracy and 
often identify large cohorts of patients at intermediate risk in whom the optimal treatment strategy 
is unclear. There remains scope for further improvement upon current risk stratification approaches. 
Parameters at right heart catheterisation have been demonstrated as useful in prognostication, but 
the resource intensity and invasive nature of the test make this an unappealing investigation to 
undertake regularly during routine follow-up. The ideal risk stratification approach would primarily 
use non-invasive investigations, be accurate in incident and prevalent populations, and would be able 
to better delineate those patients at intermediate risk.   
The presence of specific clinical phenotypes in patients with pulmonary hypertension, such as the 
presence of lung disease, also has a significant effect on outcomes and this should also be considered 
when assessing patients with pulmonary hypertension. 
The overall hypothesis of this project is that non-invasive assessment of patients with pulmonary 
hypertension can identify distinct phenotypes and improve risk stratification. 
Objectives 
• To determine whether comorbid lung disease in patients with IPAH affects the risk profile  
• To establish whether a threshold approach can be used for cardiac MRI and the incremental 
shuttle walking test to risk stratify patients with pulmonary arterial hypertension and assess 
their role in conjunction with other risk stratification tools 
• To assess the role of health-related quality of life scoring as a prognostic tool in pulmonary 
arterial hypertension 
• To assess whether improvements in maximal exercise capacity predict outcome in patients 
with pulmonary arterial hypertension 
Whilst exploring relevant phenotypes it became apparent that the clinical phenotype of patients with 
partial anomalous pulmonary venous drainage had not been characterised and may have a bearing on 
outcomes. A preliminary evaluation of these patients was therefore performed and is included in this 
thesis. 
1.4 Format of thesis 
This thesis constitutes an “alternative format thesis” and consists of a literature review followed by 
five papers, which are either already published or submitted to journals for consideration of 
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publication, and these are followed by a summary discussion. In each of the five papers I have been 
the primary contributor.  
In chapter 3, I designed the study in conjunction with the corresponding author, retrieved all data 
from clinical records and databases, performed radiological measurements on CT imaging, undertook 
all statistical analysis, wrote the first draft of the paper and, following suggestions from co-authors, 
wrote the final paper with input from the corresponding author. 
In chapter 4, I designed the study in conjunction with the corresponding author, retrieved all data 
from clinical records and databases, in conjunction with others reviewed clinical notes to assess extent 
of lung disease, undertook all statistical analysis, wrote the first draft of the paper and, following 
suggestions from co-authors, wrote the final paper with input from the corresponding author. 
In chapter 5, I designed the study in conjunction with the corresponding author, retrieved all data 
from clinical records and databases, undertook the vast majority of statistical analysis (the LOESS 
regression was performed by a statistician), wrote the first draft of the paper and, following 
suggestions from co-authors, wrote the final paper with input from the corresponding author. 
In chapter 6, I designed the study in conjunction with the corresponding author, retrieved all data 
from clinical records and databases, undertook all statistical, wrote the first draft of the paper and, 
following suggestions from co-authors, wrote the final paper with input from the corresponding 
author. 
In chapter 7, I designed the study in conjunction with the corresponding author, retrieved all of the 
SPVDU data from clinical records and databases and collated all data provided by other centres in a 
variety of formats, undertook all statistical analysis, wrote the first draft of the paper and, following 
suggestions from co-authors, wrote the final paper with input from the corresponding author. 
The papers are presented in the format in which they were submitted to the journals, apart from 




2. Methods  
2.1 Introduction 
Pulmonary arterial hypertension is a rare disease. For adults in the United Kingdom, management and 
treatment of this condition is limited to the National Pulmonary Hypertension Service, which consists 
of eight specialist centres. The Sheffield Pulmonary Vascular Disease Unit (SPVDU) investigates and 
treats patients from a wide area consisting of North Wales, the Midlands, Manchester, Liverpool, the 
North West, Lincolnshire and Yorkshire. It is the largest pulmonary hypertension referral centre in the 
UK, and one of the largest individual centres in the world, with a catchment population of 15 million 
(166). This provides SPVDU with a large volume of data for a relatively rare disease.  
Patients who are newly referred are usually seen in an outpatient clinic initially to determine the 
likelihood of pulmonary hypertension. Based on the clinical features, assessment of previous imaging 
and usually with the results of an echocardiogram, patients are brought back as a day-case for further 
assessment. At this time patients undergo multi-modality assessment to determine the severity of 
pulmonary hypertension and any likely underlying cause. Typical investigations include 
electrocardiogram (ECG), lung function testing, exercise testing in the form of incremental shuttle 
walking test (ISWT), computed tomography (CT) imaging of the chest (usually contrast-enhanced), 
cardiac MRI (and magnetic resonance angiography (MRA) if chronic thrombo-embolic pulmonary 
hypertension is suspected), isotope perfusion lung scan (Q scan) and right heart catheterisation. 
Patients are evaluated by a consultant clinician, and all new diagnoses are discussed in the pulmonary 
vascular multidisciplinary team (MDT) meeting to ensure a standardised diagnosis. 
Patients without pulmonary hypertension, or those in whom pulmonary hypertension is due to lung 
disease or left heart disease (and as such will not benefit from targeted pulmonary vasodilator 
therapy), are discharged from further follow-up. Patients with pulmonary arterial hypertension are 
commenced on appropriate treatment and kept under regular follow-up. Patients with chronic 
thrombo-embolic pulmonary hypertension are referred to the national pulmonary endarterectomy 
service at Royal Papworth Hospital for an assessment as to whether surgery is appropriate, and are 
commenced on treatment if necessary. Those who are not suitable for surgical intervention are usually 
commenced on treatment and kept under regular follow-up. Those who undergo surgery are usually 




2.1.1 Follow up 
Follow-up appointments consist of subjective and objective assessment of pulmonary vascular status, 
including a patient-reported outcome measure (PROM) to assess symptom burden (emPHasis-10 
score), a clinician assessment of symptom burden (WHO Functional Class), a measure of exercise 
capacity in the form of ISWT, and an assessment of right ventricular function. This is typically 
undertaken by NT-proBNP testing, but this has only recently become accessible for clinical use, and 
results are not available for the patient population under assessment in this study. An alternative 
measure of right ventricular function is cardiac MRI, which in this study has been the primary 
investigation used for follow-up assessment of right ventricular function. Cardiac MRI is a time-
consuming and expensive investigation and access is therefore limited. In our centre it is used 
routinely in the follow-up assessment of patients with idiopathic PAH, and patients typically undergo 
serial assessment every one to two years. It is also used in patients who are suspected to have had 
clinical deterioration, or where the cause of clinical deterioration is unclear and warrants direct 
assessment of right ventricular function.  
2.1.2 Investigations and assessments 
2.1.2.1 Database interrogation and data integration 
Data from baseline and follow-up investigations are stored electronically. A number of different 
computer database packages are in use in our centre. Most clinical data are stored on the Infoflex 
system, which records patient demographics, diagnosis data and results from the majority of 
investigations. Mortality data were obtained from the NHS Personal Demographics Service which is 
linked to Infoflex. Some older data (pre 2012) from the respiratory function unit consisting lung 
function and exercise testing are stored on a separate clinical database called ArQ, and some data 
were taken from the ASPIRE database. Blood test results were downloaded from Sunquest ICE. All 
clinically sensitive information was accessed on secured NHS computers and de-identified. Data from 
these sources were then combined, primarily using Microsoft Excel, and subsequently exported to 
SPSS for analysis. 
2.1.2.1 Statistical analysis 
Statistical analysis was performed using SPSS (IBM) v25 and v26, GraphPad Prism v8 and R software. 
Unless otherwise specified, all statistical analysis was performed by RL and statistical advice was 
sought, where required, from experienced statisticians at the University of Sheffield. Figures were 
developed in SPSS, GraphPad Prism and Adobe Illustrator 2019. Continuous data were typically 
presented as either mean ± standard deviation for normally-distributed data, or median (first quartile, 
third quartile) for non-parametric data. Comparison between groups was performed using paired or 
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unpaired T-Tests for normally-distributed data, and Mann-Whitney or Wilcoxon signed rank test for 
non-parametric data. Categorical data were compared using χ2.  
Multivariate analysis was performed in a forward step-wise direction on variables with a p value <0.2 
at univariate analysis. For all other statistical tests, a p value <0.05 was considered statistically 
significant.  
A number of census dates were used and these are described in the individual chapters. 
2.1.2.1.1 Specific statistical methods in chapter 4 
In chapter 4, several options were considered to identify thresholds for cardiac MRI parameters. One 
of the challenges of using cardiac MRI imaging in patients with PAH is the absence of studies that 
identify thresholds for specific metrics that could be used in clinical practice to risk stratify patients 
with PAH according to the ESC/ERS guidelines. For other non-MRI metrics used to risk stratify patients 
using this guideline approach, arbitrary thresholds were established based on expert opinion. 
Subsequent studies then assessed these arbitrary thresholds. Based on the absence of expert opinion 
or consensus regarding specific MRI thresholds for risk stratification, the purpose of this study was to 
establish thresholds in a discovery cohort and assess the performance of these thresholds in a test 
cohort.  
Based on the number of patients in this study and the number of events, and following statistical 
advice1, it was felt that using five groups to establish thresholds in the discovery cohort was preferable 
to 10 groups.  In the discovery cohort, patients were divided into five groups: subjects were ranked in 
ascending order for each variable, and split into quintile groups with an equal number of patients in 
each group. Mortality was analysed in each quintile group. Where contiguous groups shared the same 
risk level (<5%, 5-10%, >10%) these were combined, reducing the number of thresholds to either one 
or two, thereby creating two or three categories of risk. 
To provide a confirmatory assessment of thresholds a locally weighted estimated scatterplot 
smoothing (LOESS) regression was undertaken2. 
 
 
1 Statistical advice was provided by Kathleen Baster and Pete Laud, School of Mathematics and Statistics, 
University of Sheffield 
2 The R code for LOESS regression curves was provided by Pete Laud, School of Mathematics and Statistics, 




2.1.2.2 Quality of life scores 
Quality of life and patient-reported outcome measures (PROMs) are increasingly recognised as an 
important assessment in PAH (167). Three PAH-specific PROMs exist: the Cambridge Pulmonary 
Hypertension Outcome Review (CAMPHOR), the Pulmonary Arterial Hypertension-Symptoms and 
Impact (PAH-SYMPACT), and emPHasis-10. Since 2014, all centres in the UK record regular patient-
reported quality of life scores and in our unit emPHasis-10 scores are recorded at each visit.  
2.1.2.3 Pulmonary function testing 
Spirometry and lung function tests were performed at, or prior to, diagnosis in a dedicated laboratory 
on the pulmonary vascular unit by respiratory physiologists.  
2.1.2.4 Incremental Shuttle Walking Test 
The incremental shuttle walking test (ISWT) is a field walking test used to objectively measure exercise 
capacity in respiratory disease. The ISWT was performed as described by Singh et al (168). Patients 
walk between two cones placed 9m apart, with 0.5m allowed at each end for turning (Figure 6). The 
total distance of 10m is termed one shuttle. There are 12 levels in total, with an increasing number of 
shuttles in each level. Patients are required to keep up with an external pacer beep, which starts off 
slowly. Initially patients have 20 seconds to complete a shuttle (a required speed of 0.5m/s), but this 
speed increases every level. The test is discontinued when the patient it unable to keep up with the 
required pace or when they become too breathless to continue. It is possible to complete the test, 







Figure 6: Layout of the incremental shuttle walking test 
 
2.1.2.5 Computed tomography (CT) scans 
Patients who are assessed for pulmonary hypertension usually undergo contrast-enhanced CT scans. 
These scans provide important information on features of pulmonary hypertension including 





size and evidence of interventricular septal deviation (169). In addition, CT scans allow assessment of 
lung parenchyma, exclusion of thrombo-embolic disease and assessment of pulmonary venous 
drainage and interatrial communications (170).  
2.1.2.1 Right heart catheterisation 
Cardiac catheterisation was performed by experienced operators using a balloon-tipped 7.5 Fr 
thermodilution catheter, with the patient in the supine position. Catheters were inserted under sterile 
conditions using ultrasound guidance, and were positioned using fluoroscopy. Cardiac output was 
measured by the thermodilution technique. Where appropriate, a vasodilator challenge was 
performed using inhaled nitric oxide to assess for vasoreactivity. A positive vasodilator response was 
defined as a drop in mPAP by ≥10mmHg to a value ≤40mmHg without a fall in cardiac output (46).  
2.1.2.2 Cardiac MRI and image acquisition 
Cardiac cine MRI was performed on a 1.5T GE HDx MRI scanner using an 8 channel receiver array and 
multi-slice balanced steady state imaging with retrospective gating (20 frames/cardiac cycle; slice 
thickness 8 mm; field of view 48; matrix 256 x 256; band width 125 kHz/pixel; repetition time/echo 
time TR/TE, 3.7/1.6 ms). A stack of images in the short-axis plane with slice thickness of 8 mm, 2mm 
inter-slice distance) were acquired covering both ventricles from base to apex. End-systole was 
considered to be the smallest cavity area. End-diastole was defined as the first cine phase of the R-
wave triggered acquisition or largest volume. 
 
Image analysis was performed by operators blinded to diagnosis and cardiac catheter result. 
Endocardial and epicardial surfaces were manually traced on short axis imaging to obtain end-systolic 
and end-diastolic volumes for the right ventricle (RVESV, RVEDV) and left ventricle (LVESV, LVEDV); 
Figure 7. Trabeculations for the chambers were not separately traced, and were included as part of 
the volume cavity measurement (171). Right ventricular ejection fraction (RVEF) was calculated from 
these volume measurements as previously described (157). Volumes were indexed for body surface 
area (RVESVi, RVEDVi, LVESVi, LVEDVi), and then corrected for age and sex and displayed as percent-
predicted (%pred), as previously described (159). Ventricular mass index was calculated as right 
ventricular mass divided by left ventricular mass (172). Pulmonary artery relative area change (RAC) 
was measured on the magnitude images of phase contrast images and was calculated as (maximum 
pulmonary arterial area – minimal pulmonary arterial area)/minimal pulmonary arterial area. Phase 
contrast imaging parameters were as follows: repetition time TR/TE 5.6/2.7 ms; slice thickness 10 mm; 
field of view 48 cm, bandwidth 62.5 kHz; matrix 256 3128; 40 reconstructed cardiac phases; and 
velocity encoding of flow 150 cm/s. Patients were in the supine position with a surface coil and with 





Figure 7: Contouring of cardiac border at MRI during diastole. Blue and yellow contours: RV epicardial 
and endocardial surfaces. Green and red contours: LV epicardial and endocardial surfaces 
 
2.1.2.3 Ethical approval 
Ethical approval for individual projects and for use of the ASPIRE database was granted by Sheffield 
Teaching Hospitals NHS Foundation Trust (STH 14169), and was approved by the NHS Research Ethics 
Committee (16/YH/0352).  In chapter 7 ethical approval was granted by the Health Research Authority 
(HRA). Specific NHS research ethics was not required as data from all centres were de-identified prior 
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Introduction. There are limited data regarding patients with partial anomalous pulmonary venous 
drainage (PAPVD) with suspected and diagnosed pulmonary hypertension (PH).  
Methods. Patients with PAPVD presenting to a large PH referral centre during 2007-17 were identified 
from the ASPIRE registry.  
Results. Ninety patients with PAPVD were identified; this was newly diagnosed at our unit in 71 (78%) 
despite 69% of these having previously undergone computed tomography. Sixty-seven percent had a 
single right superior and 23% a single left superior anomalous vein. Patients with a sinus venosus atrial 
septal defect (SV-ASD) had a significantly larger right ventricular area, pulmonary artery and left-to-
right shunt and a higher %predicted DLco (p all <0.05). Sixty-five patients were diagnosed with PH 
(defined as mean pulmonary arterial pressure ≥25mmHg), which was post-capillary in 24 (37%). No 
additional causes of PH were identified in 28 patients; 17 of these (26% of those patients with PH) had 
a pulmonary vascular resistance >3 WU. Seven of these patients had isolated PAPVD, 5 of whom (8% 
of those patients with PH) had anomalous drainage of a single pulmonary vein. 
Conclusion. Undiagnosed PAPVD +/- ASD may be present in patients with suspected PH; cross-
sectional imaging should therefore be specifically assessed whenever this diagnosis is considered. 
Radiological and physiological markers of left-to-right shunt are higher in patients with an associated 
SV-ASD. Although many patients with PAPVD and PH may have other potential causes of PH, a 









Anomalous pulmonary venous drainage (APVD) describes a pattern where one of more of the 
pulmonary veins do not drain into the left atrium but instead are connected to the right atrium, 
superior or inferior vena cava, azygous vein, coronary sinus or brachiocephalic vein. The prevalence 
of APVD in adults was found to be 0.1% in a large study involving 45,538 consecutive thoracic 
computed tomography (CT) scans (173). 
Total APVD presents early in life with neonatal distress and circulatory compromise. Partial anomalous 
pulmonary venous drainage (PAPVD) may present later in life due to symptoms related to a volume-
loaded right ventricle (as a result of left to right shunting, L-R) or subsequent development of 
pulmonary arterial hypertension (PAH) (18, 174). Alternatively, patients may remain asymptomatic 
and PAPVD be diagnosed incidentally. PAPVD is commonly associated with other congenital heart 
defects, particularly sinus venosus atrial septal defects (SV-ASD) (175-178). Once diagnosed, 
management of patients with PAPVD may involve surgical correction, may be conservative or may 
involve medical therapy (174). 
Due to right ventricular dilatation resulting from left-to-right shunting and/or the development of 
pulmonary hypertension (PH), patients with PAPVD may present to PH referral centres but there are 
few published data regarding patients with suspected or proven PH and co-existing APVD. We 
therefore performed a study to assess patients with PAPVD presenting to a large PH referral centre 
over a ten-year period. 
 
3.3 Methods 
Records for all patients seen at a large PH referral centre between 2007 and 2017 were assessed for 
evidence of APVD. Hospital databases, including the ASPIRE (Assessing the Spectrum of Pulmonary 
hypertension Identified at a REferral centre) registry and electronic medical records, were 
interrogated for keywords including “anomalous”, “pulmonary venous drainage”, “pulmonary venous 
return”, “scimitar” and “sinus venosus”. Patients who had undergone corrective surgery for PAPVD 
prior to being seen were excluded, as were those whose cases had been referred or discussed, but 
not formally seen at our centre. Data regarding associated structural abnormalities, comorbidities, 
pulmonary haemodynamics and mortality status at the census date of 31st May 2017 were collected. 
Pulmonary venous anatomy had been assessed on CT imaging (contrast-enhanced in 88 patients). 
Cardiac chamber area, pulmonary arterial and aortic diameter were subsequently measured by one 
author (RL), blinded to clinical details. Cardiac magnetic resonance imaging had been performed in a 
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proportion of patients; pulmonary to systemic shunt assessments (Qp:Qs) derived from phase 
contrast flow measurements were retrieved. Spirometry was available for 97% and percent-predicted 
diffusing capacity for carbon monoxide (DLco %pred) for 89% of patients. At cardiac catheterisation, 
cardiac output was measured by thermodilution. Pulmonary hypertension was defined as mPAP 
≥25mmHg, in keeping with the definition at the time of study enrolment. 
Patients with uncorrected PAPVD who had undergone corrective surgery for an atrial septal defect 
(ASD) were included in the study but were excluded from comparison against patients with isolated 
PAPVD. Regional adult congenital heart disease (ACHD) centres were contacted to establish whether 
patients seen at our centre had subsequently received any surgical intervention for PAPVD or ASD.  
Statistical analysis was performed using SPSS v25 (IBM) and GraphPad Prism v8. Continuous data were 
presented with mean ± standard deviation. Comparison between groups was performed using the 
unpaired T-test and response to treatment using the paired T-test. A p-value of <0.05 was considered 
significant. 
Approval by the relevant ethics committee was sought and gained (STH14169, NHS Research Ethics 




Ninety patients with PAPVD were identified from our departmental databases. Demographics and 
haemodynamic and radiological data are displayed in Table 3. Hemodynamic data are displayed 




Table 3: Baseline Demographics 
 
 
WHO = World Health Organisation. FEV1 = Forced expiratory volume in 1 second, FVC = forced vital 
capacity, DLco = diffusion capacity for carbon monoxide, ISWD – incremental shuttle walking test 
distance.Haemodynamics measured at right heart catheterisation: mRAP = mean right atrial pressure, 
mPAP = mean pulmonary arterial pressure, PAWP = pulmonary arterial wedge pressure, CO = cardiac 
output, CI = cardiac index, PVR = pulmonary vascular resistance, PVRi = pulmonary vascular resistance 
indexed for body surface area, PA = pulmonary arterial 
  
Age (years) 60.4 ±15.2 
Gender (%female) 70 
WHO Functional Class I/II/III/IV (%) 0/24/68/8 
Lung Function  
 FEV1 (%pred) 70.4 ±20.5 
 FVC (%pred) 85.0 ±22.4 
 FEV1/FVC (%) 68.3 ±11.4 
 DLco %pred 73.5 ±23.6 
 ISWD (m) 227 ±166 
Haemodynamics  
 mRAP (mmHg) 11 ±7 
 mPAP (mmHg) 39 ±15 
 PAWP  (mmHg) 14.0  ±7.0 
 CO (L/min) 5.9 ±1.9 
 CI (L/min/m2) 3.2 ±0.9 
 PVR (WU) 4.8 ±3.8 
 PVRi (WU.m2) 8.4 ±6.3 
 PA saturations (%) 78 ±8 
Anatomical Defect (%)  
 Right superior vein 66.7 
 Total right 4.4 
 Left superior vein 23.4 
 Right and left superior vein 4.4 





Figure 8: Scatter plot demonstrating haemodynamic parameters for patients with PAPVD, categorised 
by PAWP ≤15 mmHg (circle) and >15mmHg (x). 
Abbreviations: PVR = pulmonary vascular resistance; mPAP = mean pulmonary arterial pressure; PAWP 




Pulmonary venous anatomy 
Seventy-one patients (79%) were newly diagnosed with PAPVD following review at the unit; 49 of 
these 71 patients (69%) had previously undergone contrast-enhanced CT locally where the anomalous 
venous drainage had not been appreciated. A SV-ASD was visible on cross-sectional imaging in 31 
patients (34%); the SV-ASD had not been previously diagnosed in 25 (81%) of these (Figure 9). PAPVD 
was isolated (i.e. there was no evidence of an associated ASD) in 47 patients. Six further patients had 
previously undergone ASD repair but still had PAPVD. 
The majority of patients had abnormal drainage limited to the right superior vein (n=60; 67%, Table 
3). Of these, 44 had isolated right upper lobe abnormal drainage while 16 had combined right upper 
and middle lobe abnormalities. Twenty-one patients (23%) had an isolated left superior vein anomaly. 
Five patients (6%) had anomalous connection of an entire lung; the right lung was affected in 4 
patients, and the left lung in 1 patient. 
 
Pulmonary Haemodynamics 
Eighty patients (89%) underwent right heart catheterisation (RHC) and 64 (79% of those undergoing 
RHC) were found to have PH as defined at the time of study enrolment by a mean pulmonary arterial 
pressure (mPAP) ≥25mmHg. A further patient with Eisenmenger physiology did not undergo RHC.  PH 
was post-capillary (as defined by a pulmonary arterial wedge pressure (PAWP) >15mmHg) in 24 (37%) 
patients.  
Measurement of pressure in the wedged position of the pulmonary artery supplying lung with 
anomalous venous drainage will actually measure right atrial pressure. As the lobe in which the PAWP 
was measured was not recorded at the time of catheterisation we therefore compared the left atrial 
(LA) area, measured on CT, of those with a PAWP of ≤15 mmHg and >15 mmHg. LA area was 






Figure 9: Flow chart demonstrating frequency of SV-ASD and haemodynamic parameters in patients 
with PAPVD. 
Abbreviations: PAPVD = partial anomalous pulmonary venous drainage; SV-ASD = sinus venosus atrial 
septal defect; mPAP = mean pulmonary arterial pressure; PAWP = pulmonary arterial wedge pressure; 






Cardiac chamber measurements for patients who had isolated PAPVD compared with those with an 
associated ASD are displayed in Table 4. Patients with isolated PAPVD had a smaller right ventricular 
area (31.6cm2 vs 38.6cm2; p=0.001).  There was no significant difference for left atrial area (22.8cm2 
vs 22.9cm2) or right atrial area (30.8cm2 vs 33.0cm2 respectively) between the two groups. Patients 
with an associated ASD did, however, have a larger pulmonary artery diameter (3.9cm vs 3.4cm, 
p=0.003). Right atrial, right ventricular (RV) and LA areas were larger in patients with an elevated 




Qp:Qs as assessed by flow measurements at cardiac MRI, performed in 43 patients, was significantly 
higher in patients with an associated SV-ASD compared to those without (2.2:1 vs 1.5:1; p=0.006). 
Percent-predicted DLco was significantly higher in patients with an associated SV-ASD (81% vs 67%; 
p<0.05). There was no significant difference in cardiac MRI-derived Qp:Qs between those patients 
with a normal versus an elevated PAWP. 
 
Single versus multiple anomalous pulmonary venous drainage 
In those with isolated PAPVD, both Qp:Qs measured at cardiac MRI and DLco %pred were higher (1.8:1 
vs 1.3:1 and 83% vs 63%, respectively, p both <0.05) in those with anomalous pulmonary veins draining 
>1 lobe. A mPAP ≥25 mmHg was observed in 27 patients with isolated anomalous drainage of a single 
pulmonary vein. Of these patients, 17 (63%) had a PVR >3 WU.   
 
Comorbidities 
Additional possible causes of PH were present in 37 out of the 65 patients with PH (57%): elevated left 
atrial pressure (n=18), significant lung disease (n=8), combined elevated left atrial pressure and lung 
disease (n=4), chronic thromboembolic disease (n=4), cirrhosis (n=2) and hereditary haemorrhagic 
telangiectasia (n=1). One patient with chronic thromboembolic disease and one patient with cirrhosis 
also had an elevated PAWP. No additional causes of PH were identified in 28 patients (43%). Seventeen 
of these 28 patients (26% of those patients with PH) had a PVR >3 WU. Seven (11% of those with PH) 
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of these patients had isolated PAPVD, 5 of whom (8% of those patients with PH) had anomalous 
drainage of a single pulmonary vein. 
 
Follow-up and outcomes 
By the census date, 16 patients (18%) had died. Fifteen patients were already known to congenital 
heart disease units prior to being seen at our centre. Fifty-three patients were subsequently referred 
by ourselves to regional adult congenital heart disease centres for assessment for re-routing of 
anomalous pulmonary veins and/or closure of ASDs. Fifteen patients were identified as being 
appropriate for surgical intervention (mean mPAP 28 ±8 mmHg, mean PAWP 11 ±4 mmHg, PVR 2.6 
±0.9 WU) and 13 chose to have surgical correction performed. Eleven of these fifteen patients had an 
associated SV-ASD with 3 of the 4 patients without a SV-ASD having abnormal drainage of >1 
pulmonary vein.  Twenty-nine PH patients (mean mPAP 50 ±9 mmHg, mean PAWP 10 ±4 mmHg, PVR 
8.4 ±3.5 WU) received a trial of PAH therapy (phosphodiaesterase-5 inhibitor, n=19; endothelin 
receptor antagonist, n=4; oral combination therapy, n=2 and prostanoid-based therapy, n=4). Mean 
improvement in incremental shuttle walking distance from baseline to first follow-up in the 25 




Table 4: Comparison of patients with isolated PAPVD and PAPVD + ASD* 
 Isolated PAPVD (n=47) PAPVD and ASD (n=37) p value 
CT Measurements     
 Aorta (cm) 
 3.1 ±0.5 3.0 ±0.5 0.286 
 PA (cm) 
 3.4 ±0.6 3.9 ±0.7 0.003 
 LA (cm
2)  22.8 ±9.3 22.9 ±7.0 0.956 
 RA (cm
2)  30.8 ±14.3 33.0 ±12.6 0.495 
 RV (cm
2)  31.6 ±8.5 38.6 ±8.5 0.001 
Qp:Qs (Cardiac MRI)** 1.5 ±0.4 :1 2.2 ±0.9 :1 0.006 
DLco %pred 67.4 ±24.1 80.6 ±20.7 0.015 
Haemodynamics    
 mRAP (mmHg) 10.9 ±6.4 10.1 ±6.3 0.609 
 mPAP (mmHg) 36.7 ±15.5 41.4 ±15.7 0.209 
 PAWP (mmHg) 13.2 ±6.5 13.1 ±7.1 0.955 
 CO (L/min) 5.9 ±2.0 5.9 ±1.7 0.962 
 CI (L/min/m2) 3.2 ±1.0 3.3 ±0.8 0.559 
 PVR (WU) 4.8 ±3.9 4.7 ±3.2 0.868 
 PVR (WU.m
2) 8.9 ±7.4 8.5 ±5.0 0.791 
 PA saturations (%) 76 ±8 80 ±7 0.064 
 
*Patients with a previously closed ASD were not included in this analysis.  
** 43 patients had data available from cardiac MRI 
Abbreviations: PA = pulmonary artery, LA = left atrium, RA = right atrium, RV = right ventricle, Qp:Qs = 
pulmonary to systemic blood flow, DLco = diffusing capacity for carbon monoxide. Haemodynamics 
measured at right heart catheterisation: mRAP = mean right atrial pressure, mPAP = mean pulmonary 
arterial pressure, PAWP = pulmonary arterial wedge pressure, CO = cardiac output, CI = cardiac index, 
PVR = pulmonary vascular resistance, PVRi = pulmonary vascular resistance indexed for body surface 





In the current manuscript we describe our experience of patients with PAPVD referred to a pulmonary 
hypertension referral centre over a 10-year period. To our knowledge this represents the largest, to 
date, published cohort of patients with PAPVD-associated PH. 
Out of 90 patients with PAPVD, 71 (79%) had not been previously identified as having congenital heart 
disease, despite CT scanning having been performed locally prior to referral in 49 (54%) patients. 
Furthermore, of the 31 patients with an ASD visible on CT, the diagnosis was newly made by our unit 
in 25. Jujo et al previously studied 8 patients identified with PAPVD at RHC over a 12 year period and 
found that the diagnosis had been missed on initial reporting of CT scans in 50% of cases (179). Our 
new data highlight the importance of considering the possibility of APVD +/- ASD in all patients in 
whom pulmonary hypertension is suspected. It can be difficult to identify APVD and SV-ASD using 
standard transthoracic echocardiography (180). Many patients undergo CT scanning prior to referral 
to a pulmonary hypertension specialist centre and as part of a systematic evaluation of the thoracic 
CT, the course of all 4 pulmonary veins should be assessed (Figure 10). 
The majority of patients (67%) had anomalous drainage limited to the right superior pulmonary vein, 
with 29% involving left-sided veins. Most previous clinical series of patients presenting with 
symptomatic PAPVD also reported predominantly right-sided PAPVD although 2 recent population-
based CT studies observed a left-sided predominance (173, 181). The reason for this discrepancy is 
not clear. In keeping with previous studies, however, we identified that the majority of patients with 





Figure 10: Contrast-enhanced CT scans of variants of PAPVD: a) anomalous drainage of right superior 
vein into SVC (arrow); b) SV-ASD (arrow); c) anomalous drainage of left superior vein into 
brachiocephalic vein (arrow); d) enlargement of anteriorly-located right heart chambers in a patient 
with PAPVD. 





We hypothesised that patients with >1 anomalous vein in the absence of an ASD would have evidence 
of greater L-R shunt than those with a single abnormal vein. Although there was no difference in terms 
of RV area on CT, we did observe a greater Qp:Qs and higher DLco %pred in patients with abnormal 
drainage of multiple lobes. This is consistent with previous observations by Majdalany et al who 
reported 43 patients with isolated PAPVD seen during a 20-year period; the vast majority of patients 
with RV dilatation who required surgery had >1 abnormal pulmonary vein (183). We similarly 
hypothesised that the 31 patients with associated ASDs would have larger L-R shunts than those 
without associated defects and, indeed, in those patients RV and pulmonary artery diameters and 
cardiac MRI-assessed Qp:Qs were higher. We also hypothesised that this increased Qp:Qs would be 
reflected in standard non-invasive physiological measurements. DLco %pred was higher in those 
patients with associated septal defects, in keeping with increased pulmonary capillary blood flow. 
These observations were contrary to those of Sahay et al who did not see any effect of the presence 
or absence of an associated ASD difference on Qp:Qs in patients identified at a large ACHD centre over 
a 5-year period (184). The number of patients in that study was, however, relatively small (n=14, 6 of 
whom had PAH).  
Left atrial pressure as assessed by PAWP was elevated in 24 patients. In a normal person, each 
pulmonary vein drains approximately 25% of the total pulmonary blood flow (185). However, in 
anomalous pulmonary venous drainage, the shunt flow may be higher since the circulation is 
preferentially directed to the right side due to lower pressure in the RA and superior vena cava than 
in the left atrium. This effect becomes more pronounced in conditions that increase left atrial pressure 
such as systemic hypertension or left heart disease. It is interesting to note that the right-sided 
chambers were significantly larger and there was a trend towards a larger pulmonary artery in those 
patients with an elevated PAWP.   
In addition to elevated left atrial pressure, other potential causes of PH were present in 29% of 
patients with PH. In their report of 43 patients with isolated PAPVD, Majdalany et al observed 
emphysema or interstitial lung disease in 6 patients, chronic thromboembolic disease in 4 patients 
and cirrhosis in 2 patients (183). It is possible that these associated conditions may act as a “second 
hit” on a pulmonary vasculature already exposed to increased flow leading to the development of PH.  
Optimal treatment of patients with PAPVD depends on the anatomical and haemodynamic picture. 
Our practice is to recommend subsequent referral of all patients with newly diagnosed PAPVD +/- ASD 
to their regional ACHD centre for an evaluation regarding surgical suitability. The role of PAH therapy 
in patients with PAH associated with PAPVD +/- ASD is not clear. Although there are several case 
studies and small case series reporting improvement with PAH therapy in patients with PAPVD and 
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PAH, no such patients have been studied in randomised controlled trials (174, 186-188). Consideration 
for PAH therapy should therefore be done on a case-by-case basis taking into account pulmonary 
haemodynamics and the extent of L-R shunt. In certain circumstances, reassessment of 
haemodynamics following PAH therapy may alter initial decisions regarding suitability for 
intervention. 
Limitations 
This was a retrospective study and hence data for certain investigations, including inferior venocaval 
saturations enabling invasive Qp:Qs calculation, were not available for all patients. Some 
haemodynamic data provided should be interpreted with caution: the PA lobe in which the PAWP was 
measured was not recorded, and the PAWP will be inaccurate if the catheter is wedged in an artery 
supplying an anomalous lobe. In addition, previous studies have highlighted that cardiac output 
measured by thermodilution may be inaccurate in patients with left-to-right intra-cardiac shunts, 
which may affect the data described in patients with PAPVD with associated ASD (189, 190). We have 
therefore presented data regarding Qp:Qs based on patients who had undergone Qp and Qs 
measurement at cardiac MRI.  
 
3.6 Conclusions 
Undiagnosed PAPVD +/- ASD may be present in patients with suspected PH who are referred to a 
specialist referral centre. The presence or absence of PAPVD on cross-sectional imaging should 
therefore be specifically assessed in all patients with suspected PH. Radiological and physiological 
markers of pulmonary blood flow are higher in patients with an associated SV-ASD in keeping with 
increased L-R shunt. Although many patients with PAPVD and PH may have other potential causes of 
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There are limited published data defining survival and treatment response in patients with mild lung 
disease and/or reduced gas transfer who fulfil diagnostic criteria for idiopathic pulmonary arterial 
hypertension (IPAH).  
Patients diagnosed with IPAH between 2001-19 were identified in the ASPIRE registry. Using pre-
specified criteria based on CT imaging and spirometry, patients with a diagnosis of IPAH and no lung 
disease were termed IPAHno-LD (n=303), and those with minor-mild emphysema or fibrosis were 
described as IPAHmild-LD (n=190).  
Survival was significantly better in IPAHno-LD than in IPAHmild-LD (1 and 5-year survival 95% and 70% 
versus 78% and 22% respectively, p<0.0001). In the combined group of IPAHno-LD and IPAHmild-LD, 
independent predictors of higher mortality were increasing age, lower DLCO, lower exercise capacity 
and a diagnosis of IPAHmild-LD (p all <0.05). Exercise capacity and quality of life improved (p both 
<0.0001) following treatment in patients with IPAHno-LD but not IPAHmild-LD. A proportion of patients 
with IPAHno-LD had a DLCO <45%; these patients had poorer survival than patients with DLCO ≥45% 
although demonstrated improved exercise capacity following treatment.  
The presence of even mild parenchymal lung disease in patients who would be classified as IPAH 
according to current recommendations has a significant adverse effect on outcomes. This phenotype 
can be identified using lung function testing and clinical CT reports. Patients with IPAH, no lung disease 
and severely reduced DLCO may represent a further distinct phenotype. These data suggest that RCTs 





Idiopathic pulmonary arterial hypertension (IPAH) is a rare condition (estimated incidence 
<5/million/year) defined haemodynamically as a mean pulmonary arterial pressure (mPAP) >20 
mmHg, a left atrial pressure ≤15 mmHg and a pulmonary vascular resistance (PVR) >3 WU (12, 191). 
It is defined clinically as the absence of conditions or risk factors associated with the development of 
pre-capillary pulmonary hypertension (PH) including connective tissue disease, congenital heart 
disease, chronic thromboembolic disease and lung disease (43). Several medical therapies have been 
shown to improve haemodynamics, exercise capacity and clinical events while survival has improved 
significantly over the last 3 decades (84, 192, 193). Chronic lung disease associated pulmonary 
hypertension (CLD-PH) is common; 90% of patients with severe chronic obstructive pulmonary disease 
(COPD) have a mPAP >20 mmHg (194). Significant pulmonary hypertension in association with lung 
disease is less common with ≤5% of COPD patients having a mPAP ≥35 mmHg (97).  
Mild lung disease may be present in patients with severe pre-capillary haemodynamics. This can 
create diagnostic uncertainty as to whether a patient has group 1 (pulmonary arterial hypertension; 
PAH) or group 3 (CLD-PH) disease. The recent 6th World Symposium on Pulmonary Hypertension 
(WSPH) suggested that patients with co-existing lung disease be diagnosed with PAH when PH is 
moderate-severe, when only modest spirometric or parenchymal abnormalities are present and when 
diffusion capacity (DLCO) is low with respect to obstructive or restrictive lung function (194).  
There are few data defining survival and treatment response in patients with mild lung disease who 
fulfil the diagnostic criteria for IPAH suggested by the 6th WSPH. We hypothesised that even mild lung 
disease and/or low gas transfer have a negative effect on outcomes in patients with a diagnosis of 
IPAH. We therefore performed a study of characteristics, survival and response to therapy of patients 
who had been assigned a diagnosis of IPAH at a large PH referral centre over an 18-year period. 
 
4.3 Methods 
Patients who had been assigned a diagnosis of IPAH or heritable PAH or CLD-PH between February 
2001 and January 2019 at our centre were identified from the ASPIRE registry, a database consisting 
of consecutive patients referred to the Sheffield Pulmonary Vascular Disease Unit who undergo multi-
modality assessment and multi-disciplinary team discussion, as previously described (94). Radiology 
images and reports, lung function tests, pulmonary haemodynamics and clinical correspondence were 
retrieved, blinded to outcomes. CT images had been reported at the time of diagnosis by experienced 
pulmonary vascular radiologists, blinded to haemodynamics and spirometry, using a qualitative 
assessment of the extent of parenchymal lung disease: none, minor, mild, moderate or severe. In the 
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absence of moderate to severely abnormal spirometry (defined as FEV1 <60% and/or FVC 
<70%), patients with a diagnosis of IPAH or heritable PAH who had no parenchymal lung disease were 
termed IPAHno-LD while those who had minor or mild emphysema or fibrosis on their original CT report 
were termed IPAHmild-LD. Patients with moderate to severely abnormal spirometry and/or those with 
moderate or severe parenchymal lung disease were defined as CLD-PH. Patients with PH caused by 
respiratory disease other than COPD, emphysema or interstitial lung disease (ILD) were excluded. 
Patients with ≥2 radiological features of possible pulmonary veno-occlusive disease (PVOD; 
centrilobular ground glass opacities, mediastinal lymphadenopathy and interlobular septal lines) were 
also excluded (195). Smoking status and history was retrieved from clinical notes. 
Quality of life was assessed by emPHasis-10 score (196); scored out of 50, lower score represents 
lower symptom burden. 
 
Mortality Data 
Mortality data were obtained from systems linked to the NHS Personal Demographics Service (PDS), 
which is updated when a death is registered in the UK. Patients who emigrated (n=3) were excluded, 
as were patients without a record on the PDS (n=2). Patients undergoing lung transplantation were 




Two follow-up time points were used to assess treatment response: first follow-up beyond 90 days of 
diagnosis and first follow-up between 9 and 15 months in patients receiving oral combination therapy 
within 6 months of diagnosis. The latter time point was used to enable comparison between patients 
who had received a similar therapeutic approach. 
 
Statistics 
Statistical analysis was performed using SPSS v25 and GraphPad Prism v8. Unless otherwise specified, 
continuous data were displayed as mean ±standard deviation (compared using paired/unpaired T-
tests), or median (first quartile, third quartile) for non-parametric data (compared using Wilcoxon 
signed-rank/Mann-Whitney U-tests). Frequencies were compared using the χ2 test. Multivariate Cox 
regression was performed in a forward direction on parameters with a p value <0.2 at univariate 
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analysis. To allow comparison at univariate and multivariate analysis, continuous variables were scaled 
to the mean. For other statistical tests, a p value of <0.05 was considered significant. Kaplan-Meier 
survival curves were compared using the log-rank test, truncated at 5 years. Where appropriate, 95% 
confidence intervals were derived for median values using a bootstrap resampling technique. 
 
Ethics 
Ethical approval was granted by Sheffield Teaching Hospitals NHS Foundation Trust (STH14169) and 
approved by the National Research Ethics Service (16/YH/0352). 
 
4.4 Results 
Of 5643 patients diagnosed with all forms of PH, 493 incident patients were identified who had a 
diagnosis of either idiopathic or heritable PAH (hereafter grouped as IPAH, who formed the main study 
population),  
Figure 11. Following reassessment of patients assigned a diagnosis of IPAH, 303 had no evidence of 
parenchymal lung disease (IPAHno-LD) while 190 had minor or mild parenchymal lung disease (IPAHmild-
LD).  Baseline right heart catheterisation data were available in 98%, spirometry in 97% and DLCO in 83% 
of patients with IPAHno-LD and IPAHmild-LD.  
Comparison of IPAHno-LD vs IPAHmild-LD  
Patients with IPAHno-LD were younger (mean age 53 vs 70 years; p<0.0001), had a female predominance 
(73% vs 47%; p<0.0001), a higher mean mPAP and mixed venous oxygen saturations (mPAP 55mmHg 
vs 50mmHg, SvO2 60% vs 62%; p both <0.05) and were less likely to have a smoking history than 
patients with IPAHmild-LD (p<0.0001,  Table 5). Spirometric volumes were well preserved in patients with 
IPAHno-LD and IPAHmild-LD. Patients with IPAHno-LD had significantly better survival than patients who had 
IPAHmild-LD (1 and 5-year survival 95% and 70% vs 78% and 22%; p<0.0001, Figure 12). When patients 
with IPAHno-LD and IPAHmild-LD were analysed together in a multivariate model, independent predictors 
of higher mortality were increasing age, lower DLCO %predicted, lower ISWD and a diagnosis of IPAHmild-
LD (Table 6). In view of the different forms of parenchymal lung disease encompassed by IPAHmild-LD, 
this multivariate model was reanalysed using data for the emphysema or interstitial lung disease 
subtypes separately. Increasing age, lower ISWD and a diagnosis of IPAHmild-LD remained as 
independent predictors of mortality. There was no significant difference in survival between patients 
with IPAHmild-LD who had emphysema or ILD (Figure 13). Baseline demographics and haemodynamics 
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of these groups were also very similar (Table 7). Lung function data for subtypes of IPAHmild-LD are also 





Figure 11: Flow chart demonstrating selection of patients for participation in study 
Abbreviations: CTEPH = chronic thromboembolic pulmonary hypertension, PH-LHD = pulmonary 
hypertension due to left heart disease, OHS = obesity hypoventilation syndrome, OSA = obstructive 
sleep apnoea, PAH = pulmonary arterial hypertension, IPAH = idiopathic pulmonary arterial 
hypertension, HPAH = heritable pulmonary arterial hypertension, IPAHno-LD = IPAH with no lung 
disease, IPAHDLCO≥45 = IPAH with no lung disease with DLCO ≥45% predicted, IPAHDLCO<45 = IPAH with no 
lung disease with DLCO <45% predicted, IPAHmild-LD = IPAH with mild lung disease, COPD = chronic 
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Figure 12: Survival from diagnosis in IPAHno-LD and IPAHmild-LD  
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, IPAHno-LD = IPAH with no lung 
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Figure 13: Survival by subtype of lung disease in IPAHmild-LD  




Table 5: Baseline demographics and maximal treatment data 
 
IPAHno-LD  IPAHmild-LD   p value 
Number 303 190  
Female (%) 73 47 <0.0001 
Age (years) 53 ±17  70 ±10  <0.0001 
WHO FC I/II/III/IV (%) 0/21/60/19 0/9/56/35  
BMI (kg/m2) 29 ±6  28 ±6  0.15 
mRAP (mmHg) 11 ±6  11 ±5  0.39 
mPAP (mmHg) 55 ±13  50 ±9  <0.0001 
PAWP (mmHg) 10 ±3  11 ±3 0.10 
PVR (WU) 11.9 ±5.8   11.1 ±4.5  0.10 
SvO2 (%) 62 ±9 59 ±9  0.02 
Cardiac Output (L/min) 4.3 ±1.6 4.0 ±1.4 0.04 
Cardiac Index (L/min/m2) 2.3 ±0.8  2.2 ±0.7 0.07 
FEV1 % 89 ±15  89 ±17  0.64 
FVC % 100 ±17 103 ±18  <0.05 
FEV1/FVC 75 ±9  68 ±8 <0.0001 
DLCO %pred 56 ±20 30 ±13 <0.0001 
ISWD (m) 210 (80, 360) 80 (40, 180)  <0.0001 
% smokers 40 82 <0.0001 
Pack-years in smokers 25 ±17 32 ±18 0.03 
 
   
Maximal Treatment (%)*    
None 1 1  
CCB 5 1  
Oral mono 19 34  
Combo oral 44 50  
Prostanoid +/- oral 31 14  
 
*This refers to the maximal treatment received during the study. Data are presented as mean ±SD or 
median (Q1, Q3).  Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, IPAHno-LD = IPAH 
with no lung disease, IPAHmild-LD = IPAH with mild lung disease, WHO FC = World Health Organisation 
functional class, BMI = body mass index, mRAP = mean right atrial pressure, mPAP = mean pulmonary 
arterial pressure, PAWP = pulmonary arterial wedge pressure, PVR = pulmonary vascular resistance, 
SvO2 = mixed venous oxygen saturations, DLCO %pred= diffusing capacity for carbon monoxide percent-
predicted, ISWD = incremental shuttle walking test distance, CCB = calcium-channel blockers.  
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Table 6: Univariate and Multivariate Cox regression analysis of prognostic factors in patients with 




Scaled HR p-value Scaled HR p-value 
IPAHmild-LD (ref. IPAHno-LD) 4.287 <0.0001 2.168 <0.0001 
Age (yrs) 2.320 <0.0001 1.432 0.014 
Gender (ref. female) 1.549 0.001   
Smoking history (ref. none) 2.373 <0.0001   
WHO FC III&IV (ref. I&II) 3.246 <0.0001 
  
FEV1 %pred 0.995 0.945   
FVC %pred 1.072 0.328   
FEV1/FVC  0.767 <0.0001   
DLCO %pred 0.340 <0.0001 0.739 0.039 
mRAP (mmHg) 1.239 <0.0005 
  
PVR (WU) 0.999 0.986 
  
SvO2 (%) 0.740 <0.0001 
  
Cardiac Index (L/min/m2) 0.788 0.003 
  
ISWD (m) 0.434 <0.0001 0.559 <0.0001 
 
For continuous variables, hazard ratios are scaled to the mean. 
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, IPAHno-LD = IPAH with no lung 
disease, IPAHmild-LD = IPAH with mild lung disease, ref = reference, WHO FC = World Health Organisation 
functional class, DLCO %pred= diffusing capacity for carbon monoxide percent-predicted, mRAP = mean 
right atrial pressure, PVR = pulmonary vascular resistance, SvO2 = mixed venous oxygen saturations, 




Table 7: Baseline demographics in patients with subtypes of IPAHmild-LD compared with IPAHno-LD 
 
IPAHno-LD IPAHmild-LD emphysema IPAHmild-LD fibrosis IPAHmild-LD Mixed 
Number 303 125 39 26 
Female (%) 73 52 39 39 
Age 53 ±17 ¶ , * , # 70 ±9 z 71 ±10 z 69 ±11 z 
WHO FC I/II/III/IV 
(%) 
0/21/60/19 0/9/60/31 0/13/49/38 0/4/50/46 
BMI (kg/m2) 29 ±6  28 ±6 29 ±5 28 ±5 
mRAP (mmHg) 11 ±6 11 ±5 11 ±5 10 ±5 
mPAP (mmHg) 55 ±13 ¶ , * , # 51 ±9 z 48 ±10 z 51 ±8 z 
PAWP (mmHg) 10 ±3  ¶  11 ±3 z 10 ±4 10 ±3 
PVR (WU) 11.9 ±5.8   10.9 ±4.4 11.1 ±4.5 11.8 ±5.2 
SvO2 (%) 62 ±9  # 60 ±8 60 ±10 57 ±9 z 
Cardiac Output 
(L/min) 
4.3 ±1.6  4.1 ±1.5 3.8 ±1.2 3.7 ±1.1 
Cardiac Index 
(L/min/m2) 
2.3 ±0.8  2.2 ±0.7 2.1 ±0.6 2.0 ±0.6 
FEV1 % 89 ±15  88 ±16 88 ±17 91 ±20 
FVC % 100 ±17 ¶ 105 ±17 z , * 97±19 ¶ 100 ±19 
FEV1/FVC 75 ±9 ¶ , * , # 66 ±8 z ,* 72 ±7 z , ¶ 71 ±10 z 
DLCO %pred 56 ±20 ¶ , * , # 31 ±14 z , # 31±13 z , # 25 ±7 ¶ , * , z 
ISWD (m) 210 (80, 360) ¶ , * , # 90 (40, 190) z 60 (20, 140) z 90 (30, 120) z 
 
Data are presented as mean ±SD or median (Q1, Q3). z p<0.05 in comparison to IPAHno-LD, ¶ p<0.05 in 
comparison to mild LD emphysema, *p<0.05 in comparison to mild LD fibrosis, # p<0.05 in comparison 
to mild LD mixed 
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, IPAHno-LD = IPAH with no lung 
disease, IPAHmild-LD = IPAH with mild lung disease, WHO FC = World Health Organisation functional 
class, BMI = body mass index, mRAP = mean right atrial pressure, mPAP = mean pulmonary arterial 
pressure, PAWP = pulmonary arterial wedge pressure, PVR = pulmonary vascular resistance, SvO2 = 
mixed venous oxygen saturations, DLCO %pred= diffusing capacity for carbon monoxide percent-
predicted, ISWD = incremental shuttle walking test distance. 
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Effect of DLCO on survival in IPAHno-LD 
A bimodal distribution of DLCO %predicted (modes 30, 65) was observed in patients with IPAHno-LD with 
an optimal cut-point of 45% (Figure 16). Patients with IPAHno-LD who had a DLCO <45%predicted 
(IPAHDLCO<45) were older (mean 65 vs 48 years), had a lower mPAP (51 vs 56 mmHg) but also a lower 
SvO2 (60% vs 63%) than patients with DLCO ≥45%predicted (IPAHDLCO≥45); p all <0.05. Detailed 
demographics are shown in Table 8. Those with IPAHDLCO<45 were more likely to have a history of 
smoking (52% v 36%, p<0.05). There was no significant difference in lung volumes (FEV1 88% vs 91%, 
FVC 100% vs 100%, p both >0.05) but FEV1/FVC ratio was lower (71% vs 76%; p<0.0001) in patients 
with IPAHDLCO<45. One and five-year survival was significantly lower in patients with IPAHDLCO<45 (86% 
and 45% vs 99% and 84%; p<0.0001, Figure 15); this survival difference persisted when adjusted for 
age. 
 
Response to treatment 
Ninety-nine percent of patients with IPAHno-LD and IPAHmild-LD received PAH therapy; treatment 
response data are shown in Table 10 and Figure 14. Baseline ISWD was significantly higher in IPAHno-
LD than IPAHmild-LD: median 210m vs 80m; p<0.0001. There was no significant difference in time to 
follow-up between patients with IPAHno-LD and IPAHmild-LD. At both first follow-up, and at one-year 
assessment in patients who received combination oral therapy within 6 months of diagnosis, patients 
with IPAHno-LD demonstrated significant improvement with respect to ISWD and quality of life score 
(p<0.0001) whereas patients with IPAHmild-LD did not. In patients receiving oral combination therapy 
within 6 months of diagnosis, survival was significantly better in patients with IPAHno-LD compared to 
patients with IPAHmild-LD (1 and 5-year survival 98% and 74% vs 71% and 13%; p<0.0001, Figure 17). 
Patients with IPAHno-LD and IPAHmild-LD who received oral combination therapy within 6 months of 
diagnosis and had one-year follow-up data available had more severe haemodynamics than those who 
did not; haemodynamic and treatment data for all patients who had follow-up assessments available 
are displayed in Table 9. 
In the IPAHno-LD group, significant change (Δ) in ISWD was seen in patients with IPAHDLCO<45 (median 
Δ+20m) and IPAHDLCO≥45 (Δ+50m) who received treatment; p both <0.05. Baseline emPHasis-10 scores 
were significantly higher in patients with IPAHDLCO<45 than in patients with IPAHDLCO≥45 (median 38 vs 
27; p<0.01). Median change in emPHasis-10 at follow-up was not significant in patients with 
IPAHDLCO<45 (ΔemPHasis-10 -4; p=0.08) but was significant in patients with IPAHDLCO≥45 (ΔemPHasis-10 -
4; p<0.05).  
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Figure 14: Change at first follow-up beyond 90 days in a) ISWD; b) emPHasis-10 
All values displayed as median with 95% confidence intervals 
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, IPAHno-LD = IPAH with no lung 
disease, IPAHmild-LD = IPAH with mild lung disease, IPAHDLCO<45 = IPAHno-LD with DLCO <45% predicted, 
IPAHDLCO≥45 = IPAHno-LD with DLCO ≥45% predicted, ISWD = incremental shuttle walking test distance, E-10 
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Figure 15: Survival in IPAH patients with no lung disease (IPAHno-LD) stratified by DLCO <45% predicted 
(IPAHDLCO<45) versus DLCO ≥45% predicted (IPAHDLCO≥45)  
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, IPAHno-LD = IPAH with no lung 
disease, DLCO = diffusion capacity for carbon monoxide, IPAHDLCO<45 = IPAHno-LD with DLCO <45% 

























Figure 16: Distribution of DLCO %predicted in patients with IPAHno-LD 
Abbreviations: DLCO %pred = percent-predicted diffusing capacity for carbon monoxide, IPAHno-LD = 
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Figure 17: Survival in patients with IPAHno-LD and IPAHmild-LD treated with oral combination therapy 
within 6 months of diagnosis  
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, IPAHno-LD = IPAH with no lung 





Table 8: Demographics for subgroups of IPAH 
 
IPAHno-LD  IPAHmild-LD   IPAHDLCO<45 IPAHDLCO≥45 
Number 303 190 79 174 
Female (%) 73 47 66 77 
Age 53 ±17  70 ±10  65 ±12 48 ±16 
WHO FC I/II/III/IV (%) 0/21/60/19 0/9/56/35 0/12/57/31 0/24/65/11 
mRAP (mmHg) 11 ±6  11 ±5  11 ±7 11 ±6 
mPAP (mmHg) 55 ±13 50 ±9  51 ±10 56 ±14 
PAWP (mmHg) 10 ±3 11 ±3  10 ±3  10 ±3  
PVR (WU) 11.9 ±5.8   11.1 ±4.5  11.4 ±5.3 12.3 ±6.1 
SvO2 (%) 62 ±9  59 ±9  60 ±9 63 ±9 
Cardiac Output (L/min) 4.3 ±1.6 4.0 ±1.4  4.2 ±1.6 4.2 ±1.4 
Cardiac Index (L/min/m2) 2.3 ±0.8  2.2 ±0.7   2.3 ±0.9 2.3 ±0.8 
FEV1 % 89 ±15  89 ±17 88 ±19 91 ±13 
FVC % 100 ±17  103 ±18  100 ±20 100 ±15 
FEV1/FVC 75 ±9  68 ±8  71 ±10 76 ±7 
DLCO %pred 56 ±20  30 ±13  32 ±7 67 ±13 
ISWD (m) 210 (80, 360)  80 (40, 180)  80 (30, 210) 260 (130, 430) 
emPHasis-10 score 32 (20,40) 32 (26, 41) 38 (33, 44) 28 (20, 35) 
One-year mortality (%) 4.9 21.5 14.2 1.2 
 
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, IPAHno-LD = IPAH with no lung disease, IPAHmild-LD = IPAH 
with mild lung disease, IPAHDLCO<45 = IPAH with DLCO <45%, IPAHDLCO≥45 = IPAH with DLCO ≥45%, WHO FC = World Health 
Organisation functional class, BMI = body mass index, mRAP = mean right atrial pressure, mPAP = mean pulmonary arterial 
pressure, PAWP = pulmonary arterial wedge pressure, PVR = pulmonary vascular resistance, SvO2 = mixed venous oxygen 




Table 9: Demographics in patients with follow-up data available  
 
IPAHno-LD  IPAHmild-LD   IPAHDLCO<45 IPAHDLCO≥45 IPAHno-LD * IPAHmild-LD  * 
Number 215 124 47 139 79 32 
Female (%) 73 ¶ 47 ¶ 66  77 85 # 31 # 
Age 51 ±17 ¶ 70 ±10 ¶ 65 ±13 ¥ 48 ±16 ¥ 51 ±17 # 69 ±9 # 
WHO FC I/II/III/IV (%) 0/23/60/17 0/10/64/26 0/11/66/23 0/26/63/11 0/16/70/14 0/3/63/34 
BMI (kg/m2) 29 ±6  28 ±6 29 ±6  29 ±6  30 ±7 30 ±6 
mRAP (mmHg) 11 ±6  11 ±5 11 ±6 11 ±6 13 ±6 12 ±4 
mPAP (mmHg) 56 ±12 ¶ 50 ±9 ¶ 52 ±9 ¥ 56 ±13 ¥ 60 ±13 # 55 ±10 # 
PAWP (mmHg) 10 ±3  11 ±3  10 ±3  10 ±3  10 ±4 # 12 ±3 # 
PVR (WU) 12.0 ±5.7 ¶ 10.7 ±4.4 ¶ 11.6 ±4.8 12.4 ±5.9 14.4 ±5.0 # 11.6 ±3.8 # 
SvO2 (%) 62 ±9 ¶ 59 ±9 ¶ 60 ±10 ¥ 63 ±9 ¥ 60 ±9 58 ±6 
Cardiac Output (L/min) 4.3 ±1.5 4.0 ±1.4 4.1 ±1.5 4.1 ±1.3 3.8 ±1.2 3.9 ±1.3 
Cardiac Index (L/min/m2) 2.3 ±0.8 2.2 ±0.7 2.2 ±0.7 2.3 ±0.7 2.1 ±0.6 2.0 ±0.6 
FEV1 % 90 ±15 88 ±17 88 ±20  91 ±13 88 ±14 91 ±17 
FVC % 101 ±17  103 ±17 102 ±22 101 ±15 101 ±18 107 ±16 
FEV1/FVC 75 ±8 ¶ 67 ±9 ¶ 70 ±10 ¥ 76 ±7 ¥ 74 ±9 # 68 ±10 # 
DLCO %pred 58 ±19 ¶ 31 ±14 ¶ 32 ±7 ¥ 67 ±13 ¥ 57 ±18 # 33 ±14 # 
ISWD (m) 210 (80, 360) ¶ 90 (40, 180) ¶ 70 (20, 200) ¥ 265 (130, 430) ¥ 210 (90, 340) # 130 (50, 210) # 
 
      
Treatment (%)       
None 1 0 0 1 0 0 
CCB 6 1 0 9 0 0 
Oral mono 13 34 17 11 0 0 
Combo oral 48 45 53 47 66 69 
Prostanoid +/- oral 32 20 30 32 34 31 
 
* denotes subgroups of patients receiving combination oral therapy within 6 months of diagnosis 
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Data are presented as mean ±SD or median (Q1, Q3). ¶ p<0.05 between IPAHno-LD and IPAHmild-LD, ¥ p<0.05 between IPAHDLCO<45 and IPAHDLCO≥45, # p<0.05 between IPAHno-LD and 
IPAHmild-LD (patients receiving oral combination therapy within 6 months of diagnosis) 
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, IPAHno-LD = IPAH with no lung disease, IPAHmild-LD = IPAH with mild lung disease, IPAHDLCO<45 = IPAH with DLCO <45%, IPAHDLCO≥45 
= IPAH with DLCO ≥45%, WHO FC = World Health Organisation functional class, BMI = body mass index, mRAP = mean right atrial pressure, mPAP = mean pulmonary arterial pressure, PAWP = 
pulmonary arterial wedge pressure, PVR = pulmonary vascular resistance, SvO2 = mixed venous oxygen saturations, DLCO %pred = diffusing capacity for carbon monoxide percent predicted , 





Table 10. Baseline and follow-up incremental shuttle walking test distance and emPHasis-10 score   
 N IPAHno-LD N IPAHmild-LD N IPAHDLCO<45 N IPAHDLCO≥45 
Baseline and first follow-up beyond 90 days 
Baseline ISWD (m) 279 210 (80, 360)  159 80 (40, 180) ****  71 80 (30, 210) 170 260 (130, 430) ++++ 
ΔISWD (m) 215 40 (-10, 120) 124 0 (-32, 30) ****  47 20 (-13, 70) 139 50 (-10, 160) + 
ΔISWD p-value   <0.0001  0.90  <0.05  <0.0001 
 
Baseline E-10 84 32 (20, 40) 83 32 (26, 41) 25 38 (33, 44) 55 27 (0, 35) ++ 
ΔE-10 64 -4 (-12, +3) 65 0 (-5, +8) * 19 -4 (-13, +2) 43 -4 (-11, +3) 
ΔE-10 p-value  0.005  0.57  0.08  0.03  
 
Baseline and 1-year follow-up: Patients treated with combination oral treatment within 6 months of diagnosis 
Baseline ISWD (m) 125 200 (80, 340) 76 60 (20, 140) ****      
ΔISWD (m) 79 40 (-10, 140) 32 -20 (-50, 50) **      
ΔISWD p-value   <0.0001  0.83     
 
Baseline E-10 57 34 (22, 42) 41 35 (28, 41)     
ΔE-10 27 -4 (-18, +5) 17 -4 (-11, +3)     
ΔE-10 p-value  0.03  0.19     
 
* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 compared to IPAHno-LD 
+ p<0.05; ++ p<0.01; +++ p<0.001; ++++ p<0.0001 compared to IPAHDLCO<45 
 
Data are presented as median (Q1, Q3). Abbreviations: IPAH = idiopathic pulmonary arterial 
hypertension, IPAHno-LD = IPAH with no lung disease, IPAHmild-LD = IPAH with mild lung disease, IPAHDLCO<45 
= IPAHno-LD with DLCO <45% predicted, IPAHDLCO≥45 = IPAHno-LD with DLCO ≥45% predicted, ISWD = 





In the current study we have reassessed a large number of patients who had been assigned a diagnosis 
of IPAH at a large PH referral centre. By using radiology reports and lung function from the time of 
diagnosis we have identified phenotypes of IPAH with different characteristics, response to therapy 
and survival. Specifically, we have demonstrated that the presence of even mild parenchymal lung 
disease in patients who have been diagnosed with IPAH (IPAHmild-LD) is associated with a distinct clinical 
picture (well-preserved spirometry, low DLCO %pred and severe PH) and has a large negative effect on 
outcomes. We have also observed that a proportion of patients with IPAH with no parenchymal lung 
disease and unremarkable spirometry have a low DLCO. Differentiation of IPAH from CLD-PH represents 
a continual diagnostic challenge to all involved in the care of patients with PH. Mild PH in the context 
of severe lung disease (assessed radiologically and/or spirometrically) is common, and easily ascribed 
to group 3 (CLD-PH). Likewise, most would agree that patients with severe pulmonary haemodynamics 
and severe lung disease, where the severity of PH is proportionate to the degree of lung disease, also 
have group 3 disease. The presence of more modest lung disease in patients who fulfil traditional 
criteria for IPAH presents greater diagnostic and therapeutic challenges. 
 
Survival and response to therapy in IPAHmild-LD 
In the current study, survival in patients with IPAHmild-LD was significantly worse than in IPAHno-LD. In 
addition, although patients with IPAHno-LD experienced significant improvements in walk distance and 
emPHasis-10 score following initiation of PAH therapies, this same improvement was not observed in 
patients with IPAHmild-LD. Some retrospective studies of patients with mild-to-moderate lung disease 
and severe PH have reported improved haemodynamics and exercise capacity following 
commencement of PAH therapies (100-102). Conversely, Brewis et al failed to demonstrate 
improvement in 6-minute walk distance (6MWD) or WHO functional class in 118 patients with severe 
PH and varying degrees of lung disease following PAH therapy, while we have previously reported 
treatment response to pulmonary vascular therapy in only 19% of patients with severe CLD-PH (103, 
197). Prospective randomised controlled studies (RCTs) of PAH therapies in patients with CLD-PH due 
to COPD/emphysema have suffered from methodological weaknesses (104, 105) or recruited patients 
with mild PH (106, 107), although Vitulo et al recently performed a RCT in 31 patients with severe CLD-
PH due to COPD and demonstrated significant improvements in pulmonary haemodynamics but no 
improvement in 6MWD (108).  
The 6th WSPH task force on CLD-PH recommended that in patients with co-existing lung disease, PAH 
should be diagnosed when PH is moderate-severe, when only modest spirometric (i.e. FEV1>60% and 
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FVC>70%) or parenchymal abnormalities are present and when DLCO is low with respect to obstructive 
or restrictive lung function (194). Using these criteria, patients in our IPAHmild-LD group would keep their 
original diagnosis of IPAH. Our observations regarding the effect that mild parenchymal lung disease 
has on response to therapy and survival suggests that IPAHmild-LD is a distinct phenotype and that 
further prospective studies to assess treatment response in these patients are warranted. Recognition 
of an IPAHmild-LD phenotype also has implications for risk stratification, decisions regarding 
transplantation and PAH therapy clinical trial design. 
 
IPAH with DLCO <45% 
Trip et al observed a bi-modal distribution of DLCO %predicted in a cohort of 166 patients diagnosed 
with IPAH, and demonstrated that a DLCO <45%predicted conferred worse survival (198). Whilst they 
included patients who had mild or moderate lung disease, we observed a similar distribution of DLCO 
%predicted in patients without any lung disease (IPAHno-LD, Figure 16). Olsson et al subsequently 
described a subgroup of patients with IPAH with no parenchymal lung disease but severely reduced 
gas transfer (199). In keeping with these two studies, our cohort of IPAHno-LD patients with DLCO 
<45%predicted (IPAHDLCO<45) was older, more likely to have a smoking history and had a lower exercise 
capacity. Although survival in patients with IPAHDLCO<45 was significantly worse than those with 
IPAHDLCO≥45, significant improvements in ISWD were observed following PAH therapy, unlike in patients 
with IPAHmild-LD. The cause of the reduced DLCO in a proportion of IPAH patients is unclear. Pulmonary 
veno-occlusive disease is a rare cause of low DLCO and is haemodynamically indistinguishable from PAH 
(195). However, we excluded patients (n=18) where there was a possibility of PVOD based on 
radiological assessment. Given the increased frequency of smoking in the IPAHDLCO<45 group it is 
possible that the reduced DLCO may represent emphysema not visible on cross-sectional imaging (200). 
Tobacco smoke has, however, also been shown to cause pulmonary vascular remodelling in animal 
models, and specifically to cause damage to the pulmonary capillaries (201). The data from the current 
study therefore provide further support for the existence of a vanishing capillary syndrome as 
proposed by Hoeper et al (21). Further histological data are required to fully explain this phenomenon. 
 
Limitations 
This is a retrospective study and hence there were some data availability issues including first follow-
up ISWD data which was not available in 19% of patients. Patients who were unable to attempt the 
incremental shuttle walking test due to their pulmonary hypertension were ascribed a distance of 0m 
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which would minimise any potential bias resulting from missing data. Baseline scores for emPHasis-
10 were only available for 34% of patients since it was only introduced in our centre in 2014. A small 
number of patients (3%) with IPAHno-LD and IPAHmild-LD did not have spirometry available and were 
categorised based on CT data alone. Parenchymal lung disease assessment was based on qualitative 
clinical reports provided by radiologists at the time of initial diagnosis in our unit, and not on fully 
quantitative assessments. Our data do, however, demonstrate that “real-world” clinical radiological 
assessments of the presence and extent of parenchymal lung disease can be used to identify patients 
groups with different outcomes.  Whilst our patients now routinely undergo high resolution CT (HRCT) 
imaging and CT pulmonary angiography, some patients did not have specific HRCT imaging and so 
assessment of lung parenchyma in these patients may have been more limited. As there was no 




The presence of even mild parenchymal lung disease in patients who, based on current 
recommendations would be classified as having IPAH, has a significant adverse effect on survival and, 
in this patient cohort, was associated with a lack of significant improvement in exercise capacity 
following treatment.  Patients with the phenotype of IPAHmild-LD can be identified using lung function 
testing and qualitative clinical description of the presence and extent of parenchymal lung disease on 
routine radiological reporting. In addition, a proportion of patients with IPAH and no evidence of lung 
disease or PVOD have a severely reduced diffusion capacity. Our data support the need for prospective 
RCTs in patients with these phenotypes to assess the effects of PAH therapies on short and long-term 
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What this study adds to the literature 
Improvement to, and maintenance of, a low-risk profile (<5% mortality/year) is the current goal of 
treatment strategies in patients with pulmonary arterial hypertension. We have identified and tested 
cardiac MRI thresholds to risk stratify patients at baseline and at follow-up. Cardiac MRI when used as 
a sole risk stratification tool can identify a high percentage of patients at low-risk of one-year mortality 

















Pulmonary arterial hypertension is a life-shortening condition. The European Cardiac and Respiratory 
Societies (ESC/ERS) and REVEAL 2.0 risk score calculator identify thresholds to predict 1-year mortality.  
This study evaluates whether cardiac-MRI thresholds can be identified and used to aid risk 
stratification and facilitate decision making. 
Methods 
Consecutive patients with pulmonary arterial hypertension (n=438) undergoing cardiac-MRI were 
identified from the ASPIRE-MRI database. Thresholds were identified from a discovery cohort and 
evaluated in a test cohort. 
Results 
A right ventricular-end-systolic-volume-index-%predicted threshold of 227% or a left ventricular-end-
diastolic-volume-index of 58ml/m2 identified patients at low (<5%) and high (>10%) risk of 1-year 
mortality. These metrics identified 63% and 34% of patients as low risk, respectively. A right ventricular 
ejection fraction >54%, 37-54% and <37% identified 21%, 43% and 36% of patients at low, 
intermediate and high-risk of 1-year mortality, respectively. At follow-up cardiac-MRI patients who 
improved to, or were maintained in a low risk group had a one-year mortality <5%. Right ventricular-
end-systolic-volume-index-%predicted independently predicted outcome and when used in 
conjunction with the REVEAL 2.0 risk score calculator or a modified French Pulmonary Hypertension 
registry approach improved risk stratification for one-year mortality. 
Conclusion 
Cardiac-MRI can be used to risk stratify patients with pulmonary arterial hypertension using a 
threshold approach.  Right ventricular-end-systolic-volume-index-%predicted can identify a high 
percentage of patients at low-risk of one-year mortality and when used in conjunction with current 
risk stratification approaches it can improve risk stratification. This study supports further evaluation 





Pulmonary arterial hypertension (PAH) is a rare and life-shortening condition (9). Without treatment, 
life-expectancy is  less than 3 years (84), but with therapy, 5-year survival exceeds 60% in patients with 
idiopathic PAH  (91, 193, 202). Current licensed therapies directed at the pulmonary vasculature target 
three pathways (203).  There is evidence of superiority of upfront  dual (83) or sequential oral 
combination therapy (204, 205) over oral monotherapy, but decisions regarding escalation to more 
intensive treatments, as well as transplantation, can be challenging. 
The European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines proposed  
a “traffic light” risk stratification score to aid physicians in treatment decisions, dividing patients into 
low risk (“green”, <5%), intermediate risk (“amber”, 5-10%), and high risk (“red”, >10%) of mortality 
at one-year based on a number of modifiable variables (43). These include an assessment of 
symptoms, exercise capacity and right ventricular function (43, 140). Whilst the thresholds used for 
these variables were largely based on expert opinion, they have since been validated for PAH in three 
European registries (140, 142, 206). These studies demonstrated that patients who improved to a low-
risk profile at follow-up had better outcomes than those who did not. Outcomes for patients remaining 
in the intermediate risk group were significantly worse than low-risk patients and current approaches 
aim to improve and maintain patients in the low-risk group (43, 207). Similar results were observed in 
the North American Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) risk 
score (26). Risk stratification approaches typically include multiple variables (43, 140), however, right 
ventricular function is thought to be the primary determinant of morbidity and mortality in PAH (121, 
151). Cardiac magnetic resonance imaging (MRI) is the recognised gold-standard for assessment of 
right ventricular function (147, 208, 209). Whilst echocardiography is more widely available, cheaper 
and the most commonly used imaging modality for right ventricular assessment, it is limited by lack 
of inter and intra-observer reproducibility (210) and acoustic windows (147, 211, 212).  
Whilst studies have demonstrated the prognostic value of cardiac MRI in PAH (150-152, 160, 213), 
cardiac changes evaluated by current risk stratification tools are limited to atrial and pericardial 
assessment. Cardiac MRI metrics which are known to be prognostic in PAH are not included in either 
the REVEAL 2.0 or ESC/ERS risk score (43, 138). We sought to identify whether cardiac MRI metrics 
could accurately risk stratify patients using the ESC/ERS criteria of three levels of risk, and whether 
thresholds could be used to aid risk stratification. Some of the results of this study have been 





Patients with PAH were identified from the ASPIRE (Assessing-the-Spectrum-of-Pulmonary 
hypertension-Identified-at-a-Referral-centre) cardiac MRI database between April 2012 and March 
2017. Patients underwent systematic evaluation (94, 214), including echocardiography, blood testing, 
exercise testing, lung function testing, multimodality imaging and right heart catheterisation. Patients 
were required to have a mean pulmonary artery pressure (mPAP) ≥25mmHg and to have had a 
pulmonary arterial wedge pressure (PAWP) recorded and were excluded if PAWP >15mmHg. Patients 
with co-existing lung or left-heart disease were excluded. Patients were listed in date order of cardiac 
MRI scan and assigned in alternate date order to discovery or test cohorts.   
 
MRI image acquisition and analysis 
Cardiac cine MRI was performed on a 1.5T GE HDx MRI scanner using an 8 channel receiver array and 
multi-slice balanced steady state imaging with retrospective gating (20 frames/cardiac cycle; slice 
thickness 8 mm; field of view 48; matrix 256 x 256; band width 125 kHz/pixel; repetition time/echo 
time TR/TE, 3.7/1.6 ms). A stack of images in the short-axis plane with slice thickness of 8 mm, 2mm 
inter-slice distance) were acquired covering both ventricles from base to apex. End-systole was 
considered to be the smallest cavity area. End-diastole was defined as the first cine phase of the R-
wave triggered acquisition or largest volume. 
Image analysis was performed by operators blinded to diagnosis and cardiac catheter result. 
Endocardial and epicardial surfaces were manually traced on short axis imaging to obtain end-systolic 
and end-diastolic volumes for the right ventricle (RVESV, RVEDV) and left ventricle (LVESV, LVEDV). 
Trabeculations for the chambers were not separately traced, and were included as part of the volume 
cavity measurement (171). Right ventricular ejection fraction (RVEF) was calculated from these 
volume measurements as previously described (157). Volumes were indexed for body surface area 
(RVESVi, RVEDVi, LVESVi, LVEDVi), and then corrected for age and sex and displayed as percent-
predicted, as previously described (159). Ventricular mass index was calculated as RV mass divided by 
LV mass (172). Pulmonary artery relative area change was measured on the magnitude images of 
phase contrast images and calculated as (maximum pulmonary arterial area – minimal pulmonary 
arterial area)/minimal pulmonary arterial area. Phase contrast imaging parameters were as follows: 
repetition time TR/TE 5.6/2.7ms; slice thickness 10 mm; field of view 48 cm, bandwidth 62.5 kHz; 
matrix 256 3128; 40 reconstructed cardiac phases; and velocity encoding of flow 150 cm/s. Patients 





Statistical analysis was performed using IBM SPSS version 25 and R software. In this paper, a quintile 
refers to values which divide a ranked population into five equal groups. A quintile group refers to the 
population defined by the quintile. Data for continuous variables are presented as mean ±SD, and 
categorical data are presented as absolute values. Once thresholds were derived, volumes and values 
expressed as percentage-predicted were rounded to the nearest whole integer. Patients who had 
undergone lung transplantation were censored at the time of surgery; all other surviving patients were 
censored on 28th February 2019. Survival curves were assessed using the log-rank test. 
 
Discovery cohort 
In the discovery cohort, cardiac MRI parameters were assessed for significance for one-year mortality 
using univariate Cox regression analysis. A p value of <0.05 was considered statistically significant. 
Metrics significant at univariate analysis were utilised to identify thresholds. In order to identify 
thresholds, continuous variables were categorised into quintile groups for each metric. The quintiles 
were used as inclusive thresholds, and were taken to two decimal places, unless further precision was 
required. In each quintile group, one-year percentage mortality was calculated. Contiguous quintile 
groups sharing the same level of 1-year mortality (<5%, 5-10%, >10%) were combined. 
 
Test cohort 
The derived thresholds were applied to the test cohort. For each metric, if the corresponding group 
did not have the same level of risk, no further analysis was undertaken i.e. only those variables that 
showed consistency of risk were retained.  
 
Whole cohort 
Univariate and multivariate analysis of demographics, haemodynamics and MRI parameters was 
performed using Cox regression analysis. Locally estimated scatterplot smoothing (LOESS) regression 
analysis was performed on the whole cohort for percentage mortality at one year, for MRI metrics 






Follow-up data were obtained for patients who had undergone a further cardiac MRI after a minimum 
of 3 months and before 31st March 2017.   
 
Combination with other risk stratification tools 
The REVEAL 2.0 Risk Score and number of low-risk criteria by the French Pulmonary Hypertension 
Registry (FPHR) approach were calculated in order to determine whether cardiac MRI could further 
stratify risk. This was performed in the incident population, maximising available data for each risk 
score. For the FPHR approach the 6-minute walking test distance threshold of 440 metres was 
substituted with a low-risk incremental shuttle walking test distance threshold of 330 metres (115, 




Mortality data were obtained from the NHS Personal Demographics Service, where electronic records 
are automatically updated when a death is registered in the UK. All patients on PAH therapies were 
followed up at our centre as part of the national service specification for patients with pulmonary 
hypertension.  No patients were lost to follow-up. 
Ethical approval was granted by the local ethics committee (STH14169; Assessing outcomes in patients 





Between April 2012 and March 2017, 2008 patients were identified and 438 had PAH and met 
inclusion criteria (Figure 18). Demographic data are displayed in Table 11. At the time of cardiac MRI, 
51% of patients were incident and treatment naïve and 49% prevalent. The mean age was 56.6 years 
and 75% were female. The majority (85%) had idiopathic PAH, heritable PAH or PAH in association 
with connective tissue disease. Portopulmonary hypertension and PAH in association with congenital 
heart disease comprised 14% of patients. The remainder had PAH related to HIV infection or induced 
by drugs and toxins.  
During the course of the study 72% of patients received combination therapy (Table 11). A small 
number of patients, including nitric oxide vaso-responders maintained on calcium channel blockers, 
did not receive targeted treatment. Discovery and test-cohorts were well-matched and confidence 
intervals included the value zero for all continuous variables including cardiac MRI metrics (Table 11, 







Figure 18: Flow chart demonstrating patients included and reasons for exclusion.  
Abbreviations: RHC = right heart catheterisation, PAH = pulmonary arterial hypertension, LHD = left 
heart disease, PH = pulmonary hypertension, mPAP = mean pulmonary artery pressure, PAWP = 







Table 11: Baseline demographics in patients undergoing cardiac MRI 
 
For all variables, the difference between 95% confidence intervals for the groups included the value 
zero.  
RVESVi = right ventricular end-systolic volume, indexed for body surface are; RVEDVi = right ventricular 
end-diastolic volume, indexed for body surface area; RVEF = right ventricular ejection fraction; LVESVi 
= left ventricular end-systolic volume, indexed for body surface area; LVEDVi = left ventricular end-
diastolic volume, indexed for body surface area; LVEF = left ventricular ejection fraction; VMI = 
ventricular mass index; PA = pulmonary artery; %pred = displayed as percent predicted for age and 
sex. 
 
All patients (438) Discovery (219) Test (219) 
Demographics 
Age (years) 56.6 ±15.9 56.0 ±15.7 57.2 ±16.1 
Gender F/M, (F %) 327/111 (75) 161/58 (74) 166/53 (76) 
WHO FC I n (%) 7 (2) 4 (2) 3 (1) 
WHO FC II n (%) 118 (27) 59 (27) 59 (27) 
WHO FC III n (%) 261 (60) 128 (58) 133 (61) 
WHO FC IV n (%) 52 (12) 28 (13) 24 (11) 
Incident/Prevalent (I%) 225/213 (51) 109/110 (50) 116/103 (53) 
ISWD (m) 231 ±194 237 ±196 223±193  
PAH Subtype 
IPAH/HPAH n (%) 197 (45) 101 (46) 96 (44) 
PAH-CTD n (%)  163 (37) 78 (36) 85 (39) 
PAH-CHD n (%) 38 (9) 18 (8) 20 (9) 
PoPH n (%) 25 (6)  16 (7) 9 (4) 
Other n (%) 15 (3) 6 (3) 9 (4) 
Maximal Treatment 
Nil-targeted n (%) 23 (5) 12 (6) 11 (5) 
Oral monotherapy n (%) 100 (23) 46 (21) 54 (25) 
Oral combination n (%) 205 (47) 101 (46) 104 (47) 
Prostanoid +/- oral n (%) 110 (25) 60 (27) 50 (23) 
Haemodynamics 
mRAP (mmHg) 10 ±5 10 ±5 10 ±5 
mPAP (mmHg) 48 ±14 47 ±14 48 ±15 
PAWP (mmHg) 11 ±3 11 ±3 11 ±3 
CO (l/min) 5.0 ±1.8 5.1 ±1.8 4.9 ±1.8 
CI (l/min/m2) 2.8 ± 1.0 2.8 ±1.0 2.7 ±1.0 
PVR (dynes/sec/cm-5) 711 ±447 688 ±432 735 ±462 
SvO2 (%) 65.4 ±10.1 66.3 ±9.9 64.5 ±10.3 
Survival Analysis 
Dead at 1-year post CMRI n (%) 38 (8) 20 (9) 18 (8) 
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Table 12: Cardiac MRI metrics 
 
For all continuous variables, the difference between 95% confidence intervals for the groups included 
the value zero.  
WHO FC = World Health Organisation functional class; ISWD = incremental shuttle walking test 
distance; PAH = pulmonary arterial hypertension; IPAH = idiopathic pulmonary arterial hypertension; 
HPAH = heritable pulmonary arterial hypertension; PAH-CTD = pulmonary arterial hypertension 
associated with connective tissue disease; PAH-CHD = pulmonary arterial hypertension associated with 
congenital heart disease; PoPH = portopulmonary hypertension. Haemodynamics measure at right 
heart catheterisation: mRAP = mean right atrial pressure; mPAP = mean pulmonary arterial pressure; 
PAWP = pulmonary arterial wedge pressure; CO = cardiac output; CI = cardiac index; PVR = pulmonary 




Metric All patients (438) Discovery (219) Test (219) 
Right sided measurements 
RVESVi (ml/m2) 53.0 ±27.0 54.5 ±26.9 51.5 ±27.1 
RVEDVi (ml/m2) 88.6 ±33.5 89.9 ±33.7 87.3 ±33.7 
RVESVi %pred 220.0 ±117.7 225.6 ±122.7 214.4 ±112.5 
RVEDVi %pred 120.4 ±45.3 121.9 ±46.7 118.9 ±44.0 
RVEF 42.0 ±13.3 41.0 ±13.6 43.0 ±13.0 
RVEF %pred 62.7 ±20.1 61.4 ±20.7 64.0 ±19.4 
Left sided measurements 
LVESVi (ml/m2) 17.3 ±8.2 17.9 ±9.1 16.7 ±7.1 
LVEDVi (ml/m2) 54.0 ±16.1 54.6 ±17.0 53.4 ±15.1 
LVESVi %pred 71.8 ±33.8 74.1 ±38.3 69.6 ±28.4 
LVEDVi %pred 73.0 ±21.5 73.5 ±22.8 72.5 ±20.2 
LVEF 68.3 ±10.0 67.7 ±10.6 68.9 ±9.4 
LVEF %pred 100.9 ±14.7 100.2 ±15.7 101.7 ±13.7 
Miscellaneous 
VMI 0.529 ± 0.297 0.528 ±0.296 0.531 ±0.299 
PA relative area change (%)  11.99 ±8.70 12.39 ±9.20 11.57 ±8.15 
105 
 
Table 13: Univariate and multivariate analysis on whole cohort (scaled) 
 
Hazard ratios for continuous variables are scaled by dividing individual values by the standard 
deviation (z-score). Due to the limited number of events, only 6 variables were entered into the 
multivariate analysis reflecting measures of symptoms, exercise capacity, markers of haemodynamic 
 n 
Univariate 
Hazard Ratio P value 
Multivariate 
Hazard Ratio P value 
Demographics 
Age >50 438 3.576 0.008   
Sex (F) 438 0.562 0.086   
WHO FC 
I and II vs III and IV 430 2.724 0.037   
IPAH  0.534 0.079   
PAH-CTD  3.017 0.001   
PAH-CHD  0.195 0.269   
ISWD (m) 398 0.174 <0.001 0.162 <0.001   
Haemodynamics 
mRAP (mmHg) 224 1.55 0.006   
mPAP (mmHg) 224 1.254 0.263   
MvO2 (%) 224 0.458 <0.001   
Cardiac Index (l/min/m2) 224 0.506 0.016   
PVR (dynes/sec/cm-5) 224 1.5 0.06   
Other parameters 
eGFR <60 (ml/min/1.73m2) 436 3.104 <0.001   
SBP <110 (mmHg) 217 1.025 0.968   
Heart Rate >96 417 4.123 0.001   
Pericardial effusion present 438 3.323 0.001   
Recent hospitalisation (6m)  438 1.822 0.071   
MRI metrics 
RVEDVi 438 1.285 0.07   
RVEDVI %pred 438 1.426 0.011   
RVESVi 438 1.392 0.011   
RVESVI %pred 438 1.616 <0.001 1.571 0.025 
LVEDVi 438 0.451 <0.001   
LVEDVI %pred 438 0.435 <0.001   
LVESVi 438 0.601 0.016   
LVESVI %pred 438 0.598 0.066   
RVEF 438 0.634 0.005   
LVEF 438 0.847 0.275   
RVEF %pred 438 0.586 0.001   
LVEF %pred 438 0.795 0.16   
PA relative area change (%) 438 0.642 0.029   
VMI 438 1.125 0.446   
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severity and right ventricular function. WHO FC, ISWD, mRAP, Cardiac Index, RVESVi %pred and RVEF 
were significant at univariate analysis and were entered into the multivariate model.   
WHO FC = World Health Organisation functional class; IPAH = idiopathic pulmonary arterial 
hypertension; PAH-CTD = pulmonary arterial hypertension associated with connective tissue disease; 
PAH-CHD = pulmonary arterial hypertension associated with congenital heart disease; ISWD = 
incremental shuttle walking test distance; mRAP = mean right atrial pressure; mPAP = mean pulmonary 
arterial pressure; MvO2 = mixed venous oxygen saturation; PVR = pulmonary vascular resistance; eGFR 
= estimated glomerular filtration rate; SBP = systolic blood pressure; RVEDVi = right ventricular end-
diastolic volume, indexed for body surface area; RVESVi = right ventricular end-systolic volume, indexed 
for body surface area; LVEDVi = left ventricular end-diastolic volume, indexed for body surface area; 
LVESVi = left ventricular end-systolic volume, indexed for body surface area; LVEF = left ventricular 
ejection fraction; RVEF = right ventricular ejection fraction; PA = pulmonary artery; VMI = ventricular 
















Abbreviations: RVESVi = right ventricular end-systolic volume, indexed for body surface area; RVEDVi 
= right ventricular end-diastolic volume, indexed for body surface area; RVEF = right ventricular ejection 
fraction; LVESVi = left ventricular end-systolic volume, indexed for body surface area; LVEDVi = left 
ventricular end-diastolic volume, indexed for body surface area; LVEF = left ventricular ejection 
fraction; VMI = ventricular mass index; PA = pulmonary artery; %pred = displayed as percent predicted 
for age and sex. 
 
Metric Univariate Hazard Ratio p value  n 
RVESVi (ml/m2) 1.016 0.022 219 
RVEDVi (ml/m2) 1.009 0.150 219 
RVESVi %pred 1.004 0.002 219 
RVEDVi %pred 1.008 0.045 219 
RVEF % 0.955 0.008 219 
RVEF %pred 0.966 0.003 219 
LVESVi (ml/m2) 0.935 0.055 219 
LVEDVi (ml/m2) 0.936 0.000 219 
LVESVi %pred 0.987 0.113 219 
LVEDVi %pred 0.957 0.000 219 
LVEF % 0.974 0.142 219 
LVEF %pred 0.980 0.085 219 
VMI 2.728 0.140 210 
PA Relative Area Change (%) 0.956 0.121 219 
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Table 15: Percentage mortality at 4, 6 and 12 months by quintile group 
 Discovery Cohort 
 n = % mortality   
4 months 6 months 12 months 
RVESVi (ml/m2) 
    
<30.48 43 0 2.3 2.3 
30.48-41.75 44 2.3 2.3 4.5 
41.76-54.28 44 4.5 9.1 9.1 
54.29-76.12 45 2.2 4.4 13.3 
>76.12 43 7 14 16.3 
RVESVi %pred 
    
<124.09 43 2.3 2.3 2.3 
124.09-166.11 44 2.3 4.5 6.8 
166.12-226.71 44 0 2.3 2.3 
226.72-318.53 44 2.3 6.8 11.4 
>318.53 44 9.1 15.9 22.7 
RVEDVi %pred 
    
<83.15 43 4.7 9.3 9.3 
83.15-98.75 44 0 0 2.3 
98.76-120.07 44 0 2.3 2.3 
120.08-158.67 44 9.1 13.6 20.5 
>158.67 44 2.3 6.8 11.4 
RVEF % 
    
<27.01 43 4.7 11.6 14 
27.01-37.35 44 6.8 11.4 15.9 
37.36-44.20 44 2.3 6.8 9.1 
44.21-54.00 45 2.2 2.2 6.7 
>54.00 43 0 0 0 
RVEF %pred 
    
<40.869 43 4.7 11.6 14 
40.869-54.974 42 4.5 11.4 15.9 
54.975-67.366 44 4.5 6 9.1 
67.367-81.872 43 2.3 2.3 6.8 
>81.872 44 0 0 0 
LVEDVi (ml/m2) 
    
<39.24 43 4.7 14 23.3 
39.24-48.71 44 6.6 11.4 11.4 
48.72-57.68 44 4.5 6.8 11.4 
57.69-69.27 44 0 0 0 
>69.27 44 0 0 0 
LVEDVi %pred 
    
<51.66 43 7 16.3 25.6 
51.66-66.05 44 6.8 9.1 9.1 
66.06-77.33 44 2.3 4.5 6.8 
77.34-93.64 44 0 2.3 4.5 




Abbreviations: RVESVi = right ventricular end-systolic volume, indexed for body surface area; RVEDVi 
= right ventricular end-diastolic volume, indexed for body surface area; RVEF = right ventricular ejection 
fraction; LVEDVi = left ventricular end-diastolic volume, indexed for body surface area; %pred = 







At one year post cardiac MRI 38 patients (8.7%) had died; 20 patients (9.1%) in the discovery-cohort 
and 18 patients (8.2%) in the test-cohort. Patients aged >50 years were more likely to die at one year 
(p=0.008), as were those with PAH-CTD (p=0.001); univariate and multivariate analysis for the whole 
cohort is shown in Table 13. Results of Cox-regression analysis for cardiac MRI variables in the 
discovery cohort, based on survival at one year, are shown in Table 14. 
 
Discovery and Test Cohort 
Quintile groups for each cardiac metric in the discovery group are displayed in Table 15. Calculated 
one-year mortality per quintile group is presented in graphical form (Figure 19). 
Derived thresholds were applied to the test cohort Table 16. Levels of risk were non-concordant 
between the discovery and test cohorts for RVESVi, RVEDVi %predicted, RVEF %predicted and LVEDVi 
%predicted (highlighted in blue) and excluded from further analysis.  
Three variables were concordant for levels of risk.  Using a threshold of RVESVi %predicted of 227%, 
patients could be stratified into a low-risk group (one-year mortality 4.3%), and high-risk group (one-
year mortality 15%). The low-risk group (those with an RVESVi %predicted below this threshold) 
represented 63% of the test cohort (56% of incident patients and 72% of prevalent patients; Figure 
20). Left ventricular end-diastolic volume index stratified patients into a low-risk group (one-year 
mortality 2.7%), and high-risk group (one-year mortality 11%) using a threshold of 58ml/m2. The low-
risk group (those with an LVEDVi above this threshold) represented 34% of the test cohort (26% of 
incident patients and 43% of prevalent patients).  Right ventricular ejection fraction stratified patients 
into low (one-year mortality 4.4%), intermediate (7.4%) and high (11.4%) risk groups using thresholds 
of >54%, 37-54% and <37%, respectively. Using RVEF, 21% of the test cohort were identified as low 
risk, 43% intermediate risk and 36% high risk.  
When the analysis was repeated and patients with congenital heart disease excluded, thresholds for 
RVEF and LVEDVi were unchanged. The threshold for RVESVi %predicted changed from 227% to 225%. 






Figure 19: Histograms displaying quintile groups and percentage mortality at one year for cardiac MRI 
variables (discovery). Blue dashed line represents division into categories of risk. *RVEDVi was not 
significant at univariate analysis and division into risk categories was not performed.  
Abbreviations: RVESVi = right ventricular end-systolic volume, indexed for body surface area; RVEF = 
right ventricular ejection fraction; LVEDVi = left ventricular end-diastolic volume, indexed for body 




Table 16: Percentage mortality at 4, 6 and 12 months 
 




n = % mortality   
4 months 6 months 12 months 
RVESVi (ml/m2) 
    
 
<41.76 100 2 4 6 Low (<5%) 
41.76-54.28 35 0 0 0 Intermediate (5-
 >54.29 84 8.3 8.3 14.3 High 
RVESVi %pred 
    
 
<226.72 139 1.4 2.9 4.3 Low 
>226.72 80 8.8 8.8 15 High 
RVEDVi %pred 
    
 
<120.08 134 3 4.5 6 Low (<5%) 
>120.08 85 5.9 5.9 11.8 High 
RVEF % 
    
 
<37.36 79 6.3 6.3 11.4 High 
37.36-54.00 95 3.2 5.3 7.4 Intermediate 
>54.00 45 2.2 2.2 4.4 Low 
RVEF %pred 
    
 
<54.975 76 7.9 7.9 13.2 High 
54.975-81.872 101 1 3 5 Intermediate 
>81.872 42 4.8 4.8 7.1 Low (<5%) 
LVEDVi (ml/m2) 
    
 
<57.69 145 5.5 6.9 11 High 
>57.69 74 1.4 1.4 2.7 Low 
LVEDVi %pred 
    
 
<51.66 28 7.1 7.1 17.9 High 
51.66-77.33 105 3.8 4.8 6.7 Intermediate 
>77.33 86 3.5 4.7 7 Low (<5%) 
 
Abbreviations: RVESVi = right ventricular end-systolic volume, indexed for body surface area; RVEDVi 
= right ventricular end-diastolic volume, indexed for body surface area; RVEF = right ventricular ejection 
fraction; LVEDVi = left ventricular end-diastolic volume, indexed for body surface area; %pred = 
displayed as percent predicted for age and sex. Blue highlighting indicates non-concordance for levels 






Figure 20: Histograms displaying percentage mortality at one year for derived thresholds for cardiac 
MRI variables (test cohort).  
Abbreviations: RVESVi = right ventricular end-systolic volume indexed for body surface area; RVEF = 
right ventricular ejection fraction; LVEDVi = left ventricular end-diastolic volume, indexed for body 





Follow up data 
Follow-up cardiac MRI was performed in 165 patients.  At follow-up, RVESVi %predicted and RVEF 
were able to risk stratify patients based on thresholds identified in the discovery cohort. Using RVESVi 
%predicted for those who remained in low risk (RVESVi %predicted <227%) or improved to low risk 
(67% of patients in total), the one-year survival was 96.3%, and for those who remained high risk or 
deteriorated to high risk (33% of patients in total) the one-year survival was 87.3% (Figure 21).  Right 
ventricular ejection fraction was able to stratify patients into high and low-risk of one-year mortality 
at follow-up. Patients with an RVEF of <37% (25% of patients) had a one-year survival of 83.3% 
whereas patients with an RVEF of 37-54% (45% of patients) and >54% (29% patients) had one-year 
survival of 97.3% and 95.8% respectively. 
 
Combining cardiac MRI with REVEAL and FPHR scores 
The REVEAL 2.0 and modified FPHR scores, in isolation and in combination with RVESVi %predicted, 
are displayed for the incident population (n=224) in Figure 22. For REVEAL 2.0 all patients had at least 
11 of the 13 parameters available, and for modified FPHR there were no missing data. In those with a 
REVEAL 2.0 score ≥8, and in those determined to be either intermediate or high-risk by the modified 
FPHR approach, RVESVi %predicted reclassified patients into higher or lower risk categories (Figure 
22).  
Based on REVEAL 2.0 ≤6 for low, 7-8 for intermediate, and ≥9 for high-risk categories (138), and using 
a dichotomised score of +2 or -2 for RVESVi %predicted threshold of 227%, MRI reclassified 47% of 
patients, 36% (n=82) of patients into a lower risk group and 11% (n=25) into a higher risk group. 
Receiver operating characteristic (ROC) curves are displayed in Figure 23. For the REVEAL 2.0 score, 
addition and subtraction of 2 points for RVESVi %predicted ≥227% and <227%, respectively, increased 
the c-statistic from 0.74 (95% CI, 0.65-0.83) to 0.78 (95% CI 0.70-0.87). Using the modified FPHR 
approach the c-statistic increased from 0.70 (95% CI 0.59-0.80) to 0.74 (0.63-0.84) by adding an 
additional point for patients with a RVESVi %predicted <227%. 
 
Verification of thresholds 
For LVEDVi, RVESVi %pred and RVEF, LOESS regression analysis confirmed that identified thresholds 





Figure 21: Kaplan Meier survival curves based on cardiac MRI thresholds for a) RVESVi %pred at 
baseline (test cohort); b) RVESVi %pred at follow-up cardiac MRI; c) transition of risk between baseline 
and follow-up cardiac MRI for RVESVi %pred; d) RVEF at baseline (test cohort); e) RVEF at follow-up 
cardiac MRI; f) transition of risk between baseline and follow-up cardiac MRI for RVEF.  
Abbreviations: RVESVi = right ventricular end-systolic volume, indexed for body surface area; %pred = 




Figure 22: Impact of adding cardiac MRI to widely used risk stratification approaches: REVEAL 2.0 and 
Modified French Pulmonary Hypertension Registry approach to ESC/ERS guidelines. Green = low risk of 
one-year mortality (<5%), amber = intermediate risk (5-10%) and red = high risk (>10%).Abbreviations: 
REVEAL = Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL); RVESVi = 
right ventricular end-systolic volume, indexed for body surface area; %pred = displayed as percent 









Figure 23: ROC curves showing potential added value of cardiac MRI in conjunction with risk 
stratification approaches: The REVEAL risk score calculator 2.0 (left) and modified French Pulmonary 
Hypertension Registry approach to risk stratification (right), using an RVESVi %predicted threshold of 
227% 
Abbreviations: ROC = receiver operating characteristic; REVEAL = Registry to Evaluate Early and Long-
Term PAH Disease Management; RVESVi = right ventricular end-systolic volume, indexed for body 










Figure 24: LOESS regression curve demonstrating predicted mortality at one-year for cardiac MRI 
parameters: a) RVESVi %predicted, b) LVEDVi, c) RVEF 
Abbreviations: LOESS = locally weighted scatterplot smoothing; LVEDVi = left ventricular end-diastolic 
volume, indexed for body surface area; RVESVi = right ventricular end-systolic volume indexed for body 
surface area; RVEF = right ventricular ejection fraction; %pred = displayed as percent predicted 





To our knowledge, this is the first study to identify cardiac MRI thresholds that can be used to risk 
stratify patients with PAH according to the ESC/ERS traffic light approach, at baseline and follow-up. 
Furthermore, the addition of right ventricular end systolic volume index % predicted independently 
predicted outcome and when used in conjunction with current approaches improved risk 
stratification.  
A number of studies have demonstrated the prognostic value of cardiac MRI in PAH at baseline and 
follow-up (150-152, 160, 169, 213). In addition to volumetric measurements, right ventricular ejection 
fraction (RVEF), right ventricular to pulmonary artery (PA) coupling metrics and PA relative area 
change (151, 156, 216, 217) have also been shown to be prognostic. In this study we have confirmed 
the prognostic value of cardiac MRI but specifically we have identified and tested thresholds that may 
improve its clinical utility by allowing incorporation into risk stratification scores, which are 
increasingly used to inform treatment decisions (192).  
Right ventricular ejection fraction is the most commonly reported cardiac MRI metric and this study 
confirms its prognostic value but also identifies thresholds that can be used to identify patients at low 
(RVEF >54%), intermediate (RVEF 37-54%) and high risk (RVEF<37%) of one-year mortality. The 
threshold of RVEF <35% in a previous study of 76 incident patients with PAH, identified as conferring 
a higher risk of mortality over a median follow-up period of 59 months (151), is similar to that 
identified in our study of <37% for high-risk patients. Using the ESC/ERS approach to risk stratification 
21%, 43% and 36% of patients were identified at low, intermediate and high risk of one-year mortality 
in the test cohort, similar to the results of approaches using multiple non-invasive and invasive 
parameters to assess risk (142, 206). Thresholds identified from this study for RVEF could therefore 
be incorporated into the ESC/ERS risk stratification table to aid decision making.  
In the present study, baseline volumetric measurements RVESVi %predicted and LVEDVi were both 
prognostic.  We have previously demonstrated in a large study of 576 patients with PAH that RVESVi 
%predicted  was the cardiac MRI measurement with the strongest prognostic value (157) and in this 
study also independently predicted outcome. However, it is important to recognise that right 
ventricular volumes decrease with advancing age, are larger in men and increase with body surface 
area (218). Our group and others have previously identified the need to adjust cardiac MRI variables 
for age, sex and body surface area (157, 159, 219) and this study demonstrates for right ventricular 
volumes that correction for these variables is important when risk stratifying patients.  In this study 
pulmonary artery relative area change did not predict short term mortality (one year), whereas it did 
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predict mortality during the duration of this study (p<0.005). This highlights that MRI metrics that 
measure right ventricular function may be more helpful in defining short term mortality. 
Whereas for RVEF we were able to identify low, intermediate and high risk of one-year mortality, using 
volumetric measurements RVESVi %predicted and LVEDVi we were only able to identify patients at 
low and high-risk of one-year mortality. Thresholds for RVESVi %predicted <227% and LVEDVi 
>58ml/m2 identified low-risk patients. An LVEDVi threshold of <40ml/m2 has previously been used to 
identify patients at increased risk of mortality (152),  but our study suggests that a LV volume of 
≤58ml/m2 confers a high risk of mortality at one year. Using a threshold for RVESVi %predicted of 
<227% and for LV volume of >58ml/m2, 63% and 34% of patients could be identified at low risk of one-
year mortality, respectively. Right ventricular ejection fraction identified 21% and 43% of patients as 
low risk and intermediate risk, respectively.  
Treatment strategies are currently based on maintaining or improving patients to a low-risk group and 
a dichotomised score identifying a low and high-risk group may be a preferable approach to informing 
and simplifying treatment decisions. In particular, data from a number of studies has demonstrated 
that patients identified as intermediate risk using current risk stratification scores have a significantly 
worse survival than low-risk patients.  Identification and maintenance of a low-risk status remains the 
goal of current treatment strategies. A number of registry studies have shown that in patients whose 
risk profile can be modified to low risk, outcomes are significantly improved (26, 206). However, 
registry analysis using current approaches to risk stratification has only identified small numbers of 
patients in this low-risk category at presentation (12% of patients in the COMPERA and 23% in the 
Swedish Registry). At follow-up more patients achieved low-risk status (24% in COMPERA, 39% in the 
Swedish and 42% in the French Registry). In contrast, in this study using RVESVi %predicted, 63% of 
patients overall could be identified as low risk in the test cohort with 56% of incident (newly diagnosed 
patients) and 72% of prevalent patients (following initiation of treatment). The one-year mortality of 
all incident patients in this registry was 10.7% compared to 11.0% in COMPERA and 14% in the Swedish 
Registry, whilst for prevalent patients the one-year mortality was 6.6% in our cohort, 10.3% in 
COMPERA and 9% in the Swedish Registry. Whereas the French registry included idiopathic, heritable 
and drug-induced PAH, the COMPERA, Swedish and our own registry also included patients with other 
forms of PAH, predominantly related to connective tissue diseases. The haemodynamic parameters 
of our patients were similar to those in COMPERA and French registries although COMPERA includes 
a smaller proportion of patients in WHO Functional Class II. The enrolment period in our study is more 
recent and over 70% of patients received combination therapy. Nonetheless at diagnosis cardiac MRI 
was able to identify a high percentage of patients at low risk (56%). Our findings suggest that assessing 
right ventricular function using gold standard techniques may be preferable to other investigative 
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approaches, if identification of patients at low risk of one-year mortality is the goal. Further study is 
required to test this hypothesis. Using thresholds identified in the discovery cohort we have also 
demonstrated that cardiac MRI measurements can be used at follow-up to risk stratify patients and 
that improvement to low risk or maintenance of patients in a low-risk group is strongly prognostic.  
Finally, we have assessed how cardiac MRI could be used in conjunction with current risk stratification 
approaches; RVESVi %predicted, when used in conjunction with REVEAL 2.0 and modified FPHR, was 
able to further risk stratify patients. For patients classified as low risk by the modified FPHR or with a 
REVEAL 2.0 ≤6, MRI did not impact on risk stratification. However, when used in conjunction with the 
REVEAL 2.0 risk calculator and using a dichotomised score of +2 or -2 points for a RVESVi %predicted 
threshold of 227%, for patients with a REVEAL 2.0 score >6, MRI was able to reclassify 36% of patients 
into a lower risk group, and 11% of patients into a higher risk group.   
 
Limitations 
Our approach to identify thresholds for risk stratification using quintile groups in the discovery cohort 
is a valid but empiric approach. If the sample size was larger, other cardiac MRI parameters may have 
been identified.  Like the COMPERA and Swedish registries we included patients with congenital heart 
disease.  Although, repeat analysis with these patients excluded identified unchanged or similar 
thresholds, we would recommend further study in congenital heart disease and thresholds in this 
study should be used with caution in this population. The aim of this study was to assess whether a 
threshold approach can be used to risk stratify patients using MRI and the methodology used may not 
have identified “optimal” thresholds.  Our findings would benefit from external validation. 
 
5.6 Conclusion 
Thresholds derived from cardiac MRI metrics may be used to risk stratify patients with PAH. This 
registry has identified that cardiac MRI, when used as a sole risk stratification tool, identifies a high 
percentage of patients at low-risk of one-year mortality and when used in conjunction with current 
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What is already known 
The incremental shuttle walking test is a maximal exercise test, correlates with pulmonary 
haemodynamics and in pulmonary arterial hypertension does not demonstrate a ceiling effect. 
What this study adds 
Thresholds from the incremental shuttle walking test can be used to risk-stratify patients with 
pulmonary arterial hypertension and, unlike sub-maximal walking tests, an improvement in maximal 





Exercise capacity predicts mortality in pulmonary arterial hypertension but limited data exist on the 
routine use of maximal exercise testing. This study evaluates a maximal test, the incremental shuttle 
walking test, and assesses its utility in risk stratification in pulmonary arterial hypertension.   
Consecutive patients with pulmonary hypertension were identified from the ASPIRE registry from 
2001 to 2018. Thresholds for levels of risk were identified at baseline, tested at follow-up and their 
incorporation into current risk stratification approaches assessed. 
Of 4524 treatment-naïve patients with pulmonary hypertension who underwent maximal exercise 
testing 1,847 patients had pulmonary arterial hypertension. A step-wise reduction in one-year-
mortality was seen between levels 1 (≤30m; 32% mortality) and 7 (340-420m; 1% mortality) with no 
mortality for levels 8-12 (≥430m) in idiopathic and connective tissue disease related pulmonary 
arterial hypertension. Thresholds derived at baseline of ≤180m (>10%; high-risk), 190-330m (5-10%; 
intermediate-risk) and ≥340m (<5%; low-risk of one-year mortality) were applied at follow-up and also 
accurately identified levels of risk. Thresholds were incorporated into the REVEAL 2.0 risk score 
calculator and French low-risk approach to risk stratification and distinct categories of risk remained. 
An improvement of >10% independently predicted survival, when adjusting for baseline and follow-
up distance.  
We have demonstrated that maximal exercise testing used in pulmonary arterial hypertension 
stratifies mortality-risk at baseline and follow-up. Unlike sub-maximal field walking tests, such as the 
6-minute walk, improvements in exercise capacity predict outcome. This study highlights the value of 





Pulmonary arterial hypertension (PAH) is a life-shortening condition and risk stratification is 
recommended to guide treatment decisions. Exercise limitation is an early presenting symptom in PAH 
and measures of exercise capacity are typically severely reduced (25, 220).  Exercise testing is 
recommended as part of a multi-parameter assessment in the European Society of Cardiology 
(ESC)/European Respiratory Society (ERS) and REVEAL 2.0 risk scores, and has been frequently used 
as an end-point in clinical trials (43, 221). 
The six-minute walking test (6MWT) is the most widely used exercise test in pulmonary hypertension, 
and is inexpensive and simple to perform (117, 118). Absolute 6MWT distance (6MWD) correlates 
with haemodynamic parameters in idiopathic pulmonary arterial hypertension (IPAH) and predicts 
survival at baseline and follow-up (44, 222-224). Nonetheless there are concerns about a ceiling effect 
above a distance of 450m, and younger patients with severe disease may walk beyond 500m (116, 
225-227). In addition, improvement of 6MWD in response to treatment has not been found to be 
independently prognostic in PAH (85, 227). Cardiopulmonary exercise testing (CPET) is a maximal test 
and provides comprehensive evaluation of multi-organ response to physical effort. Parameters from 
CPET are associated with prognosis in PAH but its utility in routine clinical practice may be limited by 
cost, complexity and duration of procedure (120). 
The incremental shuttle walking test (ISWT) is an alternative maximal test for assessing patients with 
PAH, and is used in other forms of cardiac and respiratory disease (110-112). Previous studies have 
demonstrated correlation between ISWT distance (ISWD) and haemodynamic parameters at right 
heart catheterisation (RHC), and have confirmed that baseline and follow-up distances predict survival 
in PAH (115). The ISWT has potential advantages over the 6MWT in that it does not suffer from a 
ceiling effect, potentially allowing better assessment in patients who are younger or have less severe 
disease (115, 228). No thresholds exist for the ISWT as a risk stratification tool in PAH; the aim of this 






Patients were identified from the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension 
Identified at a Referral Centre) registry, diagnosed with pulmonary hypertension between 1st February 
2001 and 31st May 2018. Patients underwent multi-modality assessment as previously described (94). 
Data were collected prospectively and patients were required to have an ISWT performed at time of 
PH diagnosis, prior to commencement of PAH therapy. Patients with idiopathic, drug and heritable 
PAH were grouped and referred to as IPAH. Thresholds for low, intermediate and high-risk of one-year 
mortality were defined as <5%, 5-10% and >10%, respectively, and were identified in incident, 
treatment-naïve patients based on one-year mortality for each level. Thresholds were evaluated at 
follow-up, defined as the first reassessment beyond 90 days after commencing treatment. The 
outcome event included patients who underwent lung transplantation. 
 
Incremental Shuttle Walking Test 
The ISWT was undertaken as described by Singh et al (168), and as part of the standard patient 
evaluation. Patients complete a 10m length keeping in time to an external audible signal. Level one 
consists of 3 lengths (30m) and each subsequent level adds one extra length to the preceding level. 
The initial speed is a slow walk, 0.50m/s, increasing incrementally every level to a maximum of 
2.37m/s at level 12. Each level takes one minute to complete and the test finishes at the end of level 
12, a distance of 1020m. The patient continues until they are too breathless or unable to keep up with 
the required pace (see Table 17 for details of walking speeds). Patients unable to complete one shuttle 
length without oxygen were assigned an ISWD of 0m. 
 
Mortality Data 
Mortality data were obtained from the nationally-reported NHS Personal Demographics Service, 
updated when a death is registered in the UK, and transplant data were obtained from local databases. 
Patients who emigrated (n=3) were excluded from the study, as were patients not linked to a record 
on the Personal Demographics Service (n=2). The outcome assessed was transplant-free survival and 







Statistical analysis was performed using SPSS v25 (IBM, Chicago) and GraphPad Prism v8. Continuous 
data were displayed as either mean ±SD or median (first quartile, third quartile) for non-parametric 
data. Demographics were compared using paired and unpaired T-test for parametric data, and 
Wilcoxon signed-rank and Mann-Whitney U-tests for non-parametric data. Frequencies were 
compared using Χ2. Multivariate Cox regression analysis was performed in a forward direction on all 
parameters with a p value <0.2 at univariate analysis. For all other statistical tests, a p value of <0.05 
was considered significant. Kaplan-Meier survival curves were compared using log rank Χ2. From 
receiver operating characteristic (ROC) analysis, a c-statistic was produced to compare variations on 
risk scores. Where ISWT levels demonstrated one-year mortality of 0%, these levels were combined 
for Kaplan Meier analysis and correlation with haemodynamics. 
 
Ethics 
Approval by the relevant ethics committee was sought and gained (STH14169, NHS Research Ethics 
Committee 16/YH/0352), and written consent was waived. 
 
6.4 Results 
A total of 4524 treatment-naïve patients with pulmonary hypertension, who had undergone ISWT at 
the time of diagnosis, were identified from the ASPIRE registry. Baseline characteristics for different 
forms of pulmonary hypertension are displayed in Table 18. Of these, 1240 had either IPAH or PAH 
related to connective tissue disease (PAH-CTD; Table 19). Kaplan Meier analysis for ISWD in all forms 
of PH and for IPAH/PAH-CTD at baseline are displayed in Figure 25.   
IPAH and PAH-CTD 
Incident, treatment naive patients with IPAH (n=603) had significant disease at right heart 
catheterisation, with a mean mPAP 53mmHg, pulmonary vascular resistance (PVR) 11.5 WU and 
cardiac index 2.3 l/min/m2. Patients with PAH-CTD (n=637) had a mean mPAP 44mmHg, PVR 8.9 WU 
and cardiac index 2.6 l/min/m2. The majority of patients received either combination oral treatment 
or treatment including a prostanoid.  
Within one-year of diagnosis, 197 patients (15.4%) with IPAH and PAH-CTD had died or undergone 
transplantation. Levels of the ISWT demonstrated an inverse relationship with risk of one-year 
mortality (Table 17). Patients who walked 0-30m had a one-year mortality of 32%. A step-wise 
128 
 
reduction in percentage-mortality was seen at each level until a distance of ≥430m where there was 
a 0% mortality. Assignment of risk categories required concordance for both IPAH and PAH-CTD (Table 
17). A high-risk of one-year mortality (>10%) was therefore defined as a distance of ≤180m, low-risk 
(<5%) as an ISWD ≥340m and intermediate-risk 190-330m. Corresponding values for pulmonary 
haemodynamic and cardiac MRI parameters are displayed in Table 20. 
At follow-up ISWT the thresholds accurately identified patients at low, intermediate and high-risk in 
the combined IPAH and PAH-CTD cohort (one-year survival 97%, 94%, 78%, respectively), and in the 
individual disease groups. Kaplan Meier graphs showing five-year transplant-free survival at baseline, 
follow-up and demonstrating risk transition are displayed in Figure 26.  
Age <50 years 
Using the above thresholds in incident patients aged <50, 30% were identified as low-risk and had 0% 
one-year mortality. Seventy patients (28%) were intermediate risk where observed one-year mortality 
was underestimated at 3%, whereas 42% of patients were high-risk and had a one-year mortality of 
15%. A scatterplot showing baseline and follow-up distances and one-year mortality is shown in the 




Table 17: Levels of the ISWT and mortality per level for patients with IPAH and PAH-CTD 
 n (%) one-year mortality (%) 
ISWT 
Level* 






Level 1  0-30m 0.50 267 (22) 31.8 23.4 40.8 
Level 2  40-70m 0.67 206 (17) 18.5 11.0 24.3 
Level 3  80-120m 0.84 196 (16) 15.3 12.4 17.8 
Level 4  130-180m 1.01 172 (14) 14.5 15.2 14.2 
Level 5  190-250m 1.18 137 (11) 9.5 4.5 14.1 
Level 6  260-330m 1.35 110 (9) 4.5 5.5 3.6 
Level 7  340-420m 1.52 69 (6) 1.4 2.3 0 
Level 8  430-520m 1.69 52 (4) 0 0 0 
Level 9  530-630m 1.86 18 (2) 0 0 0 
Level 10  640-750m 2.03 9 (1) 0 0 0 
Level 11  760-880m 2.20 2 (0) 0 0 - 
Level 12  890-1020m 2.37 2 (0) 0 0 - 
 
*Each level has a duration of one minute. Abbreviations: ISWT = incremental shuttle walking test; IPAH 
= idiopathic pulmonary arterial hypertension; PAH-CTD = pulmonary arterial hypertension related to 




Table 18: Baseline demographics in all forms of pulmonary hypertension 
 
All PH PAH PH-LHD PH-Lung  CTEPH Group 5 
n= 4524 1847 988 766 791 129 
Female (%) 61 69 66 46 50 60 
Age 67 (56, 75) 63 (49, 71) 74 (67, 78) 68 (62, 75) 65 53, 74) 62 (50, 70) 
WHO FC I (%) 1 1 1 0 1 3 
WHO FC II (%) 19 18 24 12 22 10 
WHO FC III (%) 62 63 66 55 64 63 
WHO FC IV (%) 18 19 9 33 13 23 
BMI  28 (24, 33) 27 (23, 32) 30 (26, 35) 27 (24, 33) 28 (25, 33) 26 (22, 32) 
mRAP (mmHg) 10 (7, 15) 9 (6, 14) 14 (11, 18) 9 (6, 13) 10 (7, 14) 10 (6, 14) 
mPAP (mmHg) 44 (35, 52) 47 (37, 55) 38 (32, 46) 41 (33, 49) 46 (37, 53) 45 (35, 52) 
PAWP (mmHg) 12 (9, 17) 11 (8, 14) 22 (19, 26) 12 (9, 15) 12 (9, 14) 12 (9, 14) 
PVR (WU) 6.2 (3.5, 10.3) 8.0 (4.8, 12.0) 3.0 (2.1, 4.7) 5.7 (3.4, 9.2) 7.3 (4.4, 11.1) 6.8 (4.3, 9.8) 
SvO2 % 65 (58, 70) 65 (57, 71) 66 (60, 70) 66 (60, 71) 62 (57, 68) 63 (56, 71) 
Cardiac Output 
(l/min) 
4.6 (3.6, 5.9) 4.5 (3.4, 5.6) 5.0 (4.1, 6.1) 5.0 (3.8, 6.4) 4.5 (3.5, 5.7) 4.7 (3.9, 6.2) 
Cardiac Index 
(l/min/m2) 
2.6 (2.0, 3.1) 2.5 (1.9, 3.2) 2.7 (2.3, 3.2) 2.7 (2.1, 3.4) 2.3 (1.9, 2.8) 2.7 (2.1, 3.3) 
ISWD (m) 120 (40, 220) 130 (50, 250) 120 (40, 200) 80 (30, 150) 160 (60, 290) 90 (40, 195) 
 
      
Treatment (%)       
None or CCB 40 8 96 65 19 28 
Oral monotherapy 34 38 4 29 68 38 
Combo oral 17 36 0 5 7 23 
Prostanoid +/- oral 9 18 0 2 5 12 
 
Continuous data were non-parametric and are presented as median (1st quartile, 3rd quartile). 
Abbreviations: PH = pulmonary hypertension; PAH = pulmonary arterial hypertension; PH-LHD = 
pulmonary hypertension due to left heart disease; PH-Lung = pulmonary hypertension due to lung 
disease; CTEPH = chronic thromboembolic pulmonary hypertension; WHO FC = World Health 
Organisation Functional Class; BMI = body mass index; mRAP = mean right atrial pressure; mPAP = 
mean pulmonary arterial pressure; PAWP = pulmonary arterial wedge pressure; PVR = pulmonary 
vascular resistance; SvO2 = mixed venous oxygen saturations; ISWD = incremental shuttle walking test 




Table 19: Baseline demographics in patients with IPAH and PAH-CTD 
 
IPAH & PAH CTD IPAH PAH-CTD 
n= 1240 603 637 
Female (%) 71 61 80 
Age 64 (53, 72) 62 (47, 72) 66 (57, 73) 
WHO FC I (%) 0 0 0 
WHO FC II (%) 13 13 13 
WHO FC III (%) 63 59 67 
WHO FC IV (%) 23 27 19 
BMI (kg/m2) 27 (23, 31) 28 (24, 33) 26 (22, 30) 
mRAP (mmHg) 9 (6, 14) 11 (7, 15) 8 (5, 12) 
mPAP (mmHg) 48 (40, 56) 52 (46, 60) 43 (34, 51) 
PAWP (mmHg) 10 (8, 13) 11 (8, 13) 10 (7, 12) 
PVR (WU) 9.1 (5.7, 13.2) 10.5 (7.8, 14.5) 7.3 (4.7, 11.7) 
SvO2 % 63 (56, 69) 61 (55, 67) 65 (58, 71) 
Cardiac Output (l/min) 4.3 (3.2, 5.1) 4.0 (3.2, 5.0) 4.4 (3.4, 5.3) 
Cardiac Index (l/min/m2) 2.4 (1.9, 2.9) 2.2 (1.8, 2.7) 2.6 (2.0, 3.1) 
ISWD (m) 110 (40-220) 120 (40-260) 100 (40-195) 
 
   
Treatment (%)    
None or CCB 2 3 1 
Oral mono 33 27 38 
Combo oral 42 43 41 
Prostanoid +/- oral 23 27 20 
 
Continuous data were non-parametric and are presented as median (1st quartile, 3rd quartile). 
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension; PAH-CTD = pulmonary arterial 
hypertension related to connective tissue disease; WHO FC = World Health Organisation Functional 
Class; BMI = body mass index; mRAP = mean right atrial pressure; mPAP = mean pulmonary arterial 
pressure; PAWP = pulmonary arterial wedge pressure; PVR = pulmonary vascular resistance; SvO2 = 



















































Figure 25: Kaplan Meier survival curves for a) ISWD in all PH; b) ISWD in IPAH and PAH-CTD 
Abbreviations: ISWT = incremental shuttle walking test; ISWD = ISWT distance; PH = pulmonary 
hypertension; IPAH = idiopathic pulmonary arterial hypertension; PAH-CTD = pulmonary arterial 





Table 20: Association between ISWT level and haemodynamic and cardiac MRI parameters 
 
Data are displayed as mean ±SD or median (first quartile, third quartile) 
Abbreviations: ISWT = incremental shuttle walking test; MRI = magnetic resonance imaging; WHO FC 
= World Health Organisation Functional Class; mRAP = mean right atrial pressure; CI = cardiac index; 
SvO2 = mixed venous oxygen saturations; RVESVi %pred = right ventricular end systolic volume, 




n WHO FC mRAP 
(mmHg) 
CI (l/min/m2) SvO2 (%) RVEF (%) RVESVi (%pred) 
1 267 3.6 ±0.5 12 (8,16) 2.04 (1.67, 2.65)  58 (52, 66) 33 (27-42) 283 (225, 405) 
2 206 3.3 ±0.5 10 (6, 15) 2.31 (1.80, 2.86) 61 (54, 67) 32 (25-44) 277 (163, 338) 
3 196 3.1 ±0.5 10 (6, 14) 2.28 (1.81, 2.90) 62 (55, 69) 35 (24, 48) 253 (159, 371) 
4 172 3.0 ±0.4 9 (6, 13) 2.40 (1.89, 2.9) 64 (58, 68) 35 (28, 43) 240 (162, 328) 
5 137 2.9 ±0.5 8 (6, 13) 2.50 (2.00, 3.05) 66 (59. 70) 34 (25, 44) 237 (152, 328) 
6 110 2.7 ±0.5 8 (5, 11) 2.60 (2.17, 3.20) 68 (63, 71) 36 (25, 48) 176 (132, 264) 
7 69 2.6 ±0.5 9 (6, 12) 2.56 (2.20, 3.17) 66 (59, 71) 42 (34, 50) 183 (122, 258) 
8-12 83 2.4 ±0.5 7 (5, 9) 2.85 (2.22, 3.22) 69 (63, 72) 40 (27, 48) 159 (120, 241) 
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Improved from high to low-risk
Improved from intermediate to low-risk
Stable low-risk
Improved from high to intermediate-risk
Stable intermediate-risk
Deteriorated from low to intermediate-risk
Stable high-risk
Deteriorated from intermediate to high-risk
Deteriorated from low to high-risk

















Lower level at follow-up c
Stable level at follow-up b
Improved level at follow-up a
a vs b p<0.0001
a vs c p<0.0001






Figure 26: Kaplan Meier survival curves for ISWT: a) ISWD risk groups at baseline; b) transition of ISWD 
risk groups between baseline and follow-up; c) comparison of patients who, at follow-up, achieved at-
least one higher ISWT level, achieved the same ISWT level, or achieved a lower level than at baseline. 






Figure 27: A scatterplot showing individual baseline and follow-up ISWT distances, and mortality or 
transplant within one-year of follow-up ISWDin patients aged <50 with idiopathic pulmonary arterial 
hypertension and pulmonary arterial hypertension due to connective tissue disease Abbreviations: 




Treatment response  
Baseline median ISWD was 110m (40, 220) and paired tests at follow-up were available for 879 
patients. At follow-up, 132 (15%) patients had improved their ISWT risk-category (i.e. had improved 
to either intermediate or low-risk distance) and 83 (9%) had deteriorated. A scatterplot demonstrating 
individual baseline and follow-up distance is displayed in Figure 28. At paired testing, a median 
improvement of +10m (-30, +50; p<0.0001) was seen overall. Patients who achieved at least one ISWT 
level higher than at baseline (n=329, 37%), and therefore achieved a higher velocity, had significantly 
better 1 and 5-year survival (90% and 54%, respectively) than those who either remained in the same 
level (n=314, 36%; 1 and 5-year survival 84% and 37%; p<0.0001) or deteriorated (n=236, 27%; 1 and 
5-year survival 79% and 36%; p<0.0001), while there was no significant survival difference between 
those who were stable or deteriorated (p=0.61; Figure 26). When adjusting for baseline and follow-up 
ISWD, an improvement of >10% in ISWD was an independent predictor of survival (scaled HR 0.754; 
p<0.05) at multivariate analysis.  
 
Use in conjunction with risk stratification scores 
Patients with baseline RHC data available including mean right atrial pressure (mRAP) and cardiac 
index (n=1076) were selected to assess whether ISWD thresholds could be used in conjunction with 
other risk stratification scores, in place of 6MWD thresholds. For the FPHR low-risk invasive approach 
to the ESC/ERS guidelines, a low-risk 6MWD of >440m was substituted with a low-risk ISWD of ≥340m. 
Survival differed significantly based on the number of low-risk criteria (0-4) between all groups 
(p<0.05) and at ROC analysis produced a c-statistic of 0.61 (95% CI 0.57-0.66), which was unchanged 
when used in the IPAH group in isolation, and higher than when the FPHR approach was used without 
any walking test (c-statistic 0.59; 95% CI 0.55-0.64). Kaplan Meier analysis for an abbreviated three-
category risk score (3 or 4 criteria = low-risk, 1 or 2 criteria = intermediate-risk, 0 criteria = high-risk) 
is displayed in Figure 29a, demonstrating separation of curves for each risk category (p all <0.0001). 
Using this three-category FPHR risk score, low and high-risk groups were accurately identified (one-
year survival 96% and 78%, respectively) but risk in the intermediate group was underestimated (one-
year survival 87%).  
When assessing the REVEAL 2.0 score in the same population, three variations for substituting 6MWD 
with ISWD were derived based on i) thresholds similar to the 6MWD thresholds used in REVEAL 2.0; 
ii) thresholds of low, intermediate and-high risk identified at baseline; and iii) thresholds of low, 
intermediate and-high risk identified at baseline with an extra point addition or deduction for very-
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high (≤30m) and very-low risk (≥430m), respectively, derived from baseline data shown in Table 17. 
The REVEAL 2.0 c-statistic for one-year mortality without a walking test was 0.66 (95% CI 0.62-0.70); 
including ISWD thresholds from variation iii produced a c-statistic of 0.71 (95% CI 0.67-0.75), 
compared to 0.69 for variations i and ii. Low (≤6), intermediate (7-8) and high-risk (≥9) REVEAL 2.0 
scores (scores grouped as previously described (138)) accurately predicted one-year mortality; 
survival curves are displayed in Figure 29, and detailed analysis of one-year mortality for REVEAL 2.0 
scores are displayed in Figure 30. In all variations, patients with a REVEAL 2.0 score ≤6 had a 0% one-





Figure 28:   A scatterplot showing individual baseline and follow-up ISWT distances, and mortality or 
transplant within one-year of follow-up ISWD in patients with idiopathic pulmonary arterial 
hypertension and pulmonary arterial hypertension due to connective tissue disease (n=879). 
Abbreviations: ISWD = incremental shuttle walking test distance
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Figure 29: Kaplan Meier analysis demonstrating survival in risk stratification approaches: 
a) FPHR low-risk approach; 
b) REVEAL 2.0 variation i (ISWD 0-180m = +1; 190-330m = 0; 340-420m = -1; ≥430m = -2 points); 
c) REVEAL 2.0 variation ii (ISWD 0-180m = +1; 190-330m = 0; ≥340m = -1 point); 
d) REVEAL 2.0 variation iii (ISWD 0-30m = +2; 40-180m = +1; 190-330m = 0, 340-420m = -1; ≥430m = -
2 points) 
Abbreviations: REVEAL = Registry to Evaluate Early and Long-Term PAH Disease Management, FPHR = 







Figure 30: Risk of mortality by REVEAL 2.0 score, using variations of REVEAL 2.0 incorporating ISWD as 
follows: 
REVEAL 2.0 variation i (ISWD 0-180m = +1; 190-330m = 0; 340-420m = -1; ≥430m = -2 points); 
REVEAL 2.0 variation ii (ISWD 0-180m = +1; 190-330m = 0; ≥340 = -1 point); 
REVEAL 2.0 variation iii (ISWD 0-30 = +2; 40-180m = +1; 190-330m = 0, 340-420m = -1; ≥430m = -2 
points) 
 
Abbreviations: REVEAL = Registry to Evaluate Early and Long-Term PAH Disease Management; ISWD = 





In a large cohort of patients with IPAH and PAH-CTD we have demonstrated that routine use of 
maximal exercise testing can risk stratify patients into low, intermediate and-high risk of one-year 
mortality/lung transplantation. We have identified ISWT thresholds at baseline, shown the clinical 
utility in conjunction with other risks stratification scores and demonstrated that thresholds identified 
at baseline risk-stratify patients at follow-up. Unlike in sub-maximal field walking tests used in PAH, 
an improvement in ISWD was an independent predictor of survival. 
Exercise capacity is recognised as an important physiological marker in PAH, and as a validated 
measure, the 6MWT has been the mainstay of exercise testing in PAH both in routine practice and in 
clinical trials (224). In early studies assessing PAH therapies, 6MWD was demonstrated to be a marker 
of treatment response (86). Absolute distances are prognostic, and deterioration of 6MWD is strongly 
associated with poor prognosis (85, 109). Despite this there has been criticism of the 6MWT, 
particularly over its role as an endpoint in clinical trials (227, 229), as prospective and retrospective 
studies have been unable to demonstrate that improvements in 6MWD are independently associated 
with survival (85, 109). Furthermore, it is a submaximal test and may suffer from a ceiling effect, 
potentially limiting its use in younger patients or those with mild disease (230).  
We have previously shown that, as an alternative but maximal field walking test, the ISWT provides a 
measure of maximal exercise capacity without a ceiling effect, is sensitive to change, predicts survival 
and can identify exercise limitation in asymptomatic patients diagnosed with pulmonary hypertension 
in WHO FC I (115, 231). Using data from the present study we have now identified that maximal 
exercise testing using the ISWT can risk-stratify patients with IPAH and PAH-CTD. At baseline, in 
incident and treatment naïve patients, levels of the ISWT demonstrated good separation for both one-
year and longer-term survival. As a risk stratification tool, thresholds established at baseline were 
applicable at follow-up. As has been demonstrated with other prognostic investigations and risk 
stratification tools, patients who improved their risk profile demonstrated comparable longer-term 
survival to patients originally displaying that level of risk (142, 206, 232).  
A criticism of the 6MWT is that it suffers from a ceiling effect, whereby patients who walk >450m at 
baseline may not improve their walking distance in response to treatment despite improvements in 
WHO functional class and haemodynamics (115). In this study we have shown that, even amongst 
patients who walked ≥340m at baseline and remained in the low-risk group at follow-up, 63% 
improved absolute ISWD in response to treatment. At higher follow-up distances of ≥430m and 
≥530m, 68% and 69% of patients, respectively, were able to improve their ISWD after commencing 
treatment. We have also demonstrated that patients who were able to achieve a higher ISWT level 
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had significantly better long-term survival than patients who either remained in the same level or 
achieved a lower level at follow-up. This is expected as each level of the ISWT requires a higher 
maximal walking or running velocity, which has been shown to correlate with maximal oxygen intake 
(peak VO2) in other cardiorespiratory diseases (111, 112, 233). Peak VO2 has been identified as a 
strongly prognostic marker of survival in PAH when measured by incremental CPET (234), and other 
centres have confirmed the value of incremental exercise testing in the assessment of patients with 
pulmonary hypertension (235). This may explain why an improvement of >10% in ISWD was an 
independent predictor of survival when compared to patients whose ISWD was stable, when adjusting 
for baseline and follow-up ISWD. While absolute distances should remain the focus of risk 
stratification and the goal of treatment in PAH, these data suggest that maximal exercise testing may 
better suited for assessing an improvement following intervention than currently used sub-maximal 
tests such as the  6MWT, where such an association has not been demonstrated (109). Associations 
between incremental exercise testing and haemodynamics have been shown previously, and we have 
expanded upon this by showing association between this incremental test and important prognostic 
parameters from cardiac MRI with a stepwise reduction in right ventricular end-systolic volume 
%predicted with each level of the ISWT  (115, 232, 235). 
Our data demonstrate that ISWT thresholds can now be considered for incorporation into widely-used 
risk stratification tools. Using the French low-risk invasive approach to risk stratification, substitution 
of the 6MWT distances with equivalent distances for low, intermediate and high-risk from the ISWT 
continued to show five distinct risk groups at survival analysis. When combined into a three-category 
risk score, patients at low (3 or 4 criteria) and high-risk (0 criteria) had a one-year mortality of 4% and 
22%, respectively. Boucly et al note the difficulties of defining an intermediate-risk group and we 
found that the presence of one or two low-risk criteria underestimated one-year mortality, which was 
also seen when this approach was applied to the REVEAL population (138, 140). The c-statistic of 0.61 
in our population of patients with IPAH is similar to that identified when the French approach was 
tested in the REVEAL registry (0.62), although no c-statistic is provided in the original research (138, 
140). 
In the REVEAL 2.0 risk score we have shown that when 6MWT distances are substituted with variations 
of ISWT thresholds, a three-level risk score accurately predicts one-year mortality in this population. 
The c-statistic of 0.71 is lower than that identified in REVEAL 2.0 (0.76), and this may be the result of 
a phenotypically-different PAH population. In our study we included only patients with IPAH and PAH-
CTD rather than other forms of PAH such as congenital heart disease (CHD). Furthermore in our study, 
risk stratification approaches were applied to treatment-naïve patients rather than a mixture of 
incident and prevalent patients as in the REVEAL study. These factors, and particularly the absence of 
143 
 
patients with PAH-CHD (the presence of which scores -2 points in REVEAL 2.0) may also explain why a 
relatively small number of our patients were identified as being at low-risk by REVEAL 2.0 when 
compared to the original study and external validation studies (138, 139). 
 
Limitations 
Distances achieved at 6MWT and ISWT are not directly comparable, and the thresholds used in this 
study were identified from baseline data. While we have assessed and confirmed that these thresholds 
remain valid at follow-up, as in any single-centre study both the thresholds and their role in risk 
stratification tools require prospective validation in a separate population. Although we are unable to 
directly compare sensitivity and specificity for 6MWT and ISWT thresholds in the same population, 
our data support the use of the ISWT as a tool in risk stratification in PAH, and we have identified that 
improvements in ISWD are independently associated with survival. All-cause mortality or 
transplantation was used as the primary end-point, and patients may have died from causes unrelated 
to PAH. Finally, while the thresholds identified a large proportion of patients at high-risk of one-year 
mortality, this may reflect a high-risk population as demonstrated by the large number of patients 
with a high REVEAL 2.0 score with a corresponding one-year mortality of around 20%. Although the 
ISWT may be considered a more complex test it does benefit from only requiring a 10m corridor with 




Maximal exercise testing can be used to risk stratify patients with pulmonary hypertension including 
IPAH and PAH-CTD, and this study supports the routine use of maximal exercise testing in conjunction 
with other risk stratification tools. Unlike in sub-maximal walking tests, an improvement in maximal 
exercise capacity predicts outcome.  
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7.1 Abstract  
Health-related quality of life (HRQoL) scores assess symptom burden in pulmonary arterial 
hypertension (PAH) but data regarding their role in prognostication and risk stratification are limited. 
We assessed these relationships using the emPHasis-10 HRQoL measure. 
1745 patients with idiopathic or connective tissue disease-associated PAH who had completed 
emPHasis-10 questionnaires between 2014-17 at 6 UK referral centres were identified. Correlations 
with exercise capacity and WHO functional class (FC) were assessed, and exploratory risk stratification 
thresholds were tested. 
Moderate correlations were seen between emPHasis-10 scores and 6-minute walk distance (r=-0.546), 
incremental shuttle walking distance (r=-0.504) and WHO FC (r=0.497; p all <0.0001). Distribution of 
emPHasis-10 differed significantly between each WHO FC (p all <0.0001). At multivariate analysis, 
emPHasis-10, but not WHO FC, was an independent predictor of mortality. In a risk stratification 
approach, scores of 0-16, 17-33 and 34-50 identified incident patients with one-year mortality of 5%, 
10% and 23%, respectively. Survival of patients in WHO FC III could be further stratified using an 
emPHasis-10 score ≥34 (p<0.01). At follow-up, patients with improved emPHasis-10 had improved 
exercise capacity (p<0.0001), and patients who transitioned risk groups demonstrated similar survival 
to patients originally in those risk groups. 
The emPHasis-10 score is an independent prognostic marker in patients with idiopathic and 
connective tissue disease-associated PAH. It has utility in risk stratification in addition to currently 







Pulmonary arterial hypertension (PAH) is a rare condition, characterised by increased pulmonary 
vascular resistance and progressive right ventricular failure leading to premature death (9). Exertional 
breathlessness and limitation in physical activity are typically the earliest reported symptoms and may 
be caused by a number of mechanisms (203, 236). Exercise limitation may be objectively assessed by 
exercise testing, but limitations of day-to-day physical activity are typically assessed by healthcare 
professionals using the World Health Organisation (WHO) functional class.  
The importance of assessing patient reported outcome measures (PROMs) in patients with pulmonary 
hypertension (PH) is now recognised (167, 237) and three PH-specific tools for assessing health-related 
quality of life (HRQoL) have been developed (196, 238, 239). One of these tools, emPHasis-10, is 
comprised of 10 fields (resulting in a score out of 50, where a higher score represents a higher 
symptom burden) which can be quickly completed by patients and is free to use and so is well suited 
to routine clinical use (196). The emPHasis-10 score was found to correlate strongly with measures of 
HRQoL, breathlessness and psychological morbidity and has high test-retest and internal consistency 
(196). In addition, the emPHasis-10 questionnaire has been translated into a number of other 
languages (240, 241). A previous single-centre study of emPHasis-10 in patients with PAH 
(predominantly congenital heart disease-associated) and chronic thrombo-embolic PH demonstrated 
prognostic significance and a correlation with WHO functional class (FC) (242). Although risk 
stratification has an established central role in the management of patients with PAH, PROMs are not 
incorporated in current risk assessment tools (43, 138, 140). 
Routine HRQoL assessment using a PH-specific tool has been a mandatory field in the UK National 
Audit of Pulmonary Hypertension since 2014 (243). We therefore performed a multi-centre study of a 
large cohort of patients with idiopathic and connective tissue disease (CTD)-associated PAH to further 
assess the relationship between emPHasis-10 score and mortality, identify correlations with clinical 
parameters including exercise capacity and determine whether a threshold approach for risk 







Local databases for 6 out of the 7 UK pulmonary hypertension referral centres, which together manage 
94% of adult patients with a diagnosis of PAH, were interrogated (243). Patients with PAH were 
diagnosed as per contemporaneous international guidelines (mean pulmonary arterial pressure 
≥25mmHg and pulmonary arterial wedge pressure ≤15mmHg in the absence of thromboembolic 
disease or conditions associated with other forms of pulmonary hypertension) (191). Anonymised 
demographic, haemodynamic, spirometric, exercise, emPHasis-10 and mortality data were retrieved 
for all patients with a diagnosis of idiopathic, drug-associated or heritable PAH (hereafter grouped as 
IPAH) or PAH related to CTD (PAH-CTD) with at least one recorded emPHasis-10 score between 
January 1st 2014 and 31st May 2018. Incident patients were required to have an emPHasis-10 score at 
the point of diagnosis, which was possible if diagnosed from 2014 onwards since its clinical use was 
introduced in the UK during that year. For prevalent patients (i.e. those diagnosed prior to 2014 or for 
whom no emPHasis-10 score was available at the time of diagnosis) the first available emPHasis-10 
score was used. In either group, the first emPHasis-10 score was described as the baseline 
measurement. All patients were under regular clinical follow-up and the outcome measured was 
death or transplant by 31st May 2019. Follow-up data were retrieved for the first visit between 3 and 
12 months after baseline emPHasis-10 score.  
 
Statistical Analysis 
Statistical analysis was performed using SPSS v26 (IBM, Chicago) and GraphPad Prism v8. Continuous 
data were displayed as either mean ± standard deviation, or median (first quartile, third quartile) for 
non-parametric data. Demographics were compared using paired and unpaired T-test for parametric 
data, and Wilcoxon signed-rank and Mann-Whitney U-tests for non-parametric data. Frequencies 
were compared using Χ2. For Cox regression modelling, parameters recognised as being prognostically 
important were utilised: age, gender, presence of CTD (rather than IPAH), mean right atrial pressure, 
cardiac index and walking distance. Collinearity was assessed by measuring the variance inflation 
factor and tolerance between variables. EmPHasis-10 score was entered as a continuous variable in 
the multivariate model. Multivariate Cox regression analysis was performed in a forward direction on 
all parameters with a p value <0.2 at univariate analysis. Data were scaled to the mean and hazard 
ratios were based on the z-score. Two types of walking test were used (the 6-minute walking test 
(6MWT) and incremental shuttle walking test (ISWT)) and so for multivariate modelling, distances 
were converted to a z-score and combined as a single variable. For all statistical tests other than 
multivariate analysis, a p value of <0.05 was considered significant. Kaplan-Meier survival curves were 
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compared using log rank Χ2, and were truncated at 4 years, based on the census date. Correlations 
were assessed using either Pearson or Spearman rank, as appropriate. Risk models were compared 
using the c-statistic identified from receiver operating characteristic (ROC) curve analysis. The minimal 
detectable change (MDC) for emPHasis-10 score was calculated using the formula: MDC = 1.96 x √2 x 
standard error of measurement (244). 
Ethical approval was granted (IRAS 254446). 
 
7.4 Results 
A total of 1745 patients with IPAH (n=994) or PAH-CTD (n=751) who had at least one recorded 
emPHasis-10 score were identified. There was a female predominance (73%), and 35% of patients 
were incident and treatment-naïve at the time of baseline emPHasis-10 score. The median emPHasis-
10 score was higher in patients with PAH-CTD (median 30 (19, 38)) than patients with IPAH (28 (17, 
37)); p=0.001. Baseline demographics are displayed in Table 21. 
 
Correlation with clinical parameters 
Moderate correlations (p all <0.0001) were seen between baseline emPHasis-10 score and WHO FC 
(r=0.50), 6-minute walking distance (6MWD; r=-0.55) and incremental shuttle walking test distance 
(ISWD; r=-0.50), Table 22. In incident patients with right heart catheter data available (n=591), there 
were weak correlations with mean right atrial pressure (mRAP; r=0.21), cardiac index (r=-0.21) and 
pulmonary vascular resistance (PVR; r=0.17); p all <0.0001. Correlations were similar in subgroups of 
IPAH and PAH-CTD, apart from PVR where correlation was significant in PAH-CTD (r=0.21; p<0.0005) 
but not in IPAH (r=0.11; p=0.8). Correlations between WHO FC and walk distance and haemodynamics 
are also shown in Table 22. 
Distribution of emPHasis-10 score by WHO FC at baseline is shown in Figure 31; median emPHasis-10 
scores were 3, 19, 31 and 40 in WHO FC I, II, III and IV, respectively, with highly significant differences 




Table 21: Patient characteristics 
 
All (n = 1745) I/D/HPAH (n = 994) PAH-CTD (n = 751) p value n 
Female (%) 73 66 82 <0.0001 1745 
Age at diagnosis (yrs) 59 ±17 55 ±18 64 ±13 <0.0001 1745 
% incident 35 29 44 <0.0001 618 
FEV1 (%pred) 82 ±21 84 ±19 80 ±23 0.0001 1457 
FVC (%pred) 92 ±23 95 ±20 89 ±27 <0.0001 1459 
FEV1/FVC 73 ±13 74 ±13 73 ±14 0.078 1459 
mRAP (mmHg) 9 ±6 10 ±6 8 ±5 <0.0001 1503 
mPAP (mmHg) 48 ±13 53 ±13 41 ±11 <0.0001 1573 
PAWP (mmHg) 9 ±4 9 ±4 9 ±3 0.56 1496 
PVR (WU) 10.5 ±5.8 12.0 ±5.7 8.7 ±5.4 <0.0001 1378 
Cardiac Output (l/min) 4.2 ±1.5 4.0 ±1.5 4.3 ±1.5 <0.0005 1465 
Cardiac Index (l/min/m2) 2.4 ±0.8 2.2 ±0.8 2.5 ±0.8 <0.0001 1305 
emPHasis-10 29 (18, 38) 28 (17, 37) 30 (19, 38) 0.001 1745 
WHO FC I/II/III/IV (%)* 3/23/61/13 4/26/57/13 1/20/67/12  1725 
6MWD* 310 (180, 408) 340 (192, 432) 241 (141, 360) <0.0001 659 
ISWD* 150 (70, 270) 160 (80, 350) 140 (60, 228) 0.001 797 
 
*Variables were recorded at time of baseline emPHasis-10; other variables were recorded at diagnosis. 
Baseline 6MWD and ISWD were available in 38% and 46% of patients, respectively, with no overlap.  
Abbreviations: I/D/HPAH = idiopathic/drug/heritable pulmonary arterial hypertension, PAH-CTD = 
connective tissue disease related pulmonary arterial hypertension, mRAP = mean right atrial pressure; 
mPAP = mean pulmonary arterial pressure; PAWP = pulmonary arterial wedge pressure; PVR = 
pulmonary vascular resistance; WHO FC = World Health Organisation functional class; 6MWD = six-











Table 22: Correlation of emPHasis-10 and WHO functional class with walk distance and pulmonary 
haemodynamics 
 6MWD (m) ISWD (m) mRAP (mmHg) CI (L/min/m2) PVR (WU) 
emPHasis-10 -0.55* (n=659) -0.50* (n=797) 0.21* (n=575) -0.21* (n=525) 0.17* (n=550) 
WHO FC -0.60* (n=653) -0.59* (n=796) 0.18* (n=572) -0.18* (n=523) 0.18* (n=548) 
 
Correlations assessed by Pearson or Spearman-Rank tests as appropriate. * = p<0.001. 
Abbreviations: 6MWD = 6-minute walking distance, ISWD = incremental shuttle walking distance, 
mRAP = mean right atrial pressure, CI = cardiac index, PVR = pulmonary vascular resistance, WHO FC 






















Figure 31: Distribution of emPHasis-10 score by WHO functional class at baseline 





During the course of the study 674 (39%) patients died, of which 240 (14%) died within one-year of 
baseline emPHasis-10 score; one-year mortality in incident and prevalent patients was 16% and 12%, 
respectively. An exploratory three-level score was developed based on a tertile group approach: 
scores of 0-16 were defined as low-risk, 17-33 as intermediate-risk, and 34-50 as high-risk. Using these 
thresholds, 22% of all patients were defined as low-risk, 41% as intermediate-risk and 37% as high-risk 
of one-year mortality. Survival curves for these risk groups are shown for incident patients in Figure 
32a, prevalent patients in Figure 32b and for all patients in Figure 32c. In incident patients, one-year 
mortality for the low, intermediate and high-risk groups was 5%, 10% and 23%, respectively. In all 
patients, one-year mortality for the low, intermediate and high-risk groups was 4%, 12% and 21%, 
respectively. In all patients with IPAH, one-year mortality in low, intermediate and high-risk groups 
was 4%, 9% and 18%, whereas in PAH-CTD, one-year mortality was 6%, 15% and 25%, respectively. 
Incident patients in functional class III who were in low/intermediate emPHasis-10 risk groups 
(emPHasis-10 score 0-33) had superior survival than those in the high-risk group (emPHasis-10 score 
34-50) with 1 and 3-year survival of 90% and 67% vs 81% and 56%; p<0.01; Figure 33). Very similar 
observations were made in functional class III patients at their first follow-up visit. 
 
Survival Analysis  
Three multivariate analysis models were developed in the incident population (Table 23). Model 1 
utilised accepted prognostic parameters: age, gender, PAH-CTD rather than IPAH, WHO FC, mRAP and 
cardiac index. EmPHasis-10 and exercise capacity were sequentially added into models 2 and 3. Unlike 
WHO FC, emPHasis-10 score was an independent predictor of outcome in models 2 (scaled HR 1.565; 
p<0.0001) and 3 (scaled HR 1.226; p<0.05). There was no significant collinearity between parameters 
used in the model. 
 
Magnitude of change 
The MDC for emPHasis-10 score was calculated to be 9. Follow-up emPHasis-10 data were available 
for 1068 patients (61%). EmPHasis-10 score changed by at least 9 points in 33% of patients (IPAH 32%, 
PAH-CTD 34%) between baseline and follow-up. Thirty-seven percent of patients moved risk groups, 
of which 19% improved at least one risk group. In patients who moved from high-risk to intermediate 
or low-risk, the median change in emPHasis-10 score was -12 (-6, -19) points, and in patients who 
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deteriorated to high-risk the median change was +13 points (+8, +17). Patients who either improved 
to low or intermediate-risk, or deteriorated to high-risk demonstrated similar long-term survival to 
patients originally in those risk groups (Figure 32d).  
At paired testing, patients who improved emPHasis-10 score by ≥ the MDC of 9 points had significantly 
improved walk distances at follow-up; ISWD increased by 30m (0, 90; p<0.0001, Figure 34a) while 
6MWD increased by a median distance of 32m (-4, +113; p<0.005, Figure 34b). A significant fall in 
ISWD of -20m (-60, 0; p<0.0001, Figure 34a) and no significant change in 6MWD (0m (-29, +57), Figure 
34b) was observed in patients whose emPHasis-10 score deteriorated by at least 9 points. In the 
remaining patients in whom there was a change of <9 points there was no significant change in either 
ISWD (0m (-30, +20)) or 6MWD (0m, (-11, +53)).  The relationship between change in emPHasis-10 
and change in walk distance differed depending on whether patients were incident or prevalent at the 
time of their baseline walk (relationship being stronger in incident patients) and whether they 
performed the ISWT or 6MWT (relationship being stronger in patients who performed the ISWT). In 
patients whose emPHasis-10 score deteriorated by ≥9 points, ISWD fell significantly in both incident 
and prevalent populations. In patients whose emPHasis-10 score improved ≥9 points ISWD increased 
significantly in incident, but not prevalent, patients (Figure 34c and Figure 34e). In patients in whom a 
6MWT was performed, an improvement was observed in incident patients whose emPHasis-10 score 
either improved or deteriorated by ≥9 points (Figure 34d), while no significant change was seen in 






Table 23: Univariate and multivariate analysis in incident patients 
 
 
Univariate  Multivariate  
Model 1 Scaled HR p value Scaled HR p value 
Age 2.063 <0.0001 2.177 <0.0001 
Gender (ref. Female) 1.316 0.054   
PAH-CTD (ref. IPAH) 1.336 0.031 1.444 0.017 
WHO FC III (ref I&II) 1.817 0.009   
WHO FC IV (ref I&II) 3.642 <0.0001 2.978 <0.0001 
mRAP 1.196 0.006 1.227 0.005 
Cardiac Index 0.756 0.001   
 
  
Model 2 Scaled HR p value Scaled HR p value 
Age 2.063 <0.0001 2.180 <0.0001 
Gender (ref. Female) 1.316 0.054   
PAH-CTD (ref. IPAH) 1.336 0.031   
WHO FC III (ref I&II) 1.817 0.009   
WHO FC IV (ref I&II) 3.642 <0.0001   
mRAP 1.196 0.006   
Cardiac Index 0.756 0.001   
emPHasis-10 1.518 <0.0001 1.447 <0.0001 
 
  
Model 3 Scaled HR p value Scaled HR p value 
Age 2.063 <0.0001 1.860 <0.0001 
Gender (ref. Female) 1.316 0.054   
PAH-CTD (ref. IPAH) 1.336 0.031   
WHO FC III (ref I&II) 1.817 0.009   
WHO FC IV (ref I&II) 3.642 <0.0001   
mRAP 1.196 0.006   
Cardiac Index 0.756 0.001   
emPHasis-10 1.518 <0.0001 1.226 0.047 
Walking distance* 0.461 <0.0001 0.574 <0.0001 
 
*Two types of walking test were used (the 6-minute walking test and incremental shuttle walking test). 
For Cox regression modelling, distances were converted to a z score and combined.  
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension, CTD-PAH = connective tissue disease 
related pulmonary arterial hypertension, WHO FC = World Health Organisation functional class; mRAP 
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Figure 32: Kaplan Meier survival curves demonstrating survival from baseline emPHasis-10 score for 
a) incident patients; b) prevalent patients, c) all patients; d) risk transition in all patients between 
baseline and follow-up emPHasis-10 score 
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Figure 33: Survival in incident patients with WHO functional class III symptoms, dichotomised by 
emPHasis-10 score ≤33 or ≥34. 




































































































































Figure 34: Change in walk distance (ISWD or 6MWD) in patients whose emPHasis-10 score deteriorated 
by ≥9 or improved by ≥9 between baseline and follow-up. Figure 4a & b: all patients, figure 4c & d: 
incident patients, figure 4e & f: prevalent patients 
Abbreviations: ISWD = incremental shuttle walking test distance; 6MWD = six-minute walking test 





To our knowledge, this is the largest study to assess the role of quality of life scores in patients with 
PAH, and in this multi-centre study we report on data from centres treating the vast majority of the 
adult PAH population in the UK. We have demonstrated that the emPHasis-10 score is an independent 
predictor of outcomes when adjusting for haemodynamics and WHO FC and also has utility in risk 
stratification, including within patients in WHO FC III.  We have also observed moderate correlations 
with WHO FC and exercise capacity and weaker correlations with pulmonary haemodynamics. 
Furthermore, we have also demonstrated that improvement in emPHasis-10 score, as opposed to a 
static or worsening score, is associated with improvements in exercise capacity. 
Generic (Short Form Health Survey (SF-36)), heart failure-specific (Minnesota Living with Heart Failure 
questionnaire), and PAH-specific (emPHasis-10 and Cambridge Pulmonary Hypertension Outcome 
Review (CAMPHOR)) PROMs have previously been identified as having prognostic importance in PAH 
(242, 245-247). Correlations between CAMPHOR and SF-36 and 6-minute walking test distance have 
also been demonstrated (246, 248, 249). The widespread clinical use of the CAMPHOR score may, 
however, be limited by its length (65 fields over 3 domains: symptoms, functioning and quality of life) 
and lack of open access (250). A third PH-specific PROM, the Pulmonary Arterial Hypertension-
Symptoms and Impact (PAH-SYMPACT) tool, which consists of 22 fields over 2 domains (symptoms 
and impacts) has also been developed (239). Although PAH-SYMPACT is responsive to change, its 
relationship to haemodynamics and survival is not known (251).  
A previous single-centre study involving 687 patients (314 PAH associated with congenital heart 
disease, 109 IPAH, 111 CTD-PAH and 131 chronic thromboembolic PH) assessed the relationship 
between emPHasis-10 and survival (242). In that study, Cox regression analysis demonstrated 
emPHasis-10 to be predictive of survival, independent of WHO FC, in PAH associated with congenital 
heart disease, but not in IPAH and CTD-PAH. In our study, which included much larger numbers of 
patients with IPAH and CTD-PAH, emPHasis-10 was an independent prognostic marker in IPAH and 
CTD-PAH, even when allowing for a number of variables known to be strongly prognostic in PAH 
including mRAP and cardiac index. This was not the case for WHO FC and it is interesting to note that 
Boucly et al also observed that baseline WHO FC was not an independent predictor of outcome in 
their paper from the French Registry (140).   
In incident patients, an exploratory risk stratification approach separating emPHasis-10 scores into 
three bands based on an equal range of scores in each group (thresholds of ≤16, 17-33 and ≥34) 
identified distinct risk groups with significant survival differences (corresponding one-year mortality 
of 5%, 10% and 23%, respectively). These levels of one-year mortality are very similar to risk thresholds 
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of low (<5%), intermediate (5-10%) and high-risk (>10%) proposed by the European Society of 
Cardiology/European Respiratory Society (ESC/ERS) guidelines for risk stratification in PAH. Using 
these risk thresholds, we identified that patients who either improved to intermediate or low-risk, or 
deteriorated to high-risk at follow-up emPHasis-10 assessment had a similar longer-term survival to 
patients who were originally in those risk groups. This effect has been seen in a number of other risk 
stratification parameters and scores (142, 206, 232), and the importance of achieving specific PROM 
thresholds in PAH has also been observed with the generic SF-36 (252). The majority of patients are 
in WHO FC III at the time of diagnosis and we were therefore interested whether the emPHasis-10 
score could refine these patients into higher and lower risk groups. We observed that a threshold 
score ≥34 was indeed able to identify functional class III patients at higher and lower risk of one-year 
mortality at both diagnosis and at first follow-up.  
We observed moderate correlations between emPHasis-10 and exercise capacity (r=0.55 and 0.50) 
and WHO FC (0.50) and only weak correlations with pulmonary haemodynamics (r ranging between 
0.17 and 0.21). The correlations with exercise capacity compare favourably with some reports 
regarding the other 2 PH-specific PROMs; Gomberg-Maitland et al reported weaker correlations 
between 6MWD and the 3 domains of CAMPHOR (symptoms r=0.35, functioning 0.45, HRQoL 0.33) in 
147 PAH patients while Chin et al observed weak to moderate correlations between domains of the 
PAH-SYMPACT and 6MWD (r =-0.14 to -0.57) in 278 PAH patients (251). More recently, however, Reis 
et al observed stronger correlations between 6MWD and the 3 CAMPHOR domains (r=-0.67, -0.74 and 
-0.61) in 49 patients with PAH or chronic thromboembolic PH (249, 253). To date, there have been no 
previous reports of correlations of PH-specific PROMs and pulmonary haemodynamics. The 
correlations we observed were, however, comparable to those observed by Mathai et al between 
components of the SF-36 generic HRQoL tool and haemodynamics in 87 patients with PAH (although 
in their study, many of these correlations were non-significant) (245). 
Finally, we have demonstrated that an improvement in emPHasis-10 score of at least the MDC (≥9) at 
follow-up was associated with an increase in exercise capacity in incident patients whereas a reduction 
in emPHasis-10 score by ≥9 was associated with a decrease in exercise capacity when assessed by the 
ISWD. The vast majority of incident patients will have been started on PAH therapies, whereas in 
prevalent patients there may have been no treatment change between assessments, which may partly 
explain the stronger relationship between change in walk distance and change in emPHasis-10 score 
in the incident group. The reason for the stronger relationship between change in ISWD (as opposed 
to 6MWD) and change in emPHasis-10 is not clear but may reflect the different nature of the tests; 
the ISWT is an externally-paced measure of maximal exercise capacity while the 6MWT is an internally-
paced assessment of sub-maximal exercise capacity. These data suggest that emPHasis-10 is 
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While this study was able to demonstrate important associations between emPHasis-10 score and 
time to death or transplantation, other measures of clinical deterioration including hospitalisation due 
to heart failure and escalation of therapy were unavailable. In addition, while emPHasis-10 scores 
were prospectively collected, this was a retrospective study and there were some data availability 
issues. Treatment data were not available; it is possible that PAH-specific therapies may affect HRQoL 
both negatively, in terms of side effects and the effects of complex treatments on lifestyle, but also 
positively, in terms of improvements in right ventricular function translating into amelioration of 
symptoms. Finally, data regarding comorbidities, such as the presence and extent of parenchymal lung 
disease in patients with PAH-CTD, were unavailable. Assuming that comorbidities such as lung disease 
adversely affect HRQoL the inclusion of patients with parenchymal lung disease would likely weaken 
the relationships between emPHasis-10 and functional parameters, treatment response and survival. 
 
7.6 Conclusion 
The emPHasis-10 score correlates with WHO FC, exercise capacity and haemodynamics and is an 
independent prognostic marker in patients with IPAH and PAH-CTD. The survival of patients within 
WHO FC III can be further stratified using emPHasis-10 score. Improvement in emPHasis-10 is 
associated with improvement in exercise capacity, although further work to determine the minimal 




8. Summary and Conclusion 
This thesis comprises two main sections, the first identifying important clinical phenotypes in patients 
with pulmonary hypertension, and the second assessing whether non-invasive investigations and tools 
can be used to risk stratify patients with pulmonary arterial hypertension. 
In the first section, two specific phenotypes have been described. In chapter 3 patients with partial 
anomalous pulmonary venous drainage are discussed. Although this a rare congenital defect, 
identification is important as patients may require surgical correction, either for the anomalous 
drainage or for associated atrial septal defects. The data demonstrate that, in patients presenting with 
pulmonary hypertension, partial anomalous pulmonary venous drainage is frequently missed as a 
diagnosis prior to assessment at a specialist unit despite a majority having undergone local CT 
scanning. Furthermore, a large number of atrial septal defects were newly identified, despite these 
patients having previously undergone CT imaging. These data are supported by similar findings in 
other studies (179), although the data in chapter 3 represent the largest published cohort of patients 
with PAPVD. 
Data in chapter 4 show the importance of describing and assessing the extent of lung disease in 
patients who are classified as having IPAH based on current recommendations. Patients with 
radiologically-mild parenchymal lung disease did not demonstrate an improvement in exercise 
capacity when treated with targeted therapy and also have significantly worse outcomes, when 
compared to patients who did not have any radiological evidence of lung disease. While these data 
require confirmation in prospective RCTs, they may have important implications for clinicians 
managing patients with IPAH and for investigators assessing the effect of novel PAH therapies. 
Exclusion criteria for these trials typically only consist of spirometric criteria, and the presence of mild 
lung disease would not merit exclusion. In this study, patients had relatively preserved spirometry and 
would not have been excluded from PAH clinical trials. From a clinician perspective these data may 
advocate against aggressive treatment of PAH in these patients with parenteral treatments, although 
given the absence of a control cohort, it is possible that patients may have had an even poorer 
prognosis had they not received targeted therapy. In addition, the presence of mild parenchymal lung 
disease is not included in any current risk stratification tools for patients with IPAH despite this 
significant survival disadvantage.  
This study has not assessed the impact of lung disease in patients with PAH-CTD, and approximately 
75% of patients with systemic sclerosis develop interstitial lung disease (254). In the presence of PH, 
such patients often receive targeted therapies but the clinical benefit of these therapies is unclear. 
Some studies in patients with PH and parenchymal lung disease have shown improvement in 
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haemodynamics, but a study of 70 patients with ILD in the presence of PAH-CTD did not show clear 
benefits from treatment (255-257). Whether the extent of lung disease is important in these patients 
remains unclear, and further studies assessing the role of PAH targeted therapies in varying extents 
of lung disease in this population may be warranted. 
These two studies particularly demonstrate the role that CT imaging has in establishing the correct 
diagnosis in patients presenting with pulmonary hypertension, but also supports previous studies 
highlighting that imaging can provide important prognostic information (258). The recent Pulmonary 
Vascular Research Institute (PVRI) statement on imaging and pulmonary hypertension recognise the 
important role that CT imaging has in patients presenting with pulmonary hypertension (169), and the 
first two studies presented in this thesis support the use of CT imaging at diagnosis, although its use 
as a routine risk stratification tool at follow-up is limited by ionising radiation exposure. 
The second part of this thesis focuses on risk stratification using non-invasive investigations and 
assessments. While thresholds have been proposed for a number of other non-invasive investigations 
such as the 6-minute walking test and BNP/NT-proBNP, no thresholds have previously been proposed 
for volumetric measurements taken at cardiac MRI, which has been established as the gold standard 
marker of right ventricular function and is recognised as a prognostic tool in PAH (160). In contrast to 
CT imaging, cardiac MRI is particularly attractive as a non-invasive risk-stratification tool as it does not 
involve radiation exposure, whilst also providing cine images allowing visual assessment of the cardiac 
chambers and facilitating volumetric measurements. Using discovery and test cohorts, thresholds 
have been identified that could be incorporated into clinical use. Both right ventricular ejection 
fraction (RVEF) and percent-predicted right ventricular end systolic volume index (RVESVi %pred) were 
found to be prognostic at baseline and follow-up. A large proportion of patients at low-risk of one-
year mortality were identified using RVESVi %pred and this was therefore selected for assessment 
alongside the REVEAL 2.0 risk score calculator and French low-risk approach to risk stratification. In 
both models cardiac MRI improved risk stratification, as measured by c-statistic, and further 
delineated risk in patients found to be at intermediate or high risk using either of these approaches. 
Exercise capacity is recognised as an important prognostic marker in PAH and is typically assessed 
using the sub-maximal 6-minute walking test (6MWT). Absolute distances measured using the 6MWT 
predict mortality. However, despite the widespread use of 6MWT as a primary endpoint in the 
majority of PAH clinical trials, an improvement in 6MWT distance has not been shown to be an 
independent predictor of mortality. In this study I hypothesised that an improvement in maximal 
exercise capacity, as measured by the incremental shuttle walking test, would predict outcome and 
have demonstrated that improvement of 10% at follow-up independently predicted improved 
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survival, when adjusting for baseline and follow-up distances. Cardiopulmonary exercise testing is 
recognised as the gold standard measure of exercise capacity, and this study highlights the importance 
of maximal exercise testing in patients with PAH. Compared to the incremental shuttle walking test, 
cardiopulmonary exercise testing is time-consuming and expensive but does provide a more 
comprehensive evaluation of multi-organ response to physical effort.  
Whilst objective measures of improvement such as cardiac MRI and exercise capacity are 
prognostically useful, assessing quality of life in patients with PAH is clearly important. Such measures 
have typically been physician-assessed using WHO functional class but increasingly the importance of 
patient-reported outcomes measures (PROMs) is recognised (167). Chapter 7 therefore assesses 
whether PROMs can be used to predict outcomes in patients with PAH and whether they have a role 
as a risk stratification tool. Three PAH specific PROMs exist, but only the emPHasis-10 score is in use 
in all UK PAH referral centres. Data for baseline and follow-up emPHasis-10 scores were therefore 
collected from centres representing 94% of adults receiving treatment for PAH in the UK. Using these 
data, the study identified that emPHasis-10 score is an important prognostic marker in PAH. The score 
was an independent predictor of outcomes, when adjusting for haemodynamics and WHO functional 
class, and has utility in risk stratification. In patients who presented in WHO functional class III, which 
typically represents the majority of patients diagnosed with PAH, the emPHasis-10 score was able to 
stratify patients into a lower and higher risk group. In addition, the study has confirmed that emPHasis-
10 score correlates with WHO functional class and also shows moderate correlation with exercise 
capacity (242). 
8.1 Limitations 
Specific limitations for each study are outlined in the individual chapters. While data were 
prospectively collected, the main limitation of the studies included in this thesis is that they are based 
on retrospective data and, apart from the study presented in chapter 7, from a single centre. 
Nonetheless, the studies consist of large cohorts and in several cases represent the largest data that 
have been published in the individual areas. Given the retrospective nature of these studies, 
prospective validation is required. This is particularly applicable to patients with IPAH and mild lung 
disease where there has so far been a paucity of large prospective data from well-conducted studies 
aimed at determining whether targeted treatment is beneficial for these patients. 
8.2 Future directions 
A number of areas for potential future research have been suggested by the studies in this thesis. 
Whilst lung disease has been identified as a marker of poor outcomes in IPAH, its impact in other forms 
of PAH remains unclear. Parenchymal lung disease is frequently seen in patients with PAH-CTD, and 
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while small studies have assessed the benefit of therapies in selected groups, it remains unclear 
whether the extent of lung disease predicts response to treatment. Therefore, further work aimed at 
identifying which patients have specifically developed a potentially treatable vasculopathy would be 
beneficial. 
There are emerging data showing the role of machine learning in the interpretation of CT images and 
lung parenchyma. Further work could compare the qualitative description of CT imaging provided in 
chapter 4 with a machine learning approach.  
The aim of this thesis was not to develop a new risk stratification calculator for patients with PAH, as 
two validated tools are already in use. Nonetheless combination of investigations identified in this 
thesis could be considered, particularly cardiac MRI and the incremental shuttle walking test, which 
identify a large proportion of patients at low and high-risk of one-year mortality, respectively.  
8.3 Conclusion 
To conclude, non-invasive assessments can identify important phenotypes and improve risk 
stratification in patients with PAH and the hypothesis is therefore accepted. These studies advance 
our understanding of PAH and it is hoped that improved accuracy of clinical phenotyping and risk 
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